,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,77,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
30,79,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
31,81,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
32,83,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
33,85,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
34,87,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
35,89,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
36,91,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
37,93,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
38,95,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
39,97,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
40,99,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
41,101,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
42,103,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
43,105,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
44,107,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
45,109,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
46,113,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
47,115,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
48,119,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
49,121,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
50,123,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
51,125,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
52,129,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
53,131,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
54,133,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
55,137,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
56,139,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
57,141,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
58,143,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
59,145,1,1,,399407,3121,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
60,155,1,1,,399407,3121,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
61,157,1,1,,399407,3121,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
62,161,1,1,,399407,3121,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
63,165,1,1,,399407,3121,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
64,167,1,1,,399407,3121,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
65,175,1,1,,399407,3121,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
66,421,1,3,,17389523,3121,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
67,426,1,2,,17389523,3121,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
68,427,1,1,,17389523,3121,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
69,433,1,1,,17389523,3121,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
70,434,1,2,,17389523,3121,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
71,435,1,2,,17389523,3121,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
72,445,3,1,,17389523,3121,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
73,530,1,1,,17389523,3121,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
74,540,1,1,,17389523,3121,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
75,541,1,1,,17389523,3121,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
76,542,1,1,,17389523,3121,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
77,543,1,1,,17389523,3121,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
78,544,2,1,,17389523,3121,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
79,545,1,1,,17389523,3121,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
80,546,1,1,,17389523,3121,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
81,584,1,3,,17389523,3121,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
82,585,1,4,,17389523,3121,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
83,595,1,3,,17389523,3121,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
84,596,1,2,,17389523,3121,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
85,603,1,2,,17389523,3121,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
86,605,1,2,,17389523,3121,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
87,654,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
88,655,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
89,656,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
90,657,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
91,658,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
92,659,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
93,660,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
94,661,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
95,662,1,1,,17389523,3121,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
96,663,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
97,664,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
98,665,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
99,666,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
100,667,1,1,,17389523,3121,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
101,875,1,2,,17389523,3121,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
102,880,2,1,,17389523,3121,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
103,880,2,1,,17389523,3121,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
104,881,2,2,,17389523,3121,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
105,884,1,2,,17389523,3121,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
106,885,1,2,,17389523,3121,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
107,886,1,2,,17389523,3121,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
108,886,1,2,,17389523,3121,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
109,887,1,2,,17389523,3121,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
110,889,1,3,,17389523,3121,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
111,892,1,2,,17389523,3121,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
112,893,1,2,,17389523,3121,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
113,893,1,2,,17389523,3121,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
114,894,2,1,,17389523,3121,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
115,900,1,3,,17389523,3121,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
116,902,1,2,,17389523,3121,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
117,912,1,2,,17389523,3121,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
118,921,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
119,923,1,2,,17389523,3121,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
120,924,1,2,,17389523,3121,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
121,925,1,2,,17389523,3121,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
122,926,1,2,,17389523,3121,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
123,938,1,2,,17389523,3121,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
124,946,1,2,,17389523,3121,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
125,947,1,2,,17389523,3121,Inconclusive,,,3.9811,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
126,948,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
127,955,1,2,,17389523,3121,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
128,960,1,2,,17389523,3121,Inconclusive,,,1.9953,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
129,961,1,2,,17389523,3121,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
130,962,1,2,,17389523,3121,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
131,963,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
132,964,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
133,965,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
134,966,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
135,967,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
136,968,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
137,969,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
138,970,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
139,971,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
140,972,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
141,973,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
142,974,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
143,975,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
144,976,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
145,977,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
146,978,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
147,979,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
148,980,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
149,981,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
150,982,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
151,983,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
152,984,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
153,985,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
154,986,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
155,987,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
156,988,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
157,989,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
158,993,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
159,994,1,2,,17389523,3121,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
160,995,1,2,,17389523,3121,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
161,1030,2,1,,17389523,3121,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
162,1195,1,2,,48416692,3121,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
163,1376,1,2,,49640649,3121,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
164,1385,2,2,,49640649,3121,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
165,1422,1,1,,49640649,3121,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
166,1452,1,1,,17389523,3121,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
167,1457,1,1,,17389523,3121,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
168,1458,1,1,,17389523,3121,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
169,1465,1,1,,49640649,3121,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
170,1469,1,1,,17389523,3121,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
171,1469,1,1,,26752920,3121,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
172,1469,1,1,,26752921,3121,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
173,1471,2,1,,17389523,3121,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
174,1476,2,1,,17389523,3121,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
175,1477,1,1,,17389523,3121,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
176,1478,2,1,,17389523,3121,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
177,1479,1,2,,17389523,3121,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
178,1479,1,2,,26752920,3121,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
179,1479,1,2,,26752921,3121,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
180,1487,1,1,,17389523,3121,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
181,1490,2,1,,17389523,3121,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
182,1511,1,3,,49640649,3121,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
183,1529,1,1,,49640649,3121,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
184,1530,1,1,,49640649,3121,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
185,1531,1,1,,49640649,3121,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
186,1532,1,1,,49640649,3121,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
187,1554,1,1,,49640649,3121,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
188,1621,1,2,,49640649,3121,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
189,1626,1,2,,49640649,3121,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
190,1662,1,2,,49640649,3121,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
191,1663,1,2,,49640649,3121,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
192,1672,1,3,,49640649,3121,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
193,1688,1,1,,17389523,3121,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
194,1766,1,1,,17389523,3121,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
195,1766,1,1,,17389523,3121,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
196,1768,1,1,,17389523,3121,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
197,1768,1,1,,17389523,3121,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
198,1813,1,2,,49640649,3121,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
199,1814,1,2,,49640649,3121,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
200,1832,2,1,,49640649,3121,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
201,1850,2,1,,49640649,3121,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
202,1863,2,1,,49640649,3121,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
203,1875,2,1,,49640649,3121,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
204,1885,2,1,,49640649,3121,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
205,1899,1,3,,49640649,3121,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
206,1903,2,3,,49640649,3121,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
207,1906,1,3,,49640649,3121,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
208,1910,1,2,,49640649,3121,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
209,1947,1,2,,49640649,3121,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
210,1948,1,1,,17389523,3121,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
211,1950,1,3,,49640649,3121,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
212,1956,1,1,,49640649,3121,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
213,1962,1,2,,49640649,3121,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
214,1974,1,2,,49640649,3121,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
215,1979,1,1,,49640649,3121,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
216,1987,1,2,,49640649,3121,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
217,2016,1,3,,49640649,3121,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
218,2023,1,3,,49640649,3121,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
219,2025,1,3,,49640649,3121,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
220,2029,1,3,,49640649,3121,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
221,2052,2,1,,49640649,3121,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
222,2057,1,2,,49640649,3121,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
223,2066,1,4,,49640649,3121,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
224,2094,1,2,,49640649,3121,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
225,2094,1,2,,49640649,3121,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
226,2094,1,2,,49640649,3121,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
227,2097,1,2,,49640649,3121,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
228,2098,1,1,,49640649,3121,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
229,2099,1,1,,49640649,3121,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
230,2101,1,1,,17389523,3121,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
231,2107,1,1,,17389523,3121,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
232,2112,1,1,,17389523,3121,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
233,2120,1,1,,17389523,3121,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
234,2129,1,2,,49640649,3121,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
235,2130,1,3,,49640649,3121,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
236,2156,2,2,,49640649,3121,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
237,2174,1,3,,49640649,3121,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
238,2177,1,3,,49640649,3121,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
239,2216,1,3,,49640649,3121,Inconclusive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
240,2221,1,2,,49640649,3121,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
241,2227,1,2,,49640649,3121,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
242,2234,1,2,,49640649,3121,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
243,2235,1,2,,49640649,3121,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
244,2237,1,2,,49640649,3121,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
245,2239,1,2,,49640649,3121,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
246,2247,1,2,,49640649,3121,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
247,2280,2,3,,49640649,3121,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
248,2300,1,3,,49640649,3121,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
249,2380,1,2,,49640649,3121,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
250,2391,1,1,,49640649,3121,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
251,2435,1,2,,49640649,3121,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
252,2445,1,2,,49640649,3121,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
253,2462,1,1,,49640649,3121,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
254,2462,1,1,,49640649,3121,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
255,2517,2,1,,17389523,3121,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
256,2520,1,4,,49640649,3121,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
257,2521,1,3,,49640649,3121,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
258,2524,1,2,,49640649,3121,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
259,2528,1,2,,17389523,3121,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
260,2540,1,2,,49640649,3121,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
261,2544,1,2,,49640649,3121,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
262,2546,1,1,,17389523,3121,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
263,2549,1,1,,17389523,3121,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
264,2550,1,3,,49640649,3121,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
265,2551,1,1,,17389523,3121,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
266,2553,1,2,,49640649,3121,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
267,2557,1,3,,49640649,3121,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
268,2563,1,1,,49640649,3121,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
269,2599,1,2,,49640649,3121,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
270,2606,1,2,,49640649,3121,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
271,2629,1,1,,49640649,3121,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
272,2642,1,2,,49640649,3121,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
273,2648,1,2,,49640649,3121,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
274,2650,2,1,,49640649,3121,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
275,2661,1,1,,49640649,3121,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
276,2662,2,1,,17389523,3121,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
277,2690,1,2,,49640649,3121,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
278,2716,1,1,,49640649,3121,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
279,2717,1,2,,49640649,3121,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
280,2718,1,1,,49640649,3121,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
281,2751,2,2,,49640649,3121,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
282,2796,1,4,,49640649,3121,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
283,2797,1,2,,49640649,3121,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
284,2805,2,2,,49640649,3121,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
285,2806,2,2,,49640649,3121,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
286,2825,1,2,,49640649,3121,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
287,19690,3,3,,103177883,3121,Unspecified,,,,,Partition coefficient (logP),Other,7650693.0,
288,22950,3,3,,103177883,3121,Unspecified,,,,,Time of peak effect (TPE) for activity,Other,1992141.0,
289,22951,3,3,,103177883,3121,Unspecified,,,,,Time of peak effect (TPE) for toxicity,Other,1992141.0,
290,27167,3,4,,103177883,3121,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
291,28625,3,4,,103177883,3121,Inconclusive,,,,,Relative lipophilicity of the compound; ND is no data,Other,2909750.0,
292,28681,3,4,,103177883,3121,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
293,29307,3,4,,103177883,3121,Unspecified,,,,,Neurotoxic dose (TD50) in mice using the rotarod test,Other,1875341.0,
294,29359,3,3,,103177883,3121,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
295,29811,4,3,,103177883,3121,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
296,47015,3,3,,103177883,3121,Unspecified,,,,,Dose elevating electroshock induced seizure by 20% in CF1 mice after ip administration.,Other,1495012.0,
297,47016,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered intraperitoneally in CF1 mice is the ability to protect the mice from MES(maximal electroshock seizure).,Other,1495012.0,
298,47018,6,2,,103177883,3121,Unspecified,,,,,Dose protecting 50% of the mice from tonic hind limb extension at the time of peak convulsant effect after ip administration.,Other,1495012.0,
299,47021,3,3,,103177883,3121,Unspecified,,,,,Dose producing neurotoxic effects in 50% of the CF1 mice after intraperitoneal administration.,Other,1495012.0,
300,47022,3,4,,103177883,3121,Unspecified,,,,,Dose showing neurotoxicity in 50% of the at the time of peak neurotoxic effect in CF1 MICE after ip administration.,Other,1495012.0,
301,47024,5,1,,103177883,3121,Unspecified,,,,,Time of peak anticonvulsant effect in CF1 MICE after ip administration.,Other,1495012.0,
302,47026,3,3,,103177883,3121,Unspecified,,,,,Time of peak anticonvulsant effect in CF1 mice,Other,1495012.0,
303,47027,5,1,,103177883,3121,Unspecified,,,,,Time of peak neurotoxic effect in CF1 MICE after ip administration.,Other,1495012.0,
304,47029,3,3,,103177883,3121,Unspecified,,,,,Time of peak neurotoxic effect in CF1 mice,Other,1495012.0,
305,50620,6,2,,103177883,3121,Unspecified,,,,,Compound was evaluated for effective dose by subcutaneous pentylenetetrazole test after intraperitoneal administration of the compound.,Other,1992141.0,
306,51429,3,3,,103177883,3121,Unspecified,,,,,Compound was evaluated for toxic dose at peak neurologic deficit after intraperitoneal administration of the compound.,Other,1992141.0,
307,52381,7,2,,103177883,3121,Unspecified,,,,,Oral dose protecting 50% of the mice from electroshock induced seizures.,Other,1495012.0,
308,53026,6,2,,103177883,3121,Unspecified,,,,,Compound was evaluated for effective dose by maximal electroshock test after intraperitoneal administration of the compound.,Other,1992141.0,
309,73513,3,8,,103177883,3121,Active,,,,,Compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase; Active,Other,11086726.0,
310,109717,4,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity after intraperitoneal injection into mice by using MES screen test after 0.25 hr,Other,8831764.0,
311,109720,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity after intraperitoneal injection into mice by using scPTZ screen after 0.5 hr,Other,8831764.0,
312,110434,7,1,,103177883,3121,Unspecified,,,,,Brain concentration after 15 min of administration,Other,7650693.0,
313,112157,6,2,,103177883,3121,Unspecified,,,,,Effective dose required to prevent tonic extension of the hind limbs in mice in the maximal electroshock seizures (MES) test when administered intraperitoneally,Other,7799408.0,
314,112175,6,2,,103177883,3121,Unspecified,,,,,Effective dose was evaluated for its anticonvulsant activity against subcutaneous induced metrazole convulsions in mice; activity value ranges from 122.64-177.02,Other,4032429.0,
315,112295,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity after intraperitoneal injection into mice by using scPTZ screen test after 0.25 hr,Other,8831764.0,
316,112301,5,3,,103177883,3121,Unspecified,,,,,"Compound was tested for anticonvulsant activity in male mice by pentylenetetrazole (80 mg/kg, sc) induced seizure test.",Other,,
317,112303,5,3,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity in male mice using maximal electric shock seizure test.,Other,,
318,112306,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity in maximal electroshock seizure(MES) test after 3 hours upon intraperitoneal administration to mice at a dose of 750 mg/kg,Other,9438018.0,
319,112364,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against mice after intraperitoneal administration,Other,7650693.0,
320,112452,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity in maximal electroshock seizure(MES) test after 30 min upon intraperitoneal administration to mice at a dose of 750 mg/kg,Other,9438018.0,
321,112455,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant potency using the 3-MPA (3-mercaptopropionic acid) test in mice upon peroral administration,Other,9484507.0,
322,112456,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant potency using the maximal electroshock test in mice,Other,9484507.0,
323,112459,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant potency using the PTX (picrotoxin) test in mice by peroral administration,Other,9484507.0,
324,112460,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant potency using the STRY (strychnine) test in mice upon peroral administration,Other,9484507.0,
325,112461,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant potency using the intravenous-BIC (bicuculline) test in mice,Other,9484507.0,
326,113153,7,2,,103177883,3121,Unspecified,,,,,Concentration required to prevent seizures upon intraperitoneal administration in mice in MES (maximal electroshock seizure) test.,Other,1875341.0,
327,113449,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against audiogenic seizures in DBA/2 mice,Other,2909750.0,
328,113699,6,2,,103177883,3121,Unspecified,,,,,Inhibition of seizures induced in mice by a convulsant dose of bicuculline through ip administration,Other,8691481.0,
329,113702,6,2,,103177883,3121,Unspecified,,,,,Inhibition of picrotoxin-induced seizures in mice by ip administration,Other,8691481.0,
330,113706,6,2,,103177883,3121,Unspecified,,,,,Inhibition of seizures induced in mice by a convulsant dose of strychnine through ip administration,Other,8691481.0,
331,113777,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity expressed as dose at which 50% of the mice were protected from clonic seizures induced by pentylenetetrazole (85 mg/Kg),Other,9016327.0,
332,113779,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity expressed as dose at which 50% of the mice were protected from tonic hindlimb seizures induced by maximal electroshock (MES),Other,9016327.0,
333,113782,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in mice against pentylenetetrazole (PTZ) induced clonic seizures,Other,8627613.0,
334,113858,7,2,,103177883,3121,Unspecified,,,,,Effective dose against maximal electroshock seizure in mice after intraperitoneal administration,Other,8627614.0,
335,113881,7,2,,103177883,3121,Unspecified,,,,,In vivo anticonvulsant activity determined as potency that blocked NMDA-induced clonic seizures induced in DBA/2 mice,Other,12825948.0,
336,113882,7,2,,103177883,3121,Unspecified,,,,,In vivo anticonvulsant activity determined as potency that blocked NMDA-induced tonic seizures induced in DBA/2 mice,Other,12825948.0,
337,113883,7,2,,103177883,3121,Unspecified,,,,,In vivo anticonvulsant activity determined as potency that blocked clonic seizures induced by audiogenic stimuli in DBA/2 mice after pretreatment with D-serine,Other,12825948.0,
338,113884,7,2,,103177883,3121,Unspecified,,,,,In vivo anticonvulsant activity determined as potency that blocked clonic seizures induced in DBA/2 mice by audiogenic stimuli,Other,12825948.0,
339,113885,7,2,,103177883,3121,Unspecified,,,,,In vivo anticonvulsant activity determined as potency that blocked tonic seizures induced by audiogenic stimuli in DBA/2 mice after pretreatment with D-serine,Other,12825948.0,
340,113886,7,2,,103177883,3121,Unspecified,,,,,In vivo anticonvulsant activity determined as potency that blocked tonic seizures induced in DBA/2 mice by audiogenic stimuli,Other,12825948.0,
341,113901,6,2,,103177883,3121,Unspecified,,,,,Median Effective dose was evaluated by Maximal electroshock seizure (MES) test in mice by oral administration,Other,8691481.0,
342,113903,6,2,,103177883,3121,Unspecified,,,,,Median Effective dose was evaluated by Subcutaneous pentylenetetrazole seizure test in mice by oral administration,Other,8691481.0,
343,113905,6,2,,103177883,3121,Unspecified,,,,,Median effective dose was evaluated by Maximal electroshock seizure test through intraperitoneal administration,Other,8691481.0,
344,113907,6,2,,103177883,3121,Unspecified,,,,,Median effective dose was evaluated by subcutaneous pentylenetetrazole seizure test through intraperitoneal administration,Other,8691481.0,
345,113971,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase II Pharmacological Evaluation),Other,3820228.0,
346,113973,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase IV Pharmacological Evaluation),Other,3820228.0,
347,113976,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions (sc MET)(Phase V Pharmacological Evaluation),Other,3820228.0,
348,113977,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase II Pharmacological Evaluation),Other,3820228.0,
349,113979,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase IV Pharmacological Evaluation),Other,3820228.0,
350,113983,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous bicuculline test (CD97=2.70 mg/kg) (Phase V Pharmacological Evaluation),Other,3820228.0,
351,113986,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous picrotoxin test (CD97=3.15 mg/kg) (Phase V Pharmacological Evaluation),Other,3820228.0,
352,113987,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was determined subcutaneous strychnine test (CD97=1.20 mg/kg) (Phase V Pharmacological Evaluation),Other,3820228.0,
353,114000,6,2,,103177883,3121,Unspecified,,,,,Effective dose evaluated against maximal electric seizures (MES) or convulsions in mice; activity value ranges from 246.97-337.89,Other,4032429.0,
354,114049,6,2,,103177883,3121,Unspecified,,,,,Neurological deficit (Loss of coordination) was measured in the mice using rotarod test when administered intraperitoneally,Other,7265133.0,
355,114116,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was evaluated by maximal electroshock induced convulsion test after subcutaneous administration,Other,6694169.0,
356,114118,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was evaluated by metrazole-induced convulsion test after subcutaneous administration,Other,6694169.0,
357,114120,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was measured by the ability to prevent maximal electroshock seizure in mice when administered intraperitoneally,Other,7265133.0,
358,114420,3,3,,103177883,3121,Unspecified,,,,,Median hypnotic dose was evaluated by loss of righting reflex,Other,8691481.0,
359,114484,6,2,,103177883,3121,Unspecified,,,,,Compound for anticonvulsant activity against maximal electroshock (MES)-induced seizures in mice after administration,Other,3735320.0,
360,114485,6,2,,103177883,3121,Unspecified,,,,,Compound for anticonvulsant activity against subcutaneous pentylenetetrazole-induced convulsions in mice after administration,Other,3735320.0,
361,114835,6,2,,103177883,3121,Unspecified,,,,,Effective dose required for antagonist activity against 3-mercaptopropionic-acid induced seizures in mice when administered intraperitoneally,Other,8289185.0,
362,114839,6,2,,103177883,3121,Unspecified,,,,,Effective dose required for antagonist activity against maximal electroshock induced seizures in mice when administered intraperitoneally,Other,8289185.0,
363,114845,6,2,,103177883,3121,Unspecified,,,,,Effective dose required for antagonist activity against pentylenetetrazole-induced seizures in mice when administered intraperitoneally; Range is 100-200,Other,8289185.0,
364,114848,6,2,,103177883,3121,Unspecified,,,,,Effective dose required for antagonist activity against strychnine induced seizures in mice when administered intraperitoneally,Other,8289185.0,
365,116877,6,2,,103177883,3121,Unspecified,,,,,Acute toxicity of was measured in rat by ip administration when administered intraperitoneally,Other,7265133.0,
366,117224,6,2,,103177883,3121,Unspecified,,,,,Median lethal dose was evaluated by mortality after 24 hr through ip injection administration,Other,8691481.0,
367,117857,3,3,,103177883,3121,Unspecified,,,,,Protective index between TD50/MES ED50 when administered intraperitoneally to mouse,Other,8627614.0,
368,121845,3,4,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was evaluated by rotarod toxicity test after subcutaneous administration.,Other,6694169.0,
369,121848,3,4,,103177883,3121,Unspecified,,,,,Compound for toxicity by rotarod assay method in mice after administration,Other,3735320.0,
370,121852,3,3,,103177883,3121,Unspecified,,,,,Compound was tested for toxicity after intraperitoneal injection into mice by using neurotoxicity screen test after 0.25 hr,Other,8831764.0,
371,121858,3,4,,103177883,3121,Unspecified,,,,,Median Effective dose was evaluated by Neurologic toxicity (rotarod test) in mice by oral administration,Other,8691481.0,
372,121859,3,4,,103177883,3121,Unspecified,,,,,Median neurologically impairing dose was determined in mice using the rotarod test,Other,7799408.0,
373,121861,3,3,,103177883,3121,Unspecified,,,,,Median toxic dose was evaluated by Maximal electroshock seizure test and subcutaneous pentylenetetrazole seizure test through intraperitoneal administration,Other,8691481.0,
374,121863,3,4,,103177883,3121,Unspecified,,,,,Neurologic toxicity activity was determined by rotarod toxicity test (Phase II Pharmacological Evaluation),Other,3820228.0,
375,121864,3,4,,103177883,3121,Unspecified,,,,,Neurologic toxicity activity was determined by rotarod toxicity test (Phase IV Pharmacological Evaluation),Other,3820228.0,
376,121999,3,4,,103177883,3121,Unspecified,,,,,Neurotoxic toxicity in mice was evaluated by rotarod test after intraperitoneal administration,Other,8627614.0,
377,122021,3,4,,103177883,3121,Unspecified,,,,,Toxic dose was determined by the rotarod test in mice; activity value ranges from 368.91-450.40,Other,4032429.0,
378,122341,3,3,,103177883,3121,Unspecified,,,,,Time to peak activity was evaluated by Maximal electroshock seizure test in hours,Other,8691481.0,
379,122455,3,3,,103177883,3121,Unspecified,,,,,Time to peak effect in mice was evaluated by Maximal electroshock seizure (MES) test in hours by oral administration,Other,8691481.0,
380,122456,3,4,,103177883,3121,Unspecified,,,,,Time to peak effect in mice was evaluated by Neurologic toxicity (rotarod test) in hours by oral administration,Other,8691481.0,
381,122458,3,3,,103177883,3121,Unspecified,,,,,Time to peak effect in mice was evaluated by Subcutaneous pentylenetetrazole seizure test in hours by oral administration,Other,8691481.0,
382,122459,3,3,,103177883,3121,Unspecified,,,,,Time to peak toxicity was evaluated by Maximal electroshock seizure test in hours,Other,8691481.0,
383,128037,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity against bicuculline-induced clonic seizures in mice at 2.7 mg/kg sc,Other,1681105.0,
384,128038,6,2,,103177883,3121,Unspecified,,,,,"Compound was tested for anticonvulsant activity against maximal electroshock-induced clonic seizures in mice at 50mA, 200 ms",Other,1681105.0,
385,128040,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity against pentylenetetrazole-induced clonic seizures in mice at 80 mg/kg sc,Other,1681105.0,
386,128044,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against picrotoxin-induced clonic seizures in mice at 3.2 mg/kg sc,Other,1681105.0,
387,128174,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in mouse maximal electroshock seizure test following i.p. administration.,Other,9171868.0,
388,128694,5,1,,103177883,3121,Unspecified,,,,,Time of peak effect activity against maximal electroshock induced seizures,Other,2308142.0,
389,129015,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity by using bicuculline test in mice,Other,2724304.0,
390,129017,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity by using maximal electroshock seizure test in mice,Other,2724304.0,
391,129018,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity by using subcutaneous pentylenetetrazole (Metrazol) seizure threshold test in mice,Other,2724304.0,
392,129171,6,2,,103177883,3121,Unspecified,,,,,"Anticonvulsant activity in mice, measured by subcutaneous pentylenetetrazole seizure (scMet) test.",Other,3336019.0,
393,129174,6,2,,103177883,3121,Unspecified,,,,,"Anticonvulsant activity in mice, measured by maximal electroshock seizure (MES) test.",Other,3336019.0,
394,131201,6,2,,103177883,3121,Unspecified,,,,,Concentration required to inhibit seizures was determined in MES test after (ip) administration in mice,Other,2308141.0,
395,131412,6,2,,103177883,3121,Unspecified,,,,,Phase II qualification against administered subcutaneously was reported,Other,3920394.0,
396,131414,6,2,,103177883,3121,Unspecified,,,,,Phase V qualification against antipicrotoxin activity administered subcutaneously at 3.2 mg/kg,Other,3920394.0,
397,131776,6,2,,103177883,3121,Unspecified,,,,,Tested for inhibition of 3-mercaptopropanoic acid induced seizures in mice.,Other,2170646.0,
398,131910,6,2,,103177883,3121,Unspecified,,,,,Tested for inhibition of bicuculline induced seizures in mice.,Other,2170646.0,
399,131913,6,2,,103177883,3121,Unspecified,,,,,Tested for inhibition of maximal electroshock -induced seizures in mice.,Other,2170646.0,
400,131926,6,2,,103177883,3121,Unspecified,,,,,Tested for inhibition of pentylenetetrazole induced seizures in mice; Value ranges from 100-200,Other,2170646.0,
401,131927,6,2,,103177883,3121,Unspecified,,,,,Tested for inhibition of quinoline-induced seizures in mice.,Other,2170646.0,
402,131932,6,2,,103177883,3121,Unspecified,,,,,Tested for inhibition of strychnine-induced seizures in mice.,Other,2170646.0,
403,131995,3,3,,103177883,3121,Unspecified,,,,,Median hypnotic dose by loss of righting reflex,Other,2308142.0,
404,132226,7,2,,103177883,3121,Unspecified,,,,,Effective dose required for maximal electroshock (MES)-induced seizures in mice.,Other,8230125.0,
405,132405,6,2,,103177883,3121,Unspecified,,,,,Evaluated against Maximal electroshock seizure test in mice after ip administration,Other,11311072.0,
406,132406,6,2,,103177883,3121,Unspecified,,,,,Evaluated against Maximal electroshock seizure test in rat after po administration,Other,11311072.0,
407,132470,6,2,,103177883,3121,Unspecified,,,,,The compound was tested for anticonvulsant activity against (subcutaneous administered) Metrazol induced seizures after intraperitoneal administration,Other,2308142.0,
408,132472,6,2,,103177883,3121,Unspecified,,,,,The compound was tested for anticonvulsant activity against (subcutaneous administered) bicuculline induced seizures after intraperitoneal administration,Other,2308142.0,
409,132474,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against subcutaneous picrotoxin induced seizures after intraperitoneal administration,Other,2308142.0,
410,132475,6,2,,103177883,3121,Unspecified,,,,,The compound was tested for anticonvulsant activity against (subcutaneous administered) strychnine induced seizures after intraperitoneal administration,Other,2308142.0,
411,132637,6,2,,103177883,3121,Unspecified,,,,,The compound was tested to inhibit 50% of induced maximal electroshock seizure in mice on ip administration.,Other,9544213.0,
412,132639,6,2,,103177883,3121,Unspecified,,,,,Inhibition of s.c. pentylenetetrazole induced seizure in mice following i.p. administration.,Other,9544213.0,
413,132645,6,2,,103177883,3121,Unspecified,,,,,The effective dose of compound was tested against maximal electroshock induced seizures after intraperitoneal administration,Other,2308142.0,
414,132648,6,2,,103177883,3121,Unspecified,,,,,The effective dose of compound was tested against maximal electroshock induced seizures after oral administration in mice,Other,2308142.0,
415,132650,6,2,,103177883,3121,Unspecified,,,,,The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures after intraperitoneal administration,Other,2308142.0,
416,132653,6,2,,103177883,3121,Unspecified,,,,,The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures in mice,Other,2308142.0,
417,134732,6,2,,103177883,3121,Unspecified,,,,,Median lethal dose was measured after 24 hr,Other,2308142.0,
418,136087,3,4,,103177883,3121,Unspecified,,,,,Anticonvulsant activity by using rotarod toxicity test in mice,Other,2724304.0,
419,136102,3,4,,103177883,3121,Unspecified,,,,,Evaluated against neurological toxicity determined from the rotarod test in mice after ip administration,Other,11311072.0,
420,136257,3,4,,103177883,3121,Unspecified,,,,,Neurologic toxicity determined using rotarod test in mice,Other,8230125.0,
421,136258,3,4,,103177883,3121,Unspecified,,,,,Neurological deficit in mouse measured by rotarod test,Other,3336019.0,
422,136259,3,3,,103177883,3121,Unspecified,,,,,Neurological toxicity was determined using horizontal screen test in mice after intraperitoneal administration,Other,2308141.0,
423,136262,3,4,,103177883,3121,Unspecified,,,,,Neurotoxicity against mice in rotarod test,Other,1681105.0,
424,136269,3,3,,103177883,3121,Unspecified,,,,,Phase II qualification against neurotoxicity administered subcutaneously was reported,Other,3920394.0,
425,136271,3,3,,103177883,3121,Unspecified,,,,,Phase V qualification against neurotoxicity administered subcutaneously at a dose (3.2 mg/kg) was reported.,Other,3920394.0,
426,136279,3,3,,103177883,3121,Unspecified,,,,,The cytotoxicity after intraperitoneal administration,Other,2308142.0,
427,136280,3,3,,103177883,3121,Unspecified,,,,,The cytotoxicity after intraperitoneal administration in mice,Other,2308142.0,
428,136515,3,3,,103177883,3121,Unspecified,,,,,Latency to the onset of generalized clonic epileptic seizures by picrotoxin was measured and evaluated as a percent of the control in mice.,Other,1847429.0,
429,136516,3,3,,103177883,3121,Unspecified,,,,,Latency to the protection against lethality by picrotoxin was measured and evaluated as a percent of the control in mice.,Other,1847429.0,
430,139746,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against Bicucullin (3.75 mg/kg) induced clonic seizure at dose 360 mg/kg subcutaneously at pretreatment time of 15 min.,Other,3920394.0,
431,139747,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against Bicucullin (3.75 mg/kg) induced clonic seizure at dose 400 mg/kg subcutaneously at pretreatment time of 15 min.,Other,3920394.0,
432,139752,4,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against Bicucullin (3.75 mg/kg) induced death at dose 400 mg/kg subcutaneously at pretreatment time of 15 min.,Other,3920394.0,
433,139757,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against Bicucullin (3.75 mg/kg) induced tonic seizure at dose 360 mg/kg subcutaneously at pretreatment time of 15 min.,Other,3920394.0,
434,139885,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against Bicucullin (3.75 mg/kg) induced tonic seizure at dose 400 mg/kg subcutaneously at pretreatment time of 15 min.,Other,3920394.0,
435,139887,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against picrotoxin (4.0 mg/kg) induced clonic seizures at 400 mg/kg subcutaneous dose 15 min pretreatment,Other,3920394.0,
436,140326,5,1,,103177883,3121,Unspecified,,,,,Time of peak effect toxicity against maximal electroshock induced seizures,Other,2308142.0,
437,167920,3,3,,103177883,3121,Inconclusive,,,,,Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 4 hr; Compound was not screened,Other,8831764.0,
438,170147,3,3,,103177883,3121,Active,,,,,Compound was evaluated for the anticonvulsant activity in amygdala kindled rats; Active,Other,11086726.0,
439,170484,3,3,,103177883,3121,Inconclusive,,,,,Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 0.25 hr; Compound was not screened,Other,8831764.0,
440,170612,3,3,,103177883,3121,Inconclusive,,,,,Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 0.5 hr; Compound was not screened,Other,8831764.0,
441,170623,3,3,,103177883,3121,Inconclusive,,,,,Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 1 hr; Compound was not screened,Other,8831764.0,
442,170633,3,3,,103177883,3121,Inconclusive,,,,,Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 2 hr; Compound was not screened,Other,8831764.0,
443,175114,3,3,,103177883,3121,Unspecified,,,,,Acute toxicity of was measured in rat by po administration when administered intraperitoneally,Other,7265133.0,
444,175132,3,3,,103177883,3121,Unspecified,,,,,Peak time of anticonvulsant activity against MES was determined,Other,7265133.0,
445,176277,6,2,,103177883,3121,Unspecified,,,,,Median Effective dose was evaluated by Maximal electroshock seizure (MES) test in Rats by oral administration,Other,8691481.0,
446,176278,6,2,,103177883,3121,Unspecified,,,,,Median Effective dose was evaluated by Subcutaneous pentylenetetrazole seizure test in Rats by oral administration,Other,8691481.0,
447,178167,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity after Oral Administration into rat by using MES screen test after 0.5 hr,Other,8831764.0,
448,178176,6,2,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity by maximal electroshock seizure(MES) test in rat upon intraperitoneal administration,Other,9171868.0,
449,178280,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against maximal electroshock seizures(MES) in rats,Other,2909750.0,
450,178301,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was measured by the ability to prevent maximal electroshock seizure in rat when administered intraperitoneally,Other,7265133.0,
451,178303,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity was measured by the ability to prevent intraperitoneally,Other,7265133.0,
452,178377,6,2,,103177883,3121,Unspecified,,,,,Effective dose against maximal electroshock seizure in rat after oral administration,Other,8627614.0,
453,179593,6,2,,103177883,3121,Unspecified,,,50.0,IC50,In vitro inhibition of [3H]GABA uptake in rat Hippocampal slices.,Confirmatory,1433224.0,
454,180530,6,2,,103177883,3121,Unspecified,,,,,The compound was tested for the effective oral dose to inhibit 50% of the anticonvulsant in rats.,Other,9544213.0,
455,180905,6,2,,103177883,3121,Unspecified,,,,,The effective dose of compound was tested against maximal electroshock induced seizures after oral administration in rat,Other,2308142.0,
456,180907,6,2,,103177883,3121,Unspecified,,,,,The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures in rat.,Other,2308142.0,
457,184612,6,2,,103177883,3121,Unspecified,,,,,Acute toxicity of was measured in rat by ip administration when administered intraperitoneally,Other,7265133.0,
458,189456,3,3,,103177883,3121,Unspecified,,,,,Protective index between TD50/MES ED50 when administered orally to rat,Other,8627614.0,
459,189459,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) was determined against MES induced seizure in rat.,Other,8691481.0,
460,189460,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) was determined against scMet induced seizure in rat.,Other,8691481.0,
461,190107,3,3,,103177883,3121,Unspecified,,,,,Compound was tested for toxicity after oral administration in rat by using neurotoxicity screen test after 0.5 hr,Other,8831764.0,
462,190114,3,4,,103177883,3121,Unspecified,,,,,Median Effective dose was evaluated by Neurologic toxicity (rotarod test) in Rats by oral administration,Other,8691481.0,
463,190116,3,3,,103177883,3121,Unspecified,,,,,Minimal motor impairment was measured in rat by rotating rod test upon intraperitoneal administration,Other,9171868.0,
464,190119,3,4,,103177883,3121,Unspecified,,,,,Neurotoxic toxicity against Rat was evaluated by rotarod test afte oral administration,Other,8627614.0,
465,190127,3,3,,103177883,3121,Unspecified,,,,,Oral dose producing neurotoxic (based on ataxia) effects in 50% of rats,Other,1495012.0,
466,190132,3,3,,103177883,3121,Unspecified,,,,,The cytotoxicity after intraperitoneal administration in rat,Other,2308142.0,
467,190294,3,3,,103177883,3121,Unspecified,,,,,Time to peak effect in Rats was evaluated by Maximal electroshock seizure (MES) test in hours by oral administration,Other,8691481.0,
468,190295,3,4,,103177883,3121,Unspecified,,,,,Time to peak effect in Rats was evaluated by Neurologic toxicity (rotarod test) in hours by oral administration,Other,8691481.0,
469,190296,3,3,,103177883,3121,Unspecified,,,,,Time to peak effect in Rats was evaluated by Subcutaneous pentylenetetrazole seizure test in hours by oral administration,Other,8691481.0,
470,208983,3,8,,103177883,3121,Active,,,,,Compound was tested for the inhibition of succinic semialdehyde dehydrogenase; Active,Other,11086726.0,
471,212187,3,6,,103177883,3121,Unspecified,,,,,"Compound was tested for anticonvulsant activity in male mice by pentylenetetrazole (80 mg/kg, sc) induced seizure test.; Protective index = TD50/ED50",Other,,
472,212189,3,4,,103177883,3121,Unspecified,,,,,Compound was tested for anticonvulsant activity in male mice using maximal electric shock seizure test; Protective index = TD50/ED50,Other,,
473,212210,3,5,,103177883,3121,Unspecified,,,,,Compound was tested for neurotoxic activity in male mice using rotarod test.,Other,,
474,212211,3,4,,103177883,3121,Unspecified,,,,,Toxicity using neurological impairment measured by rotarod test in mice,Other,9484507.0,
475,212214,3,3,,103177883,3121,Unspecified,,,,,Minimal motor impairment was measured in mouse by rotating rod test upon intraperitoneal administration,Other,9171868.0,
476,212342,3,4,,103177883,3121,Unspecified,,,,,Neurotoxicity was evaluated by a rotarod test,Other,9016327.0,
477,212343,3,4,,103177883,3121,Unspecified,,,,,The compound was determined for the dose (mg/kg) by rotarod test at the time of peak neurotoxic effect in mice on ip administration.,Other,9544213.0,
478,212544,3,3,,103177883,3121,Unspecified,,,,,The compound was tested for the toxic dose on oral administration.,Other,9544213.0,
479,221080,4,4,,103177883,3121,Unspecified,,,,,Neurologic toxicity using rotarod test in mice after intraperitoneal administration,Other,12361404.0,
480,221081,3,3,,103177883,3121,Unspecified,,,,,Therapeutic dosage was measured by ip administration in mice,Other,8246220.0,
481,221087,5,1,,103177883,3121,Unspecified,,,,,Time of peak effect of activity of compound was measured by both MES and sc Met test in mice,Other,8246220.0,
482,221089,3,3,,103177883,3121,Unspecified,,,,,Time of peak effect of toxicity of compound was measured by both MES and sc Met test in mice,Other,8246220.0,
483,222384,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) value in MES test in mice,Other,8246220.0,
484,222385,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) value in scMET test in mice,Other,8246220.0,
485,223109,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity using MES test in mice after intraperitoneal administration,Other,12361404.0,
486,223434,6,2,,103177883,3121,Unspecified,,,,,Effective dose was measured in mouse by maximal electroshock method by ip administration,Other,8246220.0,
487,223437,6,2,,103177883,3121,Unspecified,,,,,Effective dose was measured in mouse by subcutaneous pentylenetetrazole method by ip administration,Other,8246220.0,
488,223724,4,4,,103177883,3121,Unspecified,,,,,Neurologic toxicity using rotarod test in rat after oral administration,Other,12361404.0,
489,224802,3,4,,103177883,3121,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 0 mg/Kg of compound,Other,1495012.0,
490,224803,3,4,,103177883,3121,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 100 mg/Kg of compound,Other,1495012.0,
491,224805,3,4,,103177883,3121,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 150 mg/Kg of compound,Other,1495012.0,
492,224807,3,4,,103177883,3121,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 200 mg/Kg of compound,Other,1495012.0,
493,224809,3,4,,103177883,3121,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 250 mg/Kg of compound,Other,1495012.0,
494,224841,3,3,,103177883,3121,Unspecified,,,,,Onset for sleeping time after administration in mice induced by sodium pentobarbital,Other,1847429.0,
495,224876,3,4,,103177883,3121,Unspecified,,,,,Sleeping time in mice after administration in mice induced by sodium pentobarbital,Other,1847429.0,
496,225116,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity using MES test in rat after oral administration,Other,12361404.0,
497,225154,6,3,,103177883,3121,Unspecified,,,,,Dose reducing the seizure severity in rat cornea 0.5 hr after peroral administration.,Other,1495012.0,
498,225269,6,3,,103177883,3121,Unspecified,,,,,Dose reducing the seizure severity in rat cornea 1 hr after peroral administration.,Other,1495012.0,
499,226508,3,3,,103177883,3121,Unspecified,,,,,Protection index = TD50/ED50,Other,8831764.0,
500,226509,4,3,,103177883,3121,Unspecified,,,,,Protection index = TD50/ED50 (MES),Other,8831764.0,
501,226511,3,3,,103177883,3121,Unspecified,,,,,Protective Index (PI) determined as the ratio of toxic dose (TD50) and effective dose (ED50 (MES)),Other,9016327.0,
502,226512,3,3,,103177883,3121,Unspecified,,,,,Protective Index (PI) determined as the ratio of toxic dose (TD50) and effective dose (ED50 (PTZ)),Other,9016327.0,
503,226513,3,3,,103177883,3121,Unspecified,,,,,Protective Index was determined using the ratio of TD50/ED50 value,Other,7799408.0,
504,226521,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50),Other,8230125.0,
505,226522,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) value of the compound,Other,11311072.0,
506,226533,4,3,,103177883,3121,Unspecified,,,,,Protective index measured as the ratio between TD50 and ED50,Other,3735320.0,
507,226534,3,3,,103177883,3121,Unspecified,,,,,Protective index as the ratio of TD50 value against MES to that of ED50 value against MES.,Other,4032429.0,
508,226535,3,3,,103177883,3121,Unspecified,,,,,Protective index as the ratio of TD50 value against scMET to that of ED50 value against scMET.,Other,4032429.0,
509,226538,3,3,,103177883,3121,Unspecified,,,,,Protective index as the ratio of TD50 value to that of ED50 value in mice.,Other,12361404.0,
510,226539,3,4,,103177883,3121,Unspecified,,,,,Protective index as the ratio of TD50 value to that of ED50 value in rat.,Other,12361404.0,
511,226542,3,3,,103177883,3121,Unspecified,,,,,Protective index value is the ratio between ED50 and TD50,Other,9544213.0,
512,226543,4,3,,103177883,3121,Unspecified,,,,,Protective index value is the ratio between TD50 and ED50 values.,Other,9544213.0,
513,226700,3,3,,103177883,3121,Unspecified,,,,,Protective index was measured as TD50/ED50,Other,1495012.0,
514,226701,3,3,,103177883,3121,Unspecified,,,,,Protective index was measured as TD50/ED50 in rat on oral administration,Other,1495012.0,
515,226702,3,3,,103177883,3121,Unspecified,,,,,Protective index was measured as TD50/MES ED50 in mice on ip administration,Other,1495012.0,
516,226706,3,3,,103177883,3121,Unspecified,,,,,Protective index which is the ratio of TD50 to ED50 of against subcutaneous pentylenetetrazole test,Other,1992141.0,
517,226707,3,3,,103177883,3121,Unspecified,,,,,Protective index which is the ratio of TD50 to ED50 of in maximal electroshock test.,Other,1992141.0,
518,226708,3,3,,103177883,3121,Unspecified,,,,,"Protective index, measure of ratio of TD50 and ED50",Other,8627613.0,
519,226933,3,3,,103177883,3121,Unspecified,,,,,Protective index is the ratio of TD50 to that of ED50,Other,3920394.0,
520,226942,3,4,,103177883,3121,Unspecified,,,,,Protectivity index is the ratio of TD50 /MES ED50 from Phase-II evaluation,Other,3820228.0,
521,226943,3,4,,103177883,3121,Unspecified,,,,,Protectivity index is the ratio of TD50 /MES ED50 from Phase-IV evaluation,Other,3820228.0,
522,227295,3,3,,103177883,3121,Unspecified,,,,,Intraperitoneal dose (0 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
523,227296,3,3,,103177883,3121,Unspecified,,,,,Intraperitoneal dose (100 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
524,227298,3,3,,103177883,3121,Unspecified,,,,,Intraperitoneal dose (150 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
525,227300,3,3,,103177883,3121,Unspecified,,,,,Intraperitoneal dose (200 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
526,227302,3,3,,103177883,3121,Unspecified,,,,,Intraperitoneal dose (250 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
527,227699,3,3,,103177883,3121,Unspecified,,,,,Virtual screen for compounds with anticonvulsant activity,Other,12873507.0,
528,227718,7,1,,103177883,3121,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
529,230048,3,3,,103177883,3121,Unspecified,,,,,Ratio of LD50/HD50 was determined,Other,2308142.0,
530,231256,3,3,,103177883,3121,Unspecified,,,,,"Protective index (PI), anticonvulsant activity, ratio of TD50/ED50 value in maximal electroconvulsive shock seizure (MES) test",Other,3336019.0,
531,231257,3,3,,103177883,3121,Unspecified,,,,,"Protective index (PI),anticonvulsant activity, ratio of TD50/ED50 value in scMet test",Other,3336019.0,
532,231263,3,3,,103177883,3121,Unspecified,,,,,Protective index was calculated (TD50/ED50) in MES assay in mice after intraperitoneal administration,Other,2308142.0,
533,231424,3,3,,103177883,3121,Unspecified,,,,,Protective index was calculated (TD50/ED50) in MES assay in mice after oral administration,Other,2308142.0,
534,231425,3,3,,103177883,3121,Unspecified,,,,,Protective index was calculated (TD50/ED50) in MES assay in rat after oral administration,Other,2308142.0,
535,231426,3,3,,103177883,3121,Unspecified,,,,,Protective index was calculated (TD50/ED50) in scMET assay in mice after intraperitoneal administration,Other,2308142.0,
536,231427,3,3,,103177883,3121,Unspecified,,,,,Protective index was calculated (TD50/ED50) in scMET assay in mice after oral administration,Other,2308142.0,
537,231428,3,3,,103177883,3121,Unspecified,,,,,Protective index was calculated (TD50/ED50) in scMET assay in rat after oral administration,Other,2308142.0,
538,234828,3,3,,103177883,3121,Unspecified,,,,,Survival ratio was calculated for determination of dose dependency.,Other,1847429.0,
539,235019,3,3,,103177883,3121,Unspecified,,,,,Ratio of TD50/ED50; TI indicates Therapeutic index,Other,9171868.0,
540,237333,4,2,,103177883,3121,Unspecified,,,,,Calculated partition coefficient (clogP),Other,15294003.0,
541,243251,3,5,,103177883,3121,Unspecified,,,,,"Inhibitory activity against Glycogen synthase kinase-3 beta, expressed as percent control",Other,15482904.0,
542,243252,3,7,,103177883,3121,Unspecified,,,,,"Inhibitory activity against Glycogen synthase kinase-3 alpha, expressed as percent control",Other,15482904.0,
543,246902,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered orally to rat at subcutaneous metrazol test,Other,15294003.0,
544,246963,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered intra peritoneally to mouse at subcutaneous metrazol test,Other,15294003.0,
545,247080,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered orally to rat at maximal electro shock test; the interval in parenthesis stands for 95% confidence interval,Other,15294003.0,
546,247098,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered intra peritoneally to mouse at maximal electro shock test; the interval in parenthesis stands for 95% confidence interval,Other,15294003.0,
547,249458,4,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered orally to rat for the protective index of toxicity by maximal electroshock test; T D50/ED50,Other,15294003.0,
548,249468,4,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered intra peritoneally to mouse for the protective index of toxicity by maximal electroshock test; T D50/ED50,Other,15294003.0,
549,250473,3,3,,103177883,3121,Active,,,,,Anti-convulsant activity in experimental animal model; ++ = relative to valproate,Other,15482904.0,
550,250526,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered orally to rat for protective index of subcutaneous metrazol test,Other,15294003.0,
551,250806,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered intra peritoneally to mouse for protective index of subcutaneous metrazol test,Other,15294003.0,
552,253379,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered orally to rat for toxicity,Other,15294003.0,
553,253381,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity administered intra peritoneally to mouse for toxicity,Other,15294003.0,
554,255433,3,4,,103177883,3121,Unspecified,,,,,"Minimum dose required for anticonvulsant activity when given i.p., in mice upon neurotoxicity seizure using rotarod test",Other,16190747.0,
555,255438,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) produced by compound in mouse after MES test,Other,16139502.0,
556,255439,3,3,,103177883,3121,Unspecified,,,,,Protective index (TD50/ED50) produced by compound in mouse after ScMet test,Other,16139502.0,
557,255707,6,2,,103177883,3121,Unspecified,,,,,Neurotoxicity expressed as median toxic dose (TD50) produced after Rotorod ataxia test in mouse by i.p. administration (range 369-450),Other,16139502.0,
558,255733,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity of compound expressed in terms of median effective dose (ED50) produced after MES test in mouse by i.p. administration (range 247-338),Other,16139502.0,
559,255740,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity of compound expressed in terms of median effective dose (ED50) produced after ScMet test in mouse by i.p. administration (range 123-177),Other,16139502.0,
560,256406,3,3,,103177883,3121,Unspecified,,,,,"Minimum dose required for anticonvulsant activity when given i.p., in mice upon subcutaneous picrotoxin seizure",Other,16190747.0,
561,299641,3,5,,103177883,3121,Unspecified,2498443.0,3065.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
562,299641,3,5,,103177883,3121,Unspecified,3334210.0,8841.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
563,299641,3,5,,103177883,3121,Unspecified,19865267.0,9734.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
564,299641,3,5,,103177883,3121,Unspecified,26394832.0,79885.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
565,299641,3,5,,103177883,3121,Unspecified,27734403.0,83933.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
566,299641,3,5,,103177883,3121,Unspecified,29839394.0,55869.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
567,299641,3,5,,103177883,3121,Unspecified,30913097.0,51564.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
568,299641,3,5,,103177883,3121,Unspecified,68068066.0,3066.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
569,299641,3,5,,103177883,3121,Unspecified,205371758.0,10013.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
570,299641,3,5,,103177883,3121,Unspecified,259016348.0,9759.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
571,299641,3,5,,103177883,3121,Unspecified,296434519.0,10014.0,,,Inhibition of HDAC in HEK293 cells assessed as increase in histone H4 acetylation at 1 mM after 48 hrs relative to control,Other,17566732.0,
572,299643,3,4,,103177883,3121,Unspecified,,,,,Increase in GRP78 protein level in HEK293 cells at 1 mM by immunoblot,Other,17566732.0,
573,299648,3,4,,103177883,3121,Active,,,,,Increase in protein disulfide isomerase level in HEK293 cells at 1 mM by immunoblot,Other,17566732.0,
574,299653,3,7,,103177883,3121,Unspecified,,,,,Inhibition of GSK3-beta at 2 mM relative to control,Other,17566732.0,
575,299655,3,4,,103177883,3121,Active,,,,,Increase in GRP78 protein level in HEK293 cells at 1 mM by immunoblot,Other,17566732.0,
576,304108,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in Swiss Webster Vancouver mouse assessed as embryo lethality at 600 mg/kg, ip",Other,17994680.0,
577,304109,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in Swiss Webster Vancouver mouse assessed as embryo lethality at 452 mg/kg, ip",Other,17994680.0,
578,304116,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in Swiss Webster Vancouver mouse assessed as exencephaly at 600 mg/kg, ip",Other,17994680.0,
579,304117,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in Swiss Webster Vancouver mouse assessed as exencephaly at 452 mg/kg, ip",Other,17994680.0,
580,304127,5,2,,103177883,3121,Unspecified,,,,,Solubility in water,Other,17994680.0,
581,305059,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against maximal electroshock-induced seizure in Albino mouse at 300 mg/kg, ip after 0.5 hrs",Other,17046248.0,
582,305062,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against maximal electroshock-induced seizure in Albino mouse at 300 mg/kg, ip after 4 hrs",Other,17046248.0,
583,305065,3,3,,103177883,3121,Active,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Albino mouse at 300 mg/kg, ip after 0.5 hrs",Other,17046248.0,
584,305067,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Albino mouse at 300 mg/kg, ip after 4 hrs",Other,17046248.0,
585,305068,3,4,,103177883,3121,Unspecified,,,,,"Neurotoxicity in Albino mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test",Other,17046248.0,
586,305070,3,4,,103177883,3121,Unspecified,,,,,"Neurotoxicity in Albino mouse at 300 mg/kg, ip after 4 hrs by rotarod test",Other,17046248.0,
587,311524,4,3,,103177883,3121,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
588,317814,3,12,,103177883,3121,Unspecified,2498443.0,3065.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
589,317814,3,12,,103177883,3121,Unspecified,3334210.0,8841.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
590,317814,3,12,,103177883,3121,Unspecified,19865267.0,9734.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
591,317814,3,12,,103177883,3121,Unspecified,26394832.0,79885.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
592,317814,3,12,,103177883,3121,Unspecified,27734403.0,83933.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
593,317814,3,12,,103177883,3121,Unspecified,29839394.0,55869.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
594,317814,3,12,,103177883,3121,Unspecified,30913097.0,51564.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
595,317814,3,12,,103177883,3121,Unspecified,68068066.0,3066.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
596,317814,3,12,,103177883,3121,Unspecified,205371758.0,10013.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
597,317814,3,12,,103177883,3121,Unspecified,259016348.0,9759.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
598,317814,3,12,,103177883,3121,Unspecified,296434519.0,10014.0,,,Inhibition of human HDAC in HeLa cells at 100 uM,Other,18294844.0,
599,317815,11,2,,103177883,3121,Unspecified,2498443.0,3065.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
600,317815,11,2,,103177883,3121,Unspecified,3334210.0,8841.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
601,317815,11,2,,103177883,3121,Unspecified,19865267.0,9734.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
602,317815,11,2,,103177883,3121,Unspecified,26394832.0,79885.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
603,317815,11,2,,103177883,3121,Unspecified,27734403.0,83933.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
604,317815,11,2,,103177883,3121,Unspecified,29839394.0,55869.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
605,317815,11,2,,103177883,3121,Unspecified,30913097.0,51564.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
606,317815,11,2,,103177883,3121,Unspecified,68068066.0,3066.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
607,317815,11,2,,103177883,3121,Unspecified,205371758.0,10013.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
608,317815,11,2,,103177883,3121,Unspecified,259016348.0,9759.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
609,317815,11,2,,103177883,3121,Unspecified,296434519.0,10014.0,995.0,IC50,Inhibition of human HDAC in HeLa cells,Confirmatory,18294844.0,
610,317817,8,1,,103177883,3121,Unspecified,,,1.0,IC50,Antiproliferative activity against human A549 cells after 3 days,Confirmatory,18294844.0,
611,317818,3,4,,103177883,3121,Unspecified,,,,,Antiproliferative activity against human A549 cells at 1 mM after 3 days,Other,18294844.0,
612,317819,3,12,,103177883,3121,Active,2498443.0,3065.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
613,317819,3,12,,103177883,3121,Active,3334210.0,8841.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
614,317819,3,12,,103177883,3121,Active,19865267.0,9734.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
615,317819,3,12,,103177883,3121,Active,26394832.0,79885.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
616,317819,3,12,,103177883,3121,Active,27734403.0,83933.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
617,317819,3,12,,103177883,3121,Active,29839394.0,55869.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
618,317819,3,12,,103177883,3121,Active,30913097.0,51564.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
619,317819,3,12,,103177883,3121,Active,68068066.0,3066.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
620,317819,3,12,,103177883,3121,Active,205371758.0,10013.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
621,317819,3,12,,103177883,3121,Active,259016348.0,9759.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
622,317819,3,12,,103177883,3121,Active,296434519.0,10014.0,,,Inhibition of human HDAC in A549 cells assessed as increase in histone-H4 acetylation at 150 uM after 24 hrs by Western blot,Other,18294844.0,
623,319868,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ICR mouse after 30 mins by MES test,Other,18479918.0,
624,319869,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against pentylenetetrazole-induced seizure in ICR mouse after 30 mins,Other,18479918.0,
625,352070,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against audiogenic clonus seizures in ip dosed DBA/2 mouse epilepsy model administered 30 mins before auditory simulation,Other,18406016.0,
626,352071,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against audiogenic tonus seizures in ip dosed DBA/2 mouse epilepsy model administered 30 mins before auditory simulation,Other,18406016.0,
627,353899,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against maximal electroshock-induced seizures,Other,19296679.0,
628,353900,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse to ED50 for maximal electroshock-induced CF1 albino seizure mouse model",Other,19296679.0,
629,353901,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against scMet-induced seizures,Other,19296679.0,
630,353902,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse to ED50 for scMet-induced CF1 albino seizure mouse model",Other,19296679.0,
631,353903,6,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed CF1 albino mouse assessed as minimal motor impairment,Other,19296679.0,
632,353912,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures,Other,19296679.0,
633,353913,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for albino Sprague-Dawley rat to ED50 for maximal electroshock-induced albino Sprague-Dawley rat seizure model",Other,19296679.0,
634,353914,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against scMet-induced seizures,Other,19296679.0,
635,353915,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for albino Sprague-Dawley rat to ED50 for scMet-induced albino Sprague-Dawley rat seizure model",Other,19296679.0,
636,353916,3,3,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as minimal motor impairment,Other,19296679.0,
637,353917,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against 32 mA current-induced seizure by 6Hz psychomotor seizure test,Other,19296679.0,
638,353918,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse to ED50 for 32 mA current-induced CF1 albino mouse seizure model",Other,19296679.0,
639,353919,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 albino mouse assessed as protection against 44 mA-current-induced seizure by 6Hz psychomotor seizure test,Other,19296679.0,
640,353920,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse to ED50 for 44 mA-current-induced CF1 albino mouse seizure model",Other,19296679.0,
641,354133,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as number of litters at 600 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
642,354134,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as number of litters at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
643,354135,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as number of litters at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
644,354139,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as number of implants at 600 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
645,354140,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as number of implants at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
646,354141,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as number of implants at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
647,354145,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 600 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
648,354146,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
649,354147,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
650,354151,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 600 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
651,354152,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
652,354153,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
653,354157,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as dead fetuses at 600 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
654,354158,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as dead fetuses at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
655,354159,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as dead fetuses at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
656,354163,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in VPA-induced SWV mouse assessed as fetuses with neural tube deffects at 600 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
657,354164,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in VPA-induced SWV mouse assessed as fetuses with neural tube deffects at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
658,354165,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in VPA-induced SWV mouse assessed as fetuses with neural tube deffects at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,19296679.0,
659,360094,11,2,,103177883,3121,Unspecified,135666.0,2152.0,1500.0,IC50,Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay,Confirmatory,17675290.0,
660,360095,11,2,,103177883,3121,Unspecified,135666.0,2152.0,2000.0,IC50,Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay,Confirmatory,17675290.0,
661,382323,6,2,,103177883,3121,Unspecified,,,56.1,IC50,Inhibition of Wistar rat kidney aldose reductase 1,Confirmatory,18395454.0,
662,385433,3,11,,103177883,3121,Unspecified,135666.0,2152.0,,,Inhibition of TNF-alpha-induced tissue factor activity in HUVEC at 6 uM preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay,Other,17675290.0,
663,385438,3,11,,103177883,3121,Unspecified,135666.0,2152.0,,,Inhibition of LPS-induced tissue factor activity in HUVEC at 6 uM preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay,Other,17675290.0,
664,386623,4,8,,103177883,3121,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
665,394936,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs by MES test",Other,18396352.0,
666,394937,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs by MES test",Other,18396352.0,
667,394938,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for inhibition of pentylenetetrazole-induced seizures in half or more of mouse after 0.5 hrs by scPTZ test,Other,18396352.0,
668,394941,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against pentylenetetrazole-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs by scPTZ test",Other,18396352.0,
669,394947,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs by rotarod test",Other,18396352.0,
670,394951,7,1,,103177883,3121,Unspecified,,,,,"Antioxidant activity against PTZ-induced lipid peroxidation in Swiss albino mouse brain assessed as malondialdehyde content per mg of protein at 100 mg/kg, ip preincubated for 30 mins before PTZ challenge measured after 4 hrs by TBARS assay",Other,18396352.0,
671,394952,3,3,,103177883,3121,Active,,,,,"Antioxidant activity against PTZ-induced decrease in GSH-Px activity in Swiss albino mouse brain assessed as oxidized NADPH level per mg of protein at 100 mg/kg, ip administered 30 mins before PTZ challenge measured after 4 hrs by spectrophotometry",Other,18396352.0,
672,395092,7,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse after 0.25 hrs by MES test,Other,19249853.0,
673,395096,3,3,,103177883,3121,Unspecified,,,,,Ratio of valproic acid ED50 to compound ED50 in albino mouse after 0.25 hrs by MES test,Other,19249853.0,
674,395116,3,3,,103177883,3121,Unspecified,,,,,"Antioxidant activity against PTZ-induced decrease in superoxide dismutase activity in Swiss albino mouse brain assessed as enzyme units per mg of protein causing 50% inhibition in NBT reduction rate at 100 mg/kg, ip administered 30 mins before PTZ challenge measured after 4 hrs",Other,18396352.0,
675,395117,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in Swiss albino mouse at 300 mg/kg, ip after 4 hrs by rotarod test",Other,18396352.0,
676,404304,3,10,,103177883,3121,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
677,408763,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against maximal electroshock-induced seizures in orally dosed rat model,Other,18472270.0,
678,408764,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against scMet-induced seizures in orally dosed rat model,Other,18472270.0,
679,408765,3,3,,103177883,3121,Unspecified,,,,,Toxicity in orally dosed rat by rotarod test,Other,18472270.0,
680,408766,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for rat by rotarod test to ED50 for rat by scMet test",Other,18472270.0,
681,408767,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for rat by rotarod test to ED50 for rat by MES test",Other,18472270.0,
682,409600,3,4,,103177883,3121,Unspecified,,,,,Inhibition of human aquaporin 4 M23 isoform expressed in Xenopus laevis oocytes at 20 uM,Other,18178093.0,
683,409958,3,9,,103177883,3121,Inactive,124028637.0,281293.0,,,Inhibition of bovine brain MAOA,Other,18834112.0,
684,409960,3,9,,103177883,3121,Inactive,124028638.0,338445.0,,,Inhibition of bovine brain MAOB,Other,18834112.0,
685,425652,7,2,,103177883,3121,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
686,425653,7,2,,103177883,3121,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
687,434955,1,2,,49640649,3121,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
688,434962,1,2,,49640649,3121,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
689,434973,1,3,,49640649,3121,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
690,434989,1,1,,49640649,3121,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
691,435003,1,3,,49640649,3121,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
692,435005,1,1,,49640649,3121,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
693,435022,2,2,,49640649,3121,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
694,435030,1,2,,49640649,3121,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
695,435030,1,2,,49640649,3121,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
696,444050,7,1,,103177883,3121,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
697,444051,6,2,,103177883,3121,Unspecified,,,,,Total clearance in human,Other,20070106.0,
698,444052,6,2,,103177883,3121,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
699,444053,6,2,,103177883,3121,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
700,444054,6,1,,103177883,3121,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
701,444055,3,3,,103177883,3121,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
702,444056,3,3,,103177883,3121,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
703,444057,3,3,,103177883,3121,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
704,444058,6,2,,103177883,3121,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
705,447579,8,1,,103177883,3121,Unspecified,2498443.0,3065.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
706,447579,8,1,,103177883,3121,Unspecified,3334210.0,8841.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
707,447579,8,1,,103177883,3121,Unspecified,19865267.0,9734.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
708,447579,8,1,,103177883,3121,Unspecified,26394832.0,79885.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
709,447579,8,1,,103177883,3121,Unspecified,27734403.0,83933.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
710,447579,8,1,,103177883,3121,Unspecified,29839394.0,55869.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
711,447579,8,1,,103177883,3121,Unspecified,30913097.0,51564.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
712,447579,8,1,,103177883,3121,Unspecified,68068066.0,3066.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
713,447579,8,1,,103177883,3121,Unspecified,205371758.0,10013.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
714,447579,8,1,,103177883,3121,Unspecified,259016348.0,9759.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
715,447579,8,1,,103177883,3121,Unspecified,296434519.0,10014.0,,IC50,Inhibition of HDAC in human Hela cells nuclear extracts by fluorimetric assay,Confirmatory,19520580.0,
716,449728,1,2,,49640649,3121,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
717,449739,1,2,,49640649,3121,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
718,449762,1,2,,49640649,3121,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
719,449763,1,3,,49640649,3121,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
720,449768,1,1,,49640649,3121,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
721,462443,9,5,,103177883,3121,Unspecified,1703237.0,78959.0,50.1,IC50,Inhibition of rat kidney aldehyde reductase at 0.1 mM after 20 mins by spectrometric analysis,Confirmatory,20189816.0,
722,463079,1,2,,49640649,3121,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
723,463082,1,1,,49640649,3121,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
724,463104,1,2,,49640649,3121,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
725,463111,1,1,,49640649,3121,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
726,463141,1,2,,49640649,3121,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
727,463165,1,1,,49640649,3121,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
728,463190,1,2,,49640649,3121,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
729,463195,1,2,,49640649,3121,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
730,463210,1,2,,49640649,3121,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
731,463212,1,1,,49640649,3121,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
732,470102,6,2,,103177883,3121,Unspecified,,,,,Antiallodynic activity in ip dosed rat assessed as protection against spinal nerve ligation-induced neuropathic pain,Other,19877649.0,
733,470103,6,2,,103177883,3121,Unspecified,,,,,Antiepileptic activity in ip dosed CF1 mouse assessed as inhibition of maximal electroshock-induced seizures,Other,19877649.0,
734,470104,6,2,,103177883,3121,Unspecified,,,,,Ratio of ED50 for antiallodynic activity in rat assessed as protection against spinal nerve ligation-induced neuropathic pain to ED50 for antiepileptic activity in rat by maximal electroshock-induced seizures assay,Other,19877649.0,
735,471573,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against picrotoxin-induced seizure in ip dosed CF1 mouse after 0.25 hrs,Other,19388676.0,
736,471593,3,3,,103177883,3121,Active,,,,,"Anticonvulsant activity against electric stimulation-induced pharmacoresistant limbic epilepsy in Sprague-Dawley rat kindling model assessed as reduction of seizure severity and excitability at > 300 mg/kg, ip administered 15 mins after last electric stimulation",Other,19388676.0,
737,472394,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 mouse assessed as inhibition of maximal electroshock-induced seizures after 0.5 hrs,Other,20363141.0,
738,472395,3,3,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed CF1 mouse after 0.25 hrs by rotarod test,Other,20363141.0,
739,472396,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Sprague-Dawley rat assessed as inhibition of maximal electroshock-induced seizures after 0.5 hrs,Other,20363141.0,
740,472397,6,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed Sprague-Dawley rat after 0.5 hrs by rotarod test,Other,20363141.0,
741,482509,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs",Other,20420384.0,
742,482510,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in CF1 albino mouse assessed as motor impairment at 30 mg/kg, ip after 0.5 hrs",Other,20420384.0,
743,482511,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in CF1 albino mouse assessed as motor impairment at 100 mg/kg, ip after 0.5 hrs",Other,20420384.0,
744,482512,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in CF1 albino mouse assessed as motor impairment at 300 mg/kg, ip after 0.5 hrs",Other,20420384.0,
745,482513,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in CF1 albino mouse assessed as motor impairment at 30 mg/kg, ip after 4 hrs",Other,20420384.0,
746,482514,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in CF1 albino mouse assessed as motor impairment at 100 mg/kg, ip after 4 hrs",Other,20420384.0,
747,482515,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in CF1 albino mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs",Other,20420384.0,
748,482522,6,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures,Other,20420384.0,
749,482523,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse to ED50 for maximal electroshock-induced CF1 albino seizure mouse model",Other,20420384.0,
750,482524,10,1,,103177883,3121,Unspecified,,,646.0,ED50,Anticonvulsant activity in po dosed CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures,Confirmatory,20420384.0,
751,482525,3,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse to ED50 for subcutaneous pentylenetetrazole-induced CF1 albino seizure mouse model",Other,20420384.0,
752,482526,4,1,,103177883,3121,Unspecified,,,784.0,TD50,Neurotoxicity in po dosed CF1 albino mouse assessed as motor impairment,Confirmatory,20420384.0,
753,482528,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
754,482529,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
755,482530,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 181 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
756,482531,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as resorptions at 91 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
757,482554,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
758,482555,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
759,482556,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 181 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
760,482557,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as live fetuses at 91 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
761,482579,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as dead fetuses at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
762,482580,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as dead fetuses at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
763,482724,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 0.5 hrs",Other,20420384.0,
764,482725,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 100 mg/kg, ip after 0.5 hrs",Other,20420384.0,
765,482726,3,3,,103177883,3121,Active,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs",Other,20420384.0,
766,482727,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 4 hrs",Other,20420384.0,
767,482728,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 100 mg/kg, ip after 4 hrs",Other,20420384.0,
768,482729,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs",Other,20420384.0,
769,482730,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 0.5 hrs",Other,20420384.0,
770,482731,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 0.5 hrs",Other,20420384.0,
771,482732,3,3,,103177883,3121,Active,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 0.5 hrs",Other,20420384.0,
772,482733,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 4 hrs",Other,20420384.0,
773,482734,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 4 hrs",Other,20420384.0,
774,484084,6,2,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as dead fetuses at 91 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
775,484086,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as fetuses with neural tube deffects at 452 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
776,484087,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as fetuses with neural tube deffects at 301 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
777,484088,3,3,,103177883,3121,Unspecified,,,,,"Teratogenic effect in SWV mouse assessed as fetuses with neural tube deffects at 91 mg/kg, ip administered on morning of day 8 of gestation",Other,20420384.0,
778,485270,1,1,,49640649,3121,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
779,485272,1,1,,49640649,3121,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
780,485273,2,1,,49640649,3121,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
781,485275,1,3,,49640649,3121,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
782,485290,1,1,,17389523,3121,Inactive,20150581.0,,2.5119,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
783,485317,1,2,,49640649,3121,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
784,485346,1,1,,49640649,3121,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
785,485346,1,1,,49640649,3121,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
786,488839,1,1,,49640649,3121,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
787,488839,1,1,,49640649,3121,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
788,488847,1,3,,49640649,3121,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
789,488862,1,1,,49640649,3121,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
790,488890,1,2,,49640649,3121,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
791,488895,1,2,,49640649,3121,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
792,488896,1,1,,49640649,3121,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
793,488899,1,1,,49640649,3121,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
794,488922,1,2,,49640649,3121,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
795,488965,1,2,,49640649,3121,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
796,488966,1,1,,49640649,3121,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
797,488975,1,2,,49640649,3121,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
798,488977,1,2,,49640649,3121,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
799,489030,2,1,,49640649,3121,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
800,489031,2,1,,49640649,3121,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
801,489788,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 0.5 hrs",Other,20356656.0,
802,489790,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against maximal electroshock-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs",Other,20356656.0,
803,489791,3,3,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Swiss albino mouse assessed as minimum effective dose after 0.5 hrs,Other,20356656.0,
804,489794,3,3,,103177883,3121,Inactive,,,,,"Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in Swiss albino mouse at 300 mg/kg, ip after 4 hrs",Other,20356656.0,
805,489796,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in ip dosed Swiss albino mouse assessed as impair in motor coordination at 300 mg/kg, ip after 0.5 hrs by rotarod test",Other,20356656.0,
806,489798,3,3,,103177883,3121,Unspecified,,,,,"Neurotoxicity in ip dosed Swiss albino mouse assessed as impair in motor coordination at 300 mg/kg, ip after 4 hrs by rotarod test",Other,20356656.0,
807,489807,3,3,,103177883,3121,Unspecified,,,,,"Reduction of lipid peroxidation in subcutaneous pentylenetetrazole treated Swiss albino mouse brain assessed reduction of malondialdehyde level per mg of protein at 100 mg/kg, ip after 4 hrs by TBARS assay",Other,20356656.0,
808,489808,3,3,,103177883,3121,Unspecified,,,,,"Restoration of GSH level in subcutaneous pentylenetetrazole treated Swiss albino mouse brain assessed per gram of tissue at 100 mg/kg, ip after 4 hrs",Other,20356656.0,
809,489809,3,3,,103177883,3121,Unspecified,,,,,"Restoration of SOD activity in subcutaneous pentylenetetrazole treated Swiss albino mouse brain assessed per mg of protein at 100 mg/kg, ip after 4 hrs",Other,20356656.0,
810,489810,3,3,,103177883,3121,Unspecified,,,,,"Restoration of GSH peroxidase activity in subcutaneous pentylenetetrazole treated Swiss albino mouse brain assessed per mg of protein at 100 mg/kg, ip after 4 hrs",Other,20356656.0,
811,492953,1,1,,49640649,3121,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
812,492956,1,1,,49640649,3121,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
813,492961,1,1,,17389523,3121,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
814,492972,1,1,,49640649,3121,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
815,493005,1,1,,49640649,3121,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
816,493008,1,1,,49640649,3121,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
817,493008,1,1,,49640649,3121,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
818,493008,1,1,,49640649,3121,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
819,493008,1,1,,49640649,3121,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
820,493011,1,1,,49640649,3121,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
821,493012,1,1,,49640649,3121,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
822,493036,1,2,,49640649,3121,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
823,493087,1,1,,49640649,3121,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
824,493091,1,1,,49640649,3121,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
825,493098,1,1,,49640649,3121,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
826,493131,1,1,,49640649,3121,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
827,493160,1,1,,49640649,3121,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
828,493187,1,2,,49640649,3121,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
829,493244,1,1,,49640649,3121,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
830,493244,1,1,,49640649,3121,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
831,493244,1,1,,49640649,3121,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
832,493244,1,1,,49640649,3121,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
833,497227,5,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms number 1 mouse assessed as protection against maximal electroshock-induced seizure,Other,20614888.0,
834,497229,2,4,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed albino Carworth Farms number 1 mouse by rotarod test,Other,20614888.0,
835,497230,2,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxicity TD50 to anticonvulsant ED50 for ip dosed albino Carworth Farms number 1 mouse",Other,20614888.0,
836,497231,5,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizure,Other,20614888.0,
837,497232,2,4,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat by rotarod test,Other,20614888.0,
838,497233,2,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxicity TD50 to anticonvulsant ED50 for po dosed albino Spague-Dawley rat",Other,20614888.0,
839,503529,3,4,,103177883,3121,Active,2498443.0,3065.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
840,503529,3,4,,103177883,3121,Active,3334210.0,8841.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
841,503529,3,4,,103177883,3121,Active,19865267.0,9734.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
842,503529,3,4,,103177883,3121,Active,26394832.0,79885.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
843,503529,3,4,,103177883,3121,Active,27734403.0,83933.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
844,503529,3,4,,103177883,3121,Active,29839394.0,55869.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
845,503529,3,4,,103177883,3121,Active,30913097.0,51564.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
846,503529,3,4,,103177883,3121,Active,68068066.0,3066.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
847,503529,3,4,,103177883,3121,Active,205371758.0,10013.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
848,503529,3,4,,103177883,3121,Active,259016348.0,9759.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
849,503529,3,4,,103177883,3121,Active,296434519.0,10014.0,,,Inhibition of HDAC in human GM15850 cells assessed as increase in total acetylated histone level at 400 uM after 12 hrs by Western blot analysis,Other,16921367.0,
850,503668,2,4,,103177883,3121,Unspecified,,,,,Cytotoxicity against human GM15850 cells at 5 uM after 96 hrs by trypan blue exclusion assay,Other,16921367.0,
851,504326,1,2,,49640649,3121,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
852,504326,1,2,,49640649,3121,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
853,504327,1,1,,17389523,3121,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
854,504329,1,1,,49640649,3121,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
855,504332,1,1,,17389523,3121,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
856,504339,1,1,,49640649,3121,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
857,504357,1,1,,49640649,3121,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
858,504357,1,1,,49640649,3121,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
859,504406,1,1,,49640649,3121,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
860,504408,2,1,,49640649,3121,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
861,504411,1,1,,49640649,3121,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
862,504414,1,1,,49640649,3121,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
863,504414,1,1,,49640649,3121,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
864,504423,1,1,,49640649,3121,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
865,504441,1,1,,49640649,3121,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
866,504444,1,1,,49640649,3121,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
867,504454,1,3,,49640649,3121,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
868,504462,1,1,,49640649,3121,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
869,504490,1,2,,49640649,3121,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
870,504523,1,1,,49640649,3121,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
871,504523,1,1,,49640649,3121,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
872,504558,1,1,,49640649,3121,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
873,504577,2,2,,49640649,3121,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
874,504582,2,1,,49640649,3121,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
875,504621,1,1,,49640649,3121,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
876,504634,1,1,,49640649,3121,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
877,504648,1,1,,49640649,3121,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
878,504690,1,3,,49640649,3121,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
879,504692,2,2,,49640649,3121,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
880,504700,1,1,,49640649,3121,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
881,504700,1,1,,49640649,3121,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
882,504707,1,1,,49640649,3121,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
883,504707,1,1,,49640649,3121,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
884,504720,1,1,,49640649,3121,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
885,504734,1,1,,49640649,3121,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
886,504749,1,3,,17389523,3121,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
887,504749,1,3,1.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
888,504749,1,3,2.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
889,504749,1,3,3.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
890,504749,1,3,4.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
891,504749,1,3,5.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
892,504749,1,3,6.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
893,504749,1,3,7.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
894,504749,1,3,8.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
895,504749,1,3,9.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
896,504749,1,3,10.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
897,504749,1,3,11.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
898,504749,1,3,12.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
899,504749,1,3,13.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
900,504749,1,3,14.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
901,504749,1,3,15.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
902,504749,1,3,16.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
903,504749,1,3,17.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
904,504749,1,3,18.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
905,504749,1,3,19.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
906,504749,1,3,20.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
907,504749,1,3,21.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
908,504749,1,3,22.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
909,504749,1,3,23.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
910,504749,1,3,24.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
911,504749,1,3,25.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
912,504749,1,3,26.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
913,504749,1,3,27.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
914,504749,1,3,28.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
915,504749,1,3,29.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
916,504749,1,3,30.0,17389523,3121,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
917,504749,1,3,31.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
918,504749,1,3,32.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
919,504749,1,3,33.0,17389523,3121,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
920,504749,1,3,34.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
921,504749,1,3,35.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
922,504749,1,3,36.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
923,504749,1,3,37.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
924,504749,1,3,38.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
925,504749,1,3,39.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
926,504749,1,3,40.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
927,504749,1,3,41.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
928,504749,1,3,42.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
929,504749,1,3,43.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
930,504749,1,3,44.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
931,504749,1,3,45.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
932,504749,1,3,46.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
933,504749,1,3,47.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
934,504749,1,3,48.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
935,504749,1,3,49.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
936,504749,1,3,50.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
937,504749,1,3,51.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
938,504749,1,3,52.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
939,504749,1,3,53.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
940,504749,1,3,54.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
941,504749,1,3,55.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
942,504749,1,3,56.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
943,504749,1,3,57.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
944,504749,1,3,58.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
945,504749,1,3,59.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
946,504749,1,3,60.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
947,504749,1,3,61.0,17389523,3121,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
948,504766,2,1,,49640649,3121,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
949,504775,1,1,,49640649,3121,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
950,504803,1,1,,49640649,3121,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
951,504832,1,1,,17389523,3121,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
952,504834,1,1,,17389523,3121,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
953,504845,1,1,,49640649,3121,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
954,504847,1,1,,17389523,3121,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
955,504847,1,1,,49640649,3121,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
956,504865,1,1,,17389523,3121,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
957,504884,1,2,,49640649,3121,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
958,504891,1,1,,49640649,3121,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
959,504894,1,1,,49640649,3121,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
960,504937,1,2,,49640649,3121,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
961,513626,2,4,,103177883,3121,Active,,,,,Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis,Other,18391949.0,
962,513627,2,4,,103177883,3121,Active,,,,,Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis,Other,18391949.0,
963,513628,1,4,,103177883,3121,Active,,,,,Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis,Other,18391949.0,
964,513629,1,4,,103177883,3121,Unspecified,,,,,Cytotoxicity against human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs,Other,18391949.0,
965,514302,1,3,,103177883,3121,Active,,,,,Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as decrease in EGFP-HDQ74 aggregation at 10 uM,Other,18391949.0,
966,514303,1,3,,103177883,3121,Inactive,,,,,Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as loss of rhodopsin expression at 10 uM,Other,18391949.0,
967,537154,7,5,,103177883,3121,Unspecified,1703237.0,78959.0,56.1,IC50,Inhibition of Fischer-344 rat kidney AK1A1,Confirmatory,20936791.0,
968,537158,7,2,,103177883,3121,Unspecified,,,50.1,IC50,Inhibition of AK1A1,Confirmatory,20936791.0,
969,539464,4,2,,103177883,3121,Unspecified,,,,,Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis,Other,21055935.0,
970,540209,4,3,,103177883,3121,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
971,540210,4,3,,103177883,3121,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
972,540211,2,5,,103177883,3121,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
973,540212,4,3,,103177883,3121,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
974,540213,4,3,,103177883,3121,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
975,540214,4,3,,103177883,3121,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
976,540215,3,2,,103177883,3121,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
977,540216,4,3,,103177883,3121,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
978,540217,4,3,,103177883,3121,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
979,540218,4,3,,103177883,3121,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
980,540219,4,3,,103177883,3121,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
981,540220,4,3,,103177883,3121,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
982,540221,4,3,,103177883,3121,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
983,540234,2,5,,103177883,3121,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
984,540253,1,1,,49640649,3121,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
985,540253,1,1,,49640649,3121,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
986,540253,1,1,,49640649,3121,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
987,540263,1,1,,49640649,3121,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
988,540263,1,1,,49640649,3121,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
989,540267,1,1,,49640649,3121,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
990,540276,1,2,,17389523,3121,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
991,540276,1,2,,26752920,3121,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
992,540276,1,2,,26752921,3121,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
993,540276,1,2,,49640649,3121,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
994,540276,1,2,,50105536,3121,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
995,540295,1,1,,49640649,3121,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
996,540303,1,1,,49640649,3121,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
997,540303,1,1,,49640649,3121,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
998,540303,1,1,,49640649,3121,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
999,540308,1,1,,49640649,3121,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1000,540317,1,1,,49640649,3121,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1001,540336,1,1,,49640649,3121,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1002,540336,1,1,,49640649,3121,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1003,540364,1,2,,49640649,3121,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1004,569928,7,5,,103177883,3121,Active,2498443.0,3065.0,39.0,IC50,Inhibition of human recombinant HDAC1,Confirmatory,21874153.0,
1005,569929,7,5,,103177883,3121,Unspecified,68068066.0,3066.0,62.0,IC50,Inhibition of human recombinant HDAC2,Confirmatory,21874153.0,
1006,569930,7,5,,103177883,3121,Unspecified,3334210.0,8841.0,161.0,IC50,Inhibition of human recombinant HDAC3,Confirmatory,21874153.0,
1007,569931,7,5,,103177883,3121,Unspecified,29839394.0,55869.0,103.0,IC50,Inhibition of human recombinant HDAC8,Confirmatory,21874153.0,
1008,569932,5,6,,103177883,3121,Unspecified,259016348.0,9759.0,2000.0,IC50,Inhibition of human recombinant HDAC4,Confirmatory,21874153.0,
1009,569933,7,5,,103177883,3121,Unspecified,296434519.0,10014.0,2000.0,IC50,Inhibition of human recombinant HDAC5,Confirmatory,21874153.0,
1010,569934,8,5,,103177883,3121,Unspecified,30913097.0,51564.0,2000.0,IC50,Inhibition of human recombinant HDAC7,Confirmatory,21874153.0,
1011,569935,8,5,,103177883,3121,Unspecified,19865267.0,9734.0,2000.0,IC50,Inhibition of human recombinant HDAC9,Confirmatory,21874153.0,
1012,569936,7,5,,103177883,3121,Unspecified,205371758.0,10013.0,2000.0,IC50,Inhibition of human recombinant HDAC6,Confirmatory,21874153.0,
1013,569937,3,9,,103177883,3121,Inactive,205371758.0,10013.0,,,Inhibition of HDAC6 in human HeLa cells assessed as acetylation of tubulin after 24 hrs by immunofluorescence assay,Other,21874153.0,
1014,569939,1,4,,103177883,3121,Unspecified,,,,,Induction of developmental deffects in frog embryos assessed as loss of anterior structures at 2 mM after 18 hrs,Other,21874153.0,
1015,569940,1,4,,103177883,3121,Unspecified,,,,,Induction of developmental deffects in frog embryos assessed as shortening of anterior-posterior axis at 2 mM after 18 hrs,Other,21874153.0,
1016,569941,1,4,,103177883,3121,Unspecified,,,,,Induction of developmental deffects in frog embryos assessed as heart looping and pigment deffects at 2 mM after 18 hrs,Other,21874153.0,
1017,569944,3,3,,103177883,3121,Inactive,,,,,Inhibition of HDAC in mouse primary forebrain neurons assessed as acetylation of histone H2A at 92.5 uM after 24 hrs by immunofluorescence assay,Other,21874153.0,
1018,588208,2,3,,103177883,3121,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
1019,588209,2,3,,103177883,3121,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1020,588210,2,4,,103177883,3121,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1021,588211,2,3,,103177883,3121,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1022,588212,2,3,,103177883,3121,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1023,588213,2,3,,103177883,3121,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1024,588214,2,3,,103177883,3121,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1025,588215,2,3,,103177883,3121,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1026,588216,2,3,,103177883,3121,Active,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1027,588217,2,3,,103177883,3121,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1028,588218,2,3,,103177883,3121,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1029,588219,2,3,,103177883,3121,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1030,588220,2,3,,103177883,3121,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
1031,588334,1,1,,49640649,3121,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1032,588335,1,1,,49640649,3121,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1033,588352,1,2,,49640649,3121,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1034,588354,1,1,,49640649,3121,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1035,588358,1,2,,49640649,3121,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1036,588391,1,1,,49640649,3121,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1037,588405,1,1,,49640649,3121,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1038,588413,1,2,,49640649,3121,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1039,588436,1,1,,49640649,3121,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1040,588453,1,1,,49640649,3121,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1041,588456,1,1,,49640649,3121,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1042,588458,1,1,,49640649,3121,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1043,588473,1,1,,49640649,3121,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1044,588473,1,1,,49640649,3121,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1045,588475,1,2,,49640649,3121,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1046,588475,1,2,,49640649,3121,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1047,588478,1,2,,124799728,3121,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1048,588489,1,1,,49640649,3121,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1049,588492,1,1,,49640649,3121,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1050,588493,1,2,,49640649,3121,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1051,588497,1,2,,49640649,3121,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1052,588497,1,2,,49640649,3121,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1053,588497,1,2,,49640649,3121,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1054,588499,1,3,,49640649,3121,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1055,588499,1,3,,49640649,3121,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1056,588499,1,3,,49640649,3121,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1057,588501,1,2,,49640649,3121,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1058,588501,1,2,,49640649,3121,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1059,588501,1,2,,49640649,3121,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1060,588511,1,2,,49640649,3121,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1061,588513,1,1,,17389523,3121,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1062,588513,1,1,,26752920,3121,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1063,588513,1,1,,26752921,3121,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1064,588514,1,1,,17389523,3121,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1065,588514,1,1,,26752920,3121,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1066,588514,1,1,,26752921,3121,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1067,588515,1,1,,17389523,3121,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1068,588515,1,1,,26752920,3121,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1069,588515,1,1,,26752921,3121,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1070,588516,1,1,,17389523,3121,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1071,588516,1,1,,26752920,3121,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1072,588516,1,1,,26752921,3121,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1073,588526,1,1,,17389523,3121,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1074,588526,1,1,,26752920,3121,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1075,588526,1,1,,26752921,3121,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1076,588527,1,1,,17389523,3121,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1077,588527,1,1,,26752920,3121,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1078,588527,1,1,,26752921,3121,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1079,588532,1,1,,17389523,3121,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1080,588532,1,1,,26752920,3121,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1081,588532,1,1,,26752921,3121,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1082,588533,1,1,,17389523,3121,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1083,588533,1,1,,26752920,3121,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1084,588533,1,1,,26752921,3121,Inconclusive,311348376.0,2908.0,891.2510000000001,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1085,588534,1,1,,17389523,3121,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1086,588534,1,1,,26752920,3121,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1087,588534,1,1,,26752921,3121,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1088,588535,1,1,,17389523,3121,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1089,588535,1,1,,26752920,3121,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1090,588535,1,1,,26752921,3121,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1091,588536,1,1,,17389523,3121,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1092,588536,1,1,,26752920,3121,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1093,588536,1,1,,26752921,3121,Inconclusive,216409692.0,5468.0,794.328,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1094,588537,1,1,,17389523,3121,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1095,588537,1,1,,26752920,3121,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1096,588537,1,1,,26752921,3121,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1097,588541,1,1,,17389523,3121,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1098,588541,1,1,,26752920,3121,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1099,588541,1,1,,26752921,3121,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1100,588543,1,1,,17389523,3121,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1101,588543,1,1,,26752920,3121,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1102,588543,1,1,,26752921,3121,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1103,588544,1,1,,17389523,3121,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1104,588544,1,1,,26752920,3121,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1105,588544,1,1,,26752921,3121,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1106,588545,1,1,,17389523,3121,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1107,588545,1,1,,26752920,3121,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1108,588545,1,1,,26752921,3121,Inconclusive,189491771.0,7068.0,0.1122,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1109,588546,1,1,,17389523,3121,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1110,588546,1,1,,26752920,3121,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1111,588546,1,1,,26752921,3121,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1112,588547,1,1,,17389523,3121,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1113,588547,1,1,,26752920,3121,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1114,588547,1,1,,26752921,3121,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1115,588549,1,1,,49640649,3121,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1116,588579,1,1,,17389523,3121,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1117,588579,1,1,,49640649,3121,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1118,588590,1,1,,49640649,3121,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1119,588591,1,1,,49640649,3121,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1120,588621,1,1,,49640649,3121,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1121,588627,1,1,,49640649,3121,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1122,588664,1,2,,49640649,3121,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1123,588664,1,2,,49640649,3121,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1124,588674,1,2,,49640649,3121,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1125,588675,1,1,,49640649,3121,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1126,588676,1,1,,49640649,3121,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1127,588689,1,1,,49640649,3121,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1128,588692,2,1,,49640649,3121,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1129,588726,1,2,,49640649,3121,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1130,588727,1,1,,49640649,3121,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1131,588795,1,1,,49640649,3121,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1132,588814,1,3,,49640649,3121,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1133,588819,1,4,,49640649,3121,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1134,588834,2,1,,17389523,3121,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1135,588834,2,1,,144204642,3121,Inconclusive,325651834.0,3757.0,35.4813,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1136,588850,1,1,,49640649,3121,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1137,588852,1,3,,49640649,3121,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1138,588855,1,1,,49640649,3121,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1139,588856,1,1,,49640649,3121,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1140,589069,1,10,,103177883,3121,Unspecified,549152.0,54659.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A3,Other,,
1141,589073,1,10,,103177883,3121,Unspecified,29839637.0,54576.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A8,Other,,
1142,589076,1,10,,103177883,3121,Unspecified,296452854.0,10941.0,,,Substrate of human UDP-glucuronosyltransferase UGT2A1,Other,,
1143,589078,1,10,,103177883,3121,Unspecified,136727.0,7364.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B7,Other,,
1144,589226,3,7,,103177883,3121,Unspecified,308153612.0,1548.0,,Ki,Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation,Confirmatory,16248836.0,
1145,602123,1,1,,49640649,3121,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1146,602141,1,1,,49640649,3121,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1147,602162,1,1,,49640649,3121,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1148,602163,1,1,,49640649,3121,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1149,602179,1,2,,49640649,3121,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1150,602229,1,1,,49640649,3121,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1151,602233,1,1,,49640649,3121,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1152,602244,1,2,,49640649,3121,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1153,602247,1,2,,49640649,3121,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1154,602248,1,2,,49640649,3121,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1155,602250,1,2,,49640649,3121,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1156,602252,1,1,,49640649,3121,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1157,602252,1,1,,49640649,3121,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1158,602261,1,1,,49640649,3121,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1159,602274,1,2,,49640649,3121,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1160,602281,1,1,,49640649,3121,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1161,602281,1,1,,49640649,3121,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1162,602310,1,2,,49640649,3121,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1163,602313,1,1,,49640649,3121,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1164,602329,1,1,,49640649,3121,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1165,602332,1,1,,17389523,3121,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1166,602332,1,1,,49640649,3121,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1167,602340,1,2,,49640649,3121,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1168,602342,2,1,,49640649,3121,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1169,602346,1,1,,49640649,3121,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1170,602363,1,1,,49640649,3121,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1171,602393,1,1,,49640649,3121,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1172,602396,1,2,,49640649,3121,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1173,602399,1,2,,49640649,3121,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1174,602405,1,1,,49640649,3121,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1175,602410,1,1,,49640649,3121,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1176,602429,1,1,,49640649,3121,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1177,602438,1,1,,49640649,3121,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1178,602440,1,1,,49640649,3121,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1179,602449,1,2,,49640649,3121,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1180,602481,1,1,,49640649,3121,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1181,603953,1,3,,103177883,3121,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
1182,620533,1,3,,103177883,3121,Inactive,,,,,Reactivation of MeCp2 mutant expression in human GM11272 cells at 1 to 10000 nM by PCR method,Other,21840716.0,
1183,623870,1,1,,49640649,3121,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1184,623870,1,1,,49640649,3121,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1185,623877,1,1,,49640649,3121,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1186,623901,1,1,,49640649,3121,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1187,624030,1,2,,17389523,3121,Inactive,160794.0,,36.1254,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1188,624031,1,2,,17389523,3121,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1189,624032,1,2,,17389523,3121,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1190,624037,1,3,,49640649,3121,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1191,624038,1,3,,49640649,3121,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1192,624040,1,3,,49640649,3121,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1193,624044,1,2,,17389523,3121,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1194,624125,1,4,,49640649,3121,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1195,624126,1,3,,49640649,3121,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1196,624127,1,2,,49640649,3121,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1197,624168,1,1,,49640649,3121,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1198,624169,1,1,,49640649,3121,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1199,624170,1,1,,17389523,3121,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1200,624170,1,1,,49640649,3121,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1201,624171,1,1,,49640649,3121,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1202,624172,1,1,,17389523,3121,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1203,624172,1,1,,49640649,3121,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1204,624173,1,3,,17389523,3121,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1205,624173,1,3,,49640649,3121,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1206,624178,1,1,,49640649,3121,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1207,624202,1,1,,49640649,3121,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1208,624204,1,2,,49640649,3121,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1209,624246,1,1,,49640649,3121,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1210,624256,1,2,,49640649,3121,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1211,624263,1,1,,49640649,3121,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1212,624263,1,1,,49640649,3121,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1213,624267,1,2,,49640649,3121,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1214,624267,1,2,,49640649,3121,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1215,624268,1,3,,49640649,3121,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1216,624288,1,1,,49640649,3121,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1217,624296,1,1,,17389523,3121,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1218,624296,1,1,,49640649,3121,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1219,624297,1,1,,17389523,3121,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1220,624297,1,1,,49640649,3121,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1221,624304,1,2,,49640649,3121,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1222,624330,1,2,,49640649,3121,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1223,624349,1,2,,92308862,3121,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1224,624349,1,2,,121362408,3121,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1225,624352,1,1,,49640649,3121,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1226,624354,1,1,,49640649,3121,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1227,624377,1,1,,49640649,3121,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1228,624414,1,1,,49640649,3121,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1229,624415,1,2,,49640649,3121,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1230,624416,1,1,,49640649,3121,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1231,624417,1,1,,49640649,3121,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1232,624418,1,1,,49640649,3121,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1233,624463,1,1,,49640649,3121,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1234,624464,1,1,,49640649,3121,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1235,624465,1,1,,49640649,3121,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1236,624466,1,3,,49640649,3121,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1237,624467,1,1,,49640649,3121,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1238,624483,1,1,,49640649,3121,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1239,624607,1,9,,103177883,3121,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
1240,624611,1,9,,103177883,3121,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
1241,624613,1,9,,103177883,3121,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
1242,624614,1,8,,103177883,3121,Unspecified,296452854.0,10941.0,,,Specific activity of expressed human recombinant UGT2A1,Other,10836148.0,
1243,624615,1,8,,103177883,3121,Unspecified,549155.0,7365.0,,,Specific activity of expressed human recombinant UGT2B10,Other,10836148.0,
1244,624618,3,2,,103177883,3121,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
1245,624619,3,2,,103177883,3121,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7,Other,10836148.0,
1246,624634,3,7,,103177883,3121,Unspecified,29840832.0,54578.0,,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A6,Confirmatory,15781124.0,
1247,624637,3,7,,103177883,3121,Unspecified,29839451.0,54600.0,5200.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A9,Confirmatory,15781124.0,
1248,624640,3,7,,103177883,3121,Unspecified,136727.0,7364.0,2100.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT2B7,Confirmatory,15781124.0,
1249,624649,4,6,,103177883,3121,Unspecified,136727.0,7364.0,1600.0,Ki,Inhibition of AZT glucuronidation by human recombinant UGT2B7,Confirmatory,15781124.0,
1250,624650,3,4,,103177883,3121,Unspecified,,,693.0,IC50,Inhibition of AZT (0.02 mM) glucuronidation by human UGT enzymes from liver microsomes,Confirmatory,15781124.0,
1251,624655,1,8,,103177883,3121,Unspecified,332278237.0,7366.0,,,Inhibition of dihydrotestosterone (assayed at the Km) glucuronidation by human recombinant UGT2B15 (+/- 11% inhibition at 5mM VPA),Other,15781124.0,
1252,624663,1,9,,103177883,3121,Unspecified,29839451.0,54600.0,,,Inhibition of propofol (assayed at the Km) glucuronidation by human recombinant UGT1A9 (+/- 15% inhibition at 5mM VPA),Other,15781124.0,
1253,625144,5,5,,103177883,3121,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1254,625145,4,7,,103177883,3121,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1255,625146,5,5,,103177883,3121,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1256,625147,4,7,,103177883,3121,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1257,625148,4,7,,103177883,3121,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1258,625149,4,7,,103177883,3121,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1259,625150,5,5,,103177883,3121,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1260,625151,4,7,,103177883,3121,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1261,625152,4,7,,103177883,3121,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1262,625153,4,7,,103177883,3121,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1263,625154,4,7,,103177883,3121,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1264,625155,4,7,,103177883,3121,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1265,625156,1,9,,103177883,3121,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1266,625157,6,2,,103177883,3121,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1267,625158,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1268,625159,5,5,,103177883,3121,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1269,625160,1,9,,103177883,3121,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1270,625161,4,7,,103177883,3121,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1271,625162,4,7,,103177883,3121,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1272,625163,4,7,,103177883,3121,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1273,625164,1,6,,103177883,3121,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1274,625165,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1275,625166,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1276,625167,5,5,,103177883,3121,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1277,625168,4,7,,103177883,3121,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1278,625169,1,6,,103177883,3121,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1279,625170,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1280,625171,4,7,,103177883,3121,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1281,625172,4,7,,103177883,3121,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1282,625173,5,5,,103177883,3121,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1283,625174,5,5,,103177883,3121,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1284,625175,5,5,,103177883,3121,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1285,625176,1,9,,103177883,3121,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1286,625177,5,5,,103177883,3121,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1287,625178,5,5,,103177883,3121,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1288,625179,1,9,,103177883,3121,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1289,625180,5,5,,103177883,3121,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1290,625181,5,5,,103177883,3121,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1291,625182,5,5,,103177883,3121,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1292,625183,5,5,,103177883,3121,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1293,625184,5,5,,103177883,3121,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1294,625185,5,5,,103177883,3121,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1295,625186,5,5,,103177883,3121,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1296,625187,5,5,,103177883,3121,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1297,625188,1,9,,103177883,3121,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1298,625189,1,7,,103177883,3121,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1299,625190,4,5,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1300,625191,4,7,,103177883,3121,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1301,625192,4,7,,103177883,3121,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1302,625193,5,5,,103177883,3121,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1303,625194,4,7,,103177883,3121,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1304,625195,4,7,,103177883,3121,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1305,625196,5,6,,103177883,3121,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1306,625197,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1307,625198,4,7,,103177883,3121,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1308,625199,4,7,,103177883,3121,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1309,625200,4,7,,103177883,3121,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1310,625201,4,7,,103177883,3121,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1311,625202,4,7,,103177883,3121,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1312,625203,4,7,,103177883,3121,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1313,625204,4,7,,103177883,3121,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1314,625205,4,7,,103177883,3121,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1315,625206,4,7,,103177883,3121,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1316,625207,4,7,,103177883,3121,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1317,625208,5,5,,103177883,3121,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1318,625209,4,7,,103177883,3121,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1319,625210,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1320,625211,1,6,,103177883,3121,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1321,625212,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1322,625213,4,7,,103177883,3121,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1323,625214,1,9,,103177883,3121,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1324,625215,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1325,625216,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1326,625217,4,7,,103177883,3121,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1327,625218,4,7,,103177883,3121,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1328,625219,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1329,625220,4,7,,103177883,3121,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1330,625221,4,7,,103177883,3121,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1331,625222,4,7,,103177883,3121,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1332,625223,4,7,,103177883,3121,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1333,625224,3,4,,103177883,3121,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1334,625225,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1335,625226,4,7,,103177883,3121,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1336,625227,4,7,,103177883,3121,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1337,625228,4,7,,103177883,3121,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1338,625229,5,5,,103177883,3121,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1339,625230,1,6,,103177883,3121,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1340,625231,4,7,,103177883,3121,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1341,625232,1,9,,103177883,3121,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1342,625233,4,7,,103177883,3121,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1343,625234,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1344,625235,4,7,,103177883,3121,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1345,625236,5,5,,103177883,3121,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1346,625237,4,7,,103177883,3121,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1347,625238,4,7,,103177883,3121,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1348,625239,4,7,,103177883,3121,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1349,625240,1,9,,103177883,3121,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1350,625241,4,7,,103177883,3121,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1351,625242,4,7,,103177883,3121,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1352,625243,5,5,,103177883,3121,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1353,625244,5,5,,103177883,3121,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1354,625245,5,5,,103177883,3121,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1355,625246,1,9,,103177883,3121,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1356,625247,5,5,,103177883,3121,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1357,625248,5,5,,103177883,3121,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1358,625249,5,5,,103177883,3121,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1359,625250,5,5,,103177883,3121,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1360,625251,5,5,,103177883,3121,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1361,625252,4,7,,103177883,3121,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1362,625253,4,7,,103177883,3121,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1363,625254,4,7,,103177883,3121,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1364,625255,4,7,,103177883,3121,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1365,625256,4,7,,103177883,3121,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1366,625257,4,7,,103177883,3121,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1367,625258,4,7,,103177883,3121,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1368,625259,4,7,,103177883,3121,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1369,625260,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1370,625261,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1371,625262,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1372,625263,4,7,,103177883,3121,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1373,625264,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1374,625265,1,6,,103177883,3121,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1375,625266,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1376,625267,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1377,625268,4,2,,103177883,3121,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1378,625268,4,2,,103177883,3121,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1379,625268,4,2,,103177883,3121,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1380,625268,4,2,,103177883,3121,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1381,625269,4,7,,103177883,3121,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1382,625270,4,7,,103177883,3121,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1383,625271,5,5,,103177883,3121,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1384,625272,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1385,625273,4,6,,103177883,3121,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1386,625274,1,6,,103177883,3121,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1387,625275,3,4,,103177883,3121,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1388,625276,1,3,,103177883,3121,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI,Other,21624500.0,
1389,625279,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1390,625280,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1391,625281,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1392,625282,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1393,625283,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1394,625284,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1395,625285,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1396,625286,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1397,625287,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1398,625288,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1399,625289,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1400,625290,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1401,625291,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1402,625292,1,3,,103177883,3121,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1403,632993,1,3,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed mouse assessed as inability to maintain equilibrium on rotarod by rotarod test,Other,21982794.0,
1404,632994,1,3,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed rat assessed as neurological deficit by rotarod test,Other,21982794.0,
1405,632995,3,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed mouse assessed as protection against maximal electric shock-induced seizures,Other,21982794.0,
1406,632996,3,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed rat assessed as protection against maximal electric shock-induced seizures,Other,21982794.0,
1407,632997,1,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in mouse to ED50 for inhibition of maximal electroshock-induced seizures in mouse",Other,21982794.0,
1408,632998,1,3,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in rat to ED50 for inhibition of maximal electroshock-induced seizures in rat",Other,21982794.0,
1409,643383,1,6,,103177883,3121,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
1410,651550,1,1,,49640649,3121,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1411,651560,1,1,,49640649,3121,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1412,651572,1,2,,49640649,3121,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1413,651582,1,1,,49640649,3121,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1414,651602,1,1,,49640649,3121,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1415,651602,1,1,,49640649,3121,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1416,651602,1,1,,49640649,3121,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1417,651610,2,1,,49640649,3121,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1418,651631,4,1,,144204642,3121,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1419,651631,4,1,,144209161,3121,Inconclusive,269849759.0,7157.0,5.4206,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1420,651631,4,1,,144210920,3121,Inconclusive,269849759.0,7157.0,68.5896,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1421,651632,4,1,,144204642,3121,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1422,651632,4,1,,144209161,3121,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1423,651632,4,1,,144210920,3121,Inactive,296439460.0,79915.0,68.5896,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1424,651633,4,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1425,651633,4,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1426,651633,4,1,,144210920,3121,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1427,651634,4,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1428,651634,4,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1429,651634,4,1,,144210920,3121,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1430,651635,1,3,,49640649,3121,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1431,651636,1,1,,49640649,3121,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1432,651640,1,1,,49640649,3121,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1433,651644,1,1,,49640649,3121,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1434,651647,1,1,,49640649,3121,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1435,651654,1,1,,49640649,3121,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1436,651658,1,1,,49640649,3121,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1437,651661,2,1,,49640649,3121,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1438,651687,1,1,,49640649,3121,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1439,651699,1,1,,49640649,3121,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1440,651699,1,1,,49640649,3121,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1441,651702,1,2,,49640649,3121,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1442,651704,2,1,,49640649,3121,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1443,651710,1,1,,49640649,3121,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1444,651711,2,1,,49640649,3121,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1445,651718,1,2,,49640649,3121,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1446,651723,1,1,,49640649,3121,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1447,651724,1,1,,49640649,3121,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1448,651725,1,1,,49640649,3121,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1449,651741,1,1,,17389523,3121,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1450,651741,1,1,,26752920,3121,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1451,651741,1,1,,26752921,3121,Inconclusive,20149576.0,4780.0,1412.54,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1452,651743,1,1,,17389523,3121,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1453,651743,1,1,,26752920,3121,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1454,651743,1,1,,26752921,3121,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1455,651749,1,1,,17389523,3121,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1456,651749,1,1,,26752920,3121,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1457,651749,1,1,,26752921,3121,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1458,651751,1,1,,17389523,3121,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1459,651751,1,1,,26752920,3121,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1460,651751,1,1,,26752921,3121,Active,5702233.0,84385.0,501.18699999999995,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1461,651754,1,1,,17389523,3121,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1462,651755,1,1,,17389523,3121,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1463,651757,1,1,,17389523,3121,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1464,651758,1,1,,17389523,3121,Inactive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1465,651768,1,2,,49640649,3121,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1466,651777,1,1,,17389523,3121,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1467,651777,1,1,,26752920,3121,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1468,651777,1,1,,26752921,3121,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1469,651778,1,1,,17389523,3121,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1470,651778,1,1,,26752920,3121,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1471,651778,1,1,,26752921,3121,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1472,651800,1,1,,49640649,3121,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1473,651802,1,1,,17389523,3121,Inactive,49066040.0,6097.0,66.8242,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1474,651819,1,1,,49640649,3121,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1475,651820,1,1,,49640649,3121,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1476,651821,2,4,,49640649,3121,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1477,651828,1,2,,92308862,3121,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1478,651828,1,2,,121362408,3121,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1479,651838,1,1,,17389523,3121,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1480,651838,1,1,,26752920,3121,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1481,651838,1,1,,26752921,3121,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1482,651838,1,1,1.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1483,651838,1,1,1.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1484,651838,1,1,1.0,26752921,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1485,651838,1,1,2.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1486,651838,1,1,2.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1487,651838,1,1,2.0,26752921,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1488,651838,1,1,3.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1489,651838,1,1,3.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1490,651838,1,1,3.0,26752921,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1491,651838,1,1,4.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1492,651838,1,1,4.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1493,651838,1,1,4.0,26752921,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1494,651838,1,1,5.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1495,651838,1,1,5.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1496,651838,1,1,5.0,26752921,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1497,651838,1,1,6.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1498,651838,1,1,6.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1499,651838,1,1,6.0,26752921,3121,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1500,651838,1,1,7.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1501,651838,1,1,7.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1502,651838,1,1,7.0,26752921,3121,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1503,651838,1,1,8.0,17389523,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1504,651838,1,1,8.0,26752920,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1505,651838,1,1,8.0,26752921,3121,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1506,651957,1,1,,49640649,3121,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1507,651958,1,1,,49640649,3121,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1508,651965,1,1,,49640649,3121,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1509,651999,1,1,,49640649,3121,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1510,652010,1,1,,49640649,3121,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1511,652017,1,1,,49640649,3121,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1512,652025,1,1,,49640649,3121,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1513,652039,1,1,,49640649,3121,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1514,652048,1,2,,49640649,3121,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1515,652048,1,2,,144204642,3121,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1516,652051,1,1,,49640649,3121,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1517,652051,1,1,,144204642,3121,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1518,652054,1,1,,49640649,3121,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1519,652067,1,4,,49640649,3121,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1520,652104,1,1,,49640649,3121,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1521,652105,1,1,,49640649,3121,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1522,652106,1,1,,49640649,3121,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1523,652115,1,1,,49640649,3121,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1524,652126,1,3,,49640649,3121,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1525,652154,1,1,,49640649,3121,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1526,652162,2,1,,49640649,3121,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1527,652163,1,1,,49640649,3121,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1528,652197,1,1,,49640649,3121,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1529,652257,1,1,,49640649,3121,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1530,666675,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against maximal electroshock-induced seizures,Other,22727446.0,
1531,666676,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against subcutaneous pentylenetetrazol-induced clonic seizures,Other,22727446.0,
1532,666677,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed Kunming mouse measured 30 mins post compound administration by rotorod test,Other,22727446.0,
1533,666678,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Kunming mouse to ED50 for protection against MES-induced seizures in Kunming mouse",Other,22727446.0,
1534,666679,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Kunming mouse to ED50 for protection against subcutaneous pentylenetetrazol-induced clonic seizures in Kunming mouse",Other,22727446.0,
1535,678712,1,8,,103177883,3121,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1536,678713,1,8,,103177883,3121,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1537,678714,1,8,,103177883,3121,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1538,678715,1,8,,103177883,3121,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1539,678716,1,8,,103177883,3121,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1540,678717,1,8,,103177883,3121,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1541,678721,1,5,,103177883,3121,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1542,678722,1,5,,103177883,3121,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1543,681141,2,7,,103177883,3121,Unspecified,74730587.0,9376.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11306713.0,
1544,681169,2,7,,103177883,3121,Unspecified,8928257.0,6584.0,,Km,TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells,Confirmatory,10525100.0,
1545,681371,2,7,,103177883,3121,Unspecified,81879627.0,108114.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,12065749.0,
1546,681399,1,7,,103177883,3121,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, Valproic acid: 1000 uM) in Xenopus laevis oocytes",Other,12358729.0,
1547,681765,1,7,,103177883,3121,Unspecified,81886651.0,29509.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, Valproic acid; 2000 uM) in Xenopus laevis oocytes",Other,9228014.0,
1548,682069,1,7,,103177883,3121,Unspecified,1709076.0,25027.0,,,TP_TRANSPORTER: uptake of Valproic acid at a concentration of 19uM in MCT1-expressing MDA-MB231 cells,Other,10579682.0,
1549,682289,1,7,,103177883,3121,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Valproic acid: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
1550,684127,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley albino rat assessed as minimal motor impairment by rotarod test,Other,22339381.0,
1551,684339,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against maximal electroshock-induced seizures,Other,22339381.0,
1552,684342,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for po dosed Sprague-Dawley albino rat by rotarod test to ED50 for po dosed Sprague-Dawley albino rat by maximal electroshock seizures test",Other,22339381.0,
1553,684345,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against subcutaneous metrazol-induced seizures,Other,22339381.0,
1554,684348,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for po dosed Sprague-Dawley albino rat by rotarod test to ED50 for po dosed Sprague-Dawley albino rat by subcutaneous metrazol seizures test",Other,22339381.0,
1555,686940,1,1,,49640649,3121,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1556,686964,1,1,,49640649,3121,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1557,686970,1,2,,49640649,3121,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1558,686971,1,2,,49640649,3121,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1559,686978,1,1,,49640649,3121,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1560,686978,1,1,,144204642,3121,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1561,686979,1,1,,49640649,3121,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1562,686979,1,1,,144204642,3121,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1563,686992,2,1,,49640649,3121,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1564,686996,1,1,,49640649,3121,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1565,687014,1,1,,49640649,3121,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1566,687016,1,1,,49640649,3121,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1567,687765,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 mouse assessed as protection against maximal electroshock-induced seizure after 30 mins,Other,21639114.0,
1568,687767,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 mouse assessed as time of peak effect for protection against maximal electroshock-induced seizure,Other,21639114.0,
1569,687774,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed NMRI mouse assessed as minimal motor impairment after 30 mins,Other,21639114.0,
1570,687775,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed NMRI mouse assessed as time of peak effect for minimal motor impairment after 30 mins,Other,21639114.0,
1571,687785,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizure after 30 mins,Other,21639114.0,
1572,687786,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as time of peak effect for protection against maximal electroshock-induced seizure after 30 mins,Other,21639114.0,
1573,687787,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley rat assessed as minimal motor impairment after 30 mins by rotorod test,Other,21639114.0,
1574,687788,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley rat assessed as time of peak effect for minimal motor impairment after 30 mins by rotorod test,Other,21639114.0,
1575,687789,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for Sprague-Dawley rat to ED50 for Sprague-Dawley rat by maximal electroshock seizure test",Other,21639114.0,
1576,692350,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against maximal electroshock-induced seizures,Other,21664729.0,
1577,692351,2,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as protection against subcutaneous pentylenetetrazole-induced seizures,Other,21664729.0,
1578,699539,1,7,,103177883,3121,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1579,699540,1,7,,103177883,3121,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1580,699541,1,7,,103177883,3121,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1581,699752,3,2,,103177883,3121,Unspecified,,,100.0,IC50,Inhibition of SIRT5,Confirmatory,22583019.0,
1582,720504,1,1,,49640649,3121,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1583,720508,1,1,,49640649,3121,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1584,720509,1,1,,49640649,3121,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1585,720511,1,1,,49640649,3121,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1586,720516,2,1,,144204642,3121,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1587,720516,2,1,,144209161,3121,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1588,720516,2,1,,144210920,3121,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1589,720532,1,1,,144204642,3121,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1590,720533,1,1,,144204642,3121,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1591,720542,1,2,,49640649,3121,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1592,720543,1,1,,49640649,3121,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1593,720551,1,2,,49640649,3121,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1594,720552,2,1,,144204642,3121,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1595,720552,2,1,,144209161,3121,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1596,720552,2,1,,144210920,3121,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1597,720553,1,2,,49640649,3121,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1598,720554,1,3,,121362408,3121,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
1599,720579,2,1,,49640649,3121,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1600,720580,1,1,,49640649,3121,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1601,720582,1,1,,49640649,3121,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1602,720596,1,1,,49640649,3121,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1603,720634,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1604,720634,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1605,720634,2,1,,144210920,3121,Inactive,,,68.5896,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1606,720635,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1607,720635,2,1,,144209161,3121,Inconclusive,,,0.2158,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1608,720635,2,1,,144210920,3121,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1609,720636,1,1,,17389523,3121,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1610,720636,1,1,,26752920,3121,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1611,720636,1,1,,26752921,3121,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1612,720637,2,1,,144204642,3121,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1613,720637,2,1,,144209161,3121,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1614,720637,2,1,,144210920,3121,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1615,720641,1,2,,92308862,3121,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1616,720647,1,2,,49640649,3121,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1617,720648,1,1,,49640649,3121,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1618,720652,1,1,,17389523,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1619,720653,1,1,,17389523,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1620,720653,1,1,,26752920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1621,720653,1,1,,26752921,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1622,720659,1,1,,17389523,3121,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1623,720659,1,1,,26752920,3121,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1624,720659,1,1,,26752921,3121,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1625,720674,2,2,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1626,720674,2,2,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1627,720674,2,2,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1628,720675,2,2,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1629,720675,2,2,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1630,720675,2,2,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1631,720678,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1632,720678,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1633,720678,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1634,720679,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1635,720679,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1636,720679,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1637,720680,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1638,720680,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1639,720680,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1640,720681,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1641,720681,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1642,720681,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1643,720682,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1644,720682,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1645,720682,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1646,720683,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1647,720683,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1648,720683,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1649,720684,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1650,720684,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1651,720684,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1652,720685,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1653,720685,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1654,720685,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1655,720686,2,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1656,720686,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1657,720686,2,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1658,720687,2,2,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1659,720687,2,2,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1660,720687,2,2,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1661,720691,4,1,,144204642,3121,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1662,720691,4,1,,144209161,3121,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1663,720691,4,1,,144210920,3121,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1664,720692,3,1,,144204642,3121,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1665,720692,3,1,,144209161,3121,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1666,720692,3,1,,144210920,3121,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1667,720693,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1668,720693,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1669,720693,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1670,720700,1,4,,49640649,3121,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1671,720702,1,1,,49640649,3121,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1672,720704,1,4,,49640649,3121,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1673,720706,1,2,,49640649,3121,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1674,720707,1,2,,49640649,3121,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1675,720708,1,2,,49640649,3121,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1676,720709,1,2,,49640649,3121,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1677,720711,1,2,,49640649,3121,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1678,720717,1,3,,92308862,3121,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1679,720719,2,1,,144204642,3121,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1680,720719,2,1,,144209161,3121,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1681,720719,2,1,,144210920,3121,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1682,720725,2,1,,144204642,3121,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1683,720725,2,1,,144209161,3121,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1684,720725,2,1,,144210920,3121,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1685,720963,2,5,,103177883,3121,Unspecified,1168407.0,24192.0,56.1,IC50,"Inhibition of Fischer-344 rat kidney ALR1 using D,L-glyceraldehyde as substrate by spectrophotometry",Confirmatory,23312612.0,
1686,743012,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1687,743012,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1688,743012,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1689,743014,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1690,743014,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1691,743014,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1692,743015,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1693,743015,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1694,743015,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1695,743033,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1696,743033,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1697,743033,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1698,743035,2,1,,144204642,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1699,743035,2,1,,144209161,3121,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1700,743035,2,1,,144210920,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1701,743036,2,1,,144204642,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1702,743036,2,1,,144209161,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1703,743036,2,1,,144210920,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1704,743040,3,1,,144204642,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1705,743040,3,1,,144209161,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1706,743040,3,1,,144210920,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1707,743041,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1708,743041,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1709,743041,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1710,743042,3,1,,144204642,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1711,743042,3,1,,144209161,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1712,743042,3,1,,144210920,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1713,743053,2,1,,144204642,3121,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1714,743053,2,1,,144209161,3121,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1715,743053,2,1,,144210920,3121,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1716,743054,2,1,,144204642,3121,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1717,743054,2,1,,144209161,3121,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1718,743054,2,1,,144210920,3121,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1719,743063,2,1,,144204642,3121,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1720,743063,2,1,,144209161,3121,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1721,743063,2,1,,144210920,3121,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1722,743064,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1723,743064,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1724,743064,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1725,743065,3,1,,144204642,3121,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1726,743065,3,1,,144209161,3121,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1727,743065,3,1,,144210920,3121,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1728,743066,3,1,,144204642,3121,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1729,743066,3,1,,144209161,3121,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1730,743066,3,1,,144210920,3121,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1731,743067,2,1,,144204642,3121,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1732,743067,2,1,,144209161,3121,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1733,743067,2,1,,144210920,3121,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1734,743069,2,1,,144204642,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1735,743069,2,1,,144209161,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1736,743069,2,1,,144210920,3121,Inactive,348019627.0,2099.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1737,743074,2,1,,144204642,3121,Inconclusive,,,4.7716,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1738,743074,2,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1739,743074,2,1,,144210920,3121,Inconclusive,,,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1740,743075,2,1,,144204642,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1741,743075,2,1,,144209161,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1742,743075,2,1,,144210920,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1743,743077,2,1,,144204642,3121,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1744,743077,2,1,,144209161,3121,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1745,743077,2,1,,144210920,3121,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1746,743078,2,1,,144204642,3121,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1747,743078,2,1,,144209161,3121,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1748,743078,2,1,,144210920,3121,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1749,743079,3,1,,144204642,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1750,743079,3,1,,144209161,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1751,743079,3,1,,144210920,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1752,743080,3,1,,144204642,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1753,743080,3,1,,144209161,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1754,743080,3,1,,144210920,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1755,743081,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1756,743081,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1757,743081,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1758,743083,3,1,,144204642,3121,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1759,743083,3,1,,144209161,3121,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1760,743083,3,1,,144210920,3121,Inactive,119597822.0,1588.0,43.2771,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1761,743084,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1762,743084,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1763,743084,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1764,743085,3,1,,144204642,3121,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1765,743085,3,1,,144209161,3121,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1766,743085,3,1,,144210920,3121,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1767,743086,3,1,,144204642,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1768,743086,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1769,743086,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1770,743091,2,1,,144204642,3121,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1771,743091,2,1,,144209161,3121,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1772,743091,2,1,,144210920,3121,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1773,743094,3,1,,144204642,3121,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1774,743094,3,1,,144209161,3121,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1775,743094,3,1,,144210920,3121,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1776,743122,2,1,,144204642,3121,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1777,743122,2,1,,144209161,3121,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1778,743122,2,1,,144210920,3121,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1779,743126,1,1,,49640649,3121,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1780,743139,2,1,,144204642,3121,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1781,743139,2,1,,144209161,3121,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1782,743139,2,1,,144210920,3121,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1783,743140,2,1,,144204642,3121,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1784,743140,2,1,,144209161,3121,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1785,743140,2,1,,144210920,3121,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1786,743191,3,1,,144209161,3121,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1787,743191,3,1,,144210920,3121,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1788,743191,3,1,,170465446,3121,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1789,743194,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1790,743194,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1791,743194,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1792,743199,2,1,,144209161,3121,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1793,743199,2,1,,144210920,3121,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1794,743199,2,1,,170465446,3121,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1795,743202,4,1,,144209161,3121,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1796,743202,4,1,,144210920,3121,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1797,743202,4,1,,170465446,3121,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1798,743203,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1799,743203,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1800,743203,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1801,743209,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1802,743209,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1803,743209,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1804,743210,4,1,,144209161,3121,Inconclusive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1805,743210,4,1,,144210920,3121,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1806,743210,4,1,,170465446,3121,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1807,743211,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1808,743211,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1809,743211,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1810,743212,3,1,,144209161,3121,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1811,743212,3,1,,144210920,3121,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1812,743212,3,1,,170465446,3121,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1813,743213,3,1,,144209161,3121,Inconclusive,,,1.3741,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1814,743213,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1815,743213,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1816,743215,3,1,,144209161,3121,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1817,743215,3,1,,144210920,3121,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1818,743215,3,1,,170465446,3121,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1819,743217,3,1,,144209161,3121,Inconclusive,325495553.0,9971.0,21.7788,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1820,743217,3,1,,144210920,3121,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1821,743217,3,1,,170465446,3121,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1822,743218,3,1,,144209161,3121,Inconclusive,,,0.0069,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1823,743218,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1824,743218,3,1,,170465446,3121,Inconclusive,,,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1825,743219,3,1,,144209161,3121,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1826,743219,3,1,,144210920,3121,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1827,743219,3,1,,170465446,3121,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1828,743220,3,1,,144209161,3121,Inconclusive,325495553.0,9971.0,61.3809,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1829,743220,3,1,,144210920,3121,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1830,743220,3,1,,170465446,3121,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1831,743221,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1832,743221,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1833,743221,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1834,743222,3,1,,144209161,3121,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1835,743222,3,1,,144210920,3121,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1836,743222,3,1,,170465446,3121,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1837,743223,3,1,,144209161,3121,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1838,743223,3,1,,144210920,3121,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1839,743223,3,1,,170465446,3121,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1840,743224,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1841,743224,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1842,743224,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1843,743225,3,1,,144209161,3121,Inconclusive,,,13.7415,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1844,743225,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1845,743225,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1846,743226,2,1,,144209161,3121,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1847,743226,2,1,,144210920,3121,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1848,743226,2,1,,170465446,3121,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1849,743227,2,1,,144209161,3121,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1850,743227,2,1,,144210920,3121,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1851,743227,2,1,,170465446,3121,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1852,743228,3,1,,144209161,3121,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1853,743228,3,1,,144210920,3121,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1854,743228,3,1,,170465446,3121,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1855,743238,1,1,,49640649,3121,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1856,743239,2,1,,144209161,3121,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1857,743239,2,1,,144210920,3121,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1858,743239,2,1,,170465446,3121,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1859,743240,2,1,,144209161,3121,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1860,743240,2,1,,144210920,3121,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1861,743240,2,1,,170465446,3121,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1862,743241,2,1,,144209161,3121,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1863,743241,2,1,,144210920,3121,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1864,743241,2,1,,170465446,3121,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1865,743242,2,1,,144209161,3121,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1866,743242,2,1,,144210920,3121,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1867,743242,2,1,,170465446,3121,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1868,743244,1,1,,144204642,3121,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1869,743247,1,2,,49640649,3121,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1870,743255,1,1,,49640649,3121,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1871,743266,1,2,,49640649,3121,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1872,743268,1,1,,172080707,3121,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
1873,743269,1,1,,49640649,3121,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1874,743269,1,1,,49640649,3121,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1875,743270,1,1,,172080707,3121,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
1876,743271,1,1,,172080707,3121,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
1877,743272,1,1,,172080707,3121,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
1878,743279,1,2,,49640649,3121,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1879,743288,1,1,,17389523,3121,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1880,743288,1,1,,26752920,3121,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1881,743288,1,1,,26752921,3121,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1882,743292,1,1,,17389523,3121,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1883,743292,1,1,,26752920,3121,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1884,743292,1,1,,26752921,3121,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1885,743397,1,1,,49640649,3121,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1886,743398,1,1,,49640649,3121,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1887,759084,1,1,,103177883,3121,Unspecified,,,,,Toxicity in po dosed albino Sprague-Dawley rat assessed as behavioral toxicity after 0.5 hrs,Other,23772678.0,
1888,759087,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against po dosed albino Sprague-Dawley rat after 0.5 hrs by maximal electroshock seizure test,Other,23772678.0,
1889,759104,1,1,,103177883,3121,Unspecified,,,,,Toxicity in ip dosed albino CF1 mouse after 0.25 hrs by rotorod test,Other,23772678.0,
1890,759124,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against ip dosed albino CF1 mouse after 0.25 hrs by maximal electroshock seizure test,Other,23772678.0,
1891,779005,1,1,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as time to peak effect by rotorod test,Other,23993970.0,
1892,779006,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against maximal subcutaneous pentylenetetrazole-induced convulsion in po dosed albino Sprague-Dawley rat assessed as time to peak effect,Other,23993970.0,
1893,779007,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against maximal electroshock-induced seizures in po dosed albino Sprague-Dawley rat assessed as time to peak effect,Other,23993970.0,
1894,779008,1,1,,103177883,3121,Unspecified,,,,,"Protection index, ratio of TD50 for neurotoxicity in po dosed albino Sprague-Dawley rat by rotorod test to ED50 for anticonvulsant activity in po dosed albino Sprague-Dawley rat by scPTZ test",Other,23993970.0,
1895,779009,1,1,,103177883,3121,Unspecified,,,,,"Protection index, ratio of TD50 for neurotoxicity in po dosed albino Sprague-Dawley rat by rotorod test to ED50 for anticonvulsant activity in po dosed albino Sprague-Dawley rat by MES test",Other,23993970.0,
1896,779010,1,1,,103177883,3121,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as minimum motor impairment by rotorod test,Other,23993970.0,
1897,779011,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against subcutaneous pentylenetetrazole-induced convulsion,Other,23993970.0,
1898,779014,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures,Other,23993970.0,
1899,782602,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvic Mucosa, Inflammation; Study_ID: 90/5",Other,,
1900,782603,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 90/6,Other,,
1901,782604,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 90/6",Other,,
1902,782605,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 90/6",Other,,
1903,782606,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Nodule, Hepatodiaphragmatic; Study_ID: 90/7",Other,,
1904,782607,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 90/8,Other,,
1905,782608,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 90/9",Other,,
1906,782609,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Cast,Hyaline; Study_ID: 90/10",Other,,
1907,782610,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 90/11",Other,,
1908,782611,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 90/12,Other,,
1909,782612,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 90/12",Other,,
1910,782613,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Microgranuloma; Study_ID: 90/14,Other,,
1911,782614,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 90/15",Other,,
1912,782615,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 90/16",Other,,
1913,782616,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 91/5,Other,,
1914,782617,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Microgranuloma; Study_ID: 91/6,Other,,
1915,782618,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: 91/6",Other,,
1916,782619,1,2,,103177883,3121,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 91/6",Other,,
1917,809701,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/15,Other,,
1918,809702,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/15,Other,,
1919,809703,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/15,Other,,
1920,809704,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/15,Other,,
1921,809705,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/15,Other,,
1922,809706,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/15,Other,,
1923,809707,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/15,Other,,
1924,809708,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/15,Other,,
1925,809709,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/16,Other,,
1926,809710,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/16,Other,,
1927,809711,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/16,Other,,
1928,810070,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/16,Other,,
1929,810071,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/16,Other,,
1930,810072,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/16,Other,,
1931,810073,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/16,Other,,
1932,810074,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/16,Other,,
1933,810075,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/16,Other,,
1934,810076,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/16,Other,,
1935,810077,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/16,Other,,
1936,810078,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/16,Other,,
1937,810079,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/16,Other,,
1938,810080,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/16,Other,,
1939,810081,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/16,Other,,
1940,810082,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/16,Other,,
1941,810083,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/16,Other,,
1942,810177,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/5,Other,,
1943,810178,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/5,Other,,
1944,810179,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/5,Other,,
1945,810180,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/5,Other,,
1946,810181,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/5,Other,,
1947,810182,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/5,Other,,
1948,810183,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/5,Other,,
1949,810184,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/5,Other,,
1950,810185,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/5,Other,,
1951,810186,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/5,Other,,
1952,810187,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/5,Other,,
1953,810188,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/5,Other,,
1954,810189,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/5,Other,,
1955,810190,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/6,Other,,
1956,810191,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/6,Other,,
1957,810192,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/6,Other,,
1958,810193,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/6,Other,,
1959,810194,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/6,Other,,
1960,810195,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/6,Other,,
1961,810196,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/6,Other,,
1962,810197,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/6,Other,,
1963,810198,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/6,Other,,
1964,810199,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/6,Other,,
1965,810200,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/6,Other,,
1966,810201,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/6,Other,,
1967,810202,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/6,Other,,
1968,810203,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/6,Other,,
1969,810204,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/6,Other,,
1970,810215,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/16,Other,,
1971,810216,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/16,Other,,
1972,810217,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/16,Other,,
1973,810218,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/16,Other,,
1974,810219,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/16,Other,,
1975,810220,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/16,Other,,
1976,810221,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/16,Other,,
1977,810222,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/16,Other,,
1978,810223,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/5,Other,,
1979,810224,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/5,Other,,
1980,810225,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/5,Other,,
1981,810226,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/5,Other,,
1982,810227,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/5,Other,,
1983,810228,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/5,Other,,
1984,810229,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/5,Other,,
1985,810230,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/5,Other,,
1986,810231,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/5,Other,,
1987,810232,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/5,Other,,
1988,810233,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/5,Other,,
1989,810234,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/5,Other,,
1990,810235,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/5,Other,,
1991,810236,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/5,Other,,
1992,810237,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/5,Other,,
1993,810238,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/5,Other,,
1994,810239,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/5,Other,,
1995,810240,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/6,Other,,
1996,810241,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/6,Other,,
1997,810242,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/6,Other,,
1998,810243,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/6,Other,,
1999,810244,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/6,Other,,
2000,810245,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/6,Other,,
2001,810246,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/6,Other,,
2002,810247,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/6,Other,,
2003,810248,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/6,Other,,
2004,810249,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/6,Other,,
2005,810564,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/6,Other,,
2006,810565,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/6,Other,,
2007,810566,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/7,Other,,
2008,810567,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/7,Other,,
2009,810568,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/7,Other,,
2010,810569,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/7,Other,,
2011,810570,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/7,Other,,
2012,810571,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/7,Other,,
2013,810572,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/7,Other,,
2014,810573,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/7,Other,,
2015,810574,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/7,Other,,
2016,810575,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/7,Other,,
2017,810576,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/7,Other,,
2018,810577,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/7,Other,,
2019,810578,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/7,Other,,
2020,810579,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/7,Other,,
2021,810580,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/7,Other,,
2022,810581,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/7,Other,,
2023,810582,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/7,Other,,
2024,810583,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/8,Other,,
2025,810610,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/6,Other,,
2026,810611,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/6,Other,,
2027,810612,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/6,Other,,
2028,810613,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/6,Other,,
2029,810614,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/6,Other,,
2030,810615,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/6,Other,,
2031,810616,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/6,Other,,
2032,810617,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/7,Other,,
2033,810618,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/7,Other,,
2034,810619,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/7,Other,,
2035,810620,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/7,Other,,
2036,810621,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/7,Other,,
2037,811213,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/7,Other,,
2038,811214,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/7,Other,,
2039,811215,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/7,Other,,
2040,811216,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/7,Other,,
2041,811217,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/7,Other,,
2042,811218,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/7,Other,,
2043,811219,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/7,Other,,
2044,811220,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/7,Other,,
2045,811221,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/7,Other,,
2046,811222,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/7,Other,,
2047,811223,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/7,Other,,
2048,811224,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/7,Other,,
2049,811225,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/8,Other,,
2050,811226,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/8,Other,,
2051,811227,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/8,Other,,
2052,811228,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/8,Other,,
2053,811229,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/8,Other,,
2054,811230,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/8,Other,,
2055,811231,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/8,Other,,
2056,811232,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/8,Other,,
2057,811233,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/8,Other,,
2058,811234,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/8,Other,,
2059,811235,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/8,Other,,
2060,811236,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/8,Other,,
2061,811237,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/8,Other,,
2062,811238,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/8,Other,,
2063,811239,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/8,Other,,
2064,811240,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/8,Other,,
2065,811241,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/8,Other,,
2066,811242,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/9,Other,,
2067,811243,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/9,Other,,
2068,811244,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/9,Other,,
2069,811245,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/9,Other,,
2070,811246,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/9,Other,,
2071,811247,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/9,Other,,
2072,811248,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/9,Other,,
2073,811249,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/9,Other,,
2074,811591,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/9,Other,,
2075,811592,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/9,Other,,
2076,811593,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/9,Other,,
2077,811594,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/9,Other,,
2078,811595,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/9,Other,,
2079,811596,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/9,Other,,
2080,811597,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/9,Other,,
2081,811598,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/9,Other,,
2082,811599,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/9,Other,,
2083,811600,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/10,Other,,
2084,811752,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/8,Other,,
2085,811753,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/8,Other,,
2086,811754,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/8,Other,,
2087,811755,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/8,Other,,
2088,811756,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/8,Other,,
2089,811757,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/8,Other,,
2090,811758,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/8,Other,,
2091,811759,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/8,Other,,
2092,811760,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/8,Other,,
2093,811761,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/8,Other,,
2094,811762,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/8,Other,,
2095,811763,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/8,Other,,
2096,811764,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/8,Other,,
2097,811765,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/8,Other,,
2098,811766,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/8,Other,,
2099,811767,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/8,Other,,
2100,811768,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/9,Other,,
2101,811769,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/9,Other,,
2102,812086,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/9,Other,,
2103,812087,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/9,Other,,
2104,812088,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/9,Other,,
2105,812089,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/9,Other,,
2106,812090,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/9,Other,,
2107,812091,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/9,Other,,
2108,812092,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/9,Other,,
2109,812093,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/9,Other,,
2110,812094,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/9,Other,,
2111,812095,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/9,Other,,
2112,812096,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/9,Other,,
2113,812097,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/9,Other,,
2114,812098,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/9,Other,,
2115,812099,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/9,Other,,
2116,812100,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/9,Other,,
2117,812101,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/10,Other,,
2118,812102,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/10,Other,,
2119,812103,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/10,Other,,
2120,812104,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/10,Other,,
2121,812105,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/10,Other,,
2122,812106,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/10,Other,,
2123,812107,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/10,Other,,
2124,812108,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/10,Other,,
2125,812109,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/10,Other,,
2126,812110,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/10,Other,,
2127,812111,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/10,Other,,
2128,812112,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/10,Other,,
2129,812113,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/10,Other,,
2130,812114,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/10,Other,,
2131,812115,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/10,Other,,
2132,812688,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/10,Other,,
2133,812689,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/10,Other,,
2134,812690,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/10,Other,,
2135,812691,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/10,Other,,
2136,812692,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/10,Other,,
2137,812693,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/10,Other,,
2138,812694,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/10,Other,,
2139,812695,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/10,Other,,
2140,812696,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/10,Other,,
2141,812697,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/10,Other,,
2142,812698,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/10,Other,,
2143,812699,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/10,Other,,
2144,812700,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/10,Other,,
2145,812701,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/10,Other,,
2146,812702,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/10,Other,,
2147,812703,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/10,Other,,
2148,812704,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/11,Other,,
2149,812705,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/11,Other,,
2150,812706,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/11,Other,,
2151,812707,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/11,Other,,
2152,812708,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/11,Other,,
2153,812709,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/11,Other,,
2154,812710,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/11,Other,,
2155,812711,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/11,Other,,
2156,812712,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/11,Other,,
2157,812713,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/11,Other,,
2158,812714,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/11,Other,,
2159,812715,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/11,Other,,
2160,813032,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/11,Other,,
2161,813033,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/11,Other,,
2162,813034,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/11,Other,,
2163,813035,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/11,Other,,
2164,813036,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/11,Other,,
2165,813037,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/12,Other,,
2166,813038,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/12,Other,,
2167,813039,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/12,Other,,
2168,813040,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/12,Other,,
2169,813041,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/12,Other,,
2170,813042,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/12,Other,,
2171,813043,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/12,Other,,
2172,813044,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/12,Other,,
2173,813045,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/12,Other,,
2174,813046,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/12,Other,,
2175,813047,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/12,Other,,
2176,813048,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/12,Other,,
2177,813049,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/12,Other,,
2178,813202,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/10,Other,,
2179,813203,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/10,Other,,
2180,813204,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/11,Other,,
2181,813205,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/11,Other,,
2182,813206,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/11,Other,,
2183,813207,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/11,Other,,
2184,813208,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/11,Other,,
2185,813209,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/11,Other,,
2186,813210,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/11,Other,,
2187,813526,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/11,Other,,
2188,813527,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/11,Other,,
2189,813528,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/11,Other,,
2190,813529,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/11,Other,,
2191,813530,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/11,Other,,
2192,813531,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/11,Other,,
2193,813532,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/11,Other,,
2194,813533,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/11,Other,,
2195,813534,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/11,Other,,
2196,813535,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/11,Other,,
2197,813536,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/12,Other,,
2198,813537,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/12,Other,,
2199,813538,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/12,Other,,
2200,813539,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/12,Other,,
2201,813540,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/12,Other,,
2202,813541,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/12,Other,,
2203,813542,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/12,Other,,
2204,813543,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/12,Other,,
2205,813544,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/12,Other,,
2206,813545,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/12,Other,,
2207,813546,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/12,Other,,
2208,813547,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/12,Other,,
2209,813548,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/12,Other,,
2210,813549,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/12,Other,,
2211,813550,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/12,Other,,
2212,813551,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/12,Other,,
2213,813552,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/12,Other,,
2214,813553,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/13,Other,,
2215,813554,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/13,Other,,
2216,813555,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/13,Other,,
2217,813556,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/13,Other,,
2218,813557,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/13,Other,,
2219,813558,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/13,Other,,
2220,813559,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/13,Other,,
2221,813560,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/13,Other,,
2222,813561,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/13,Other,,
2223,813562,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/13,Other,,
2224,813563,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/13,Other,,
2225,813564,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/13,Other,,
2226,814137,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/12,Other,,
2227,814138,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/12,Other,,
2228,814139,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/12,Other,,
2229,814140,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/12,Other,,
2230,814141,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/13,Other,,
2231,814142,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/13,Other,,
2232,814143,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/13,Other,,
2233,814144,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/13,Other,,
2234,814145,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/13,Other,,
2235,814146,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/13,Other,,
2236,814147,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/13,Other,,
2237,814148,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/13,Other,,
2238,814149,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/13,Other,,
2239,814150,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/13,Other,,
2240,814151,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/13,Other,,
2241,814152,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/13,Other,,
2242,814153,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/13,Other,,
2243,814154,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/13,Other,,
2244,814155,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/13,Other,,
2245,814156,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/13,Other,,
2246,814473,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/13,Other,,
2247,814474,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/14,Other,,
2248,814475,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/14,Other,,
2249,814476,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/14,Other,,
2250,814477,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/14,Other,,
2251,814478,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/14,Other,,
2252,814479,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/14,Other,,
2253,814480,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/14,Other,,
2254,814481,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/14,Other,,
2255,814482,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/14,Other,,
2256,814483,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 91/14,Other,,
2257,814484,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 91/14,Other,,
2258,814485,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 91/14,Other,,
2259,814486,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 91/14,Other,,
2260,814487,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 91/14,Other,,
2261,814488,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 91/14,Other,,
2262,814489,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 91/14,Other,,
2263,814490,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 91/14,Other,,
2264,814491,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 91/15,Other,,
2265,814492,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 91/15,Other,,
2266,814493,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 91/15,Other,,
2267,814494,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 91/15,Other,,
2268,814495,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 91/15,Other,,
2269,814496,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 91/15,Other,,
2270,814497,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 91/15,Other,,
2271,814498,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 91/15,Other,,
2272,814499,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 91/15,Other,,
2273,814927,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/5,Other,,
2274,814928,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/5,Other,,
2275,814929,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/5,Other,,
2276,814930,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/5,Other,,
2277,814966,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/13,Other,,
2278,814967,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/13,Other,,
2279,814968,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/13,Other,,
2280,814969,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/13,Other,,
2281,814970,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/13,Other,,
2282,814971,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/14,Other,,
2283,814972,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/14,Other,,
2284,814973,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/14,Other,,
2285,814974,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/14,Other,,
2286,814975,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/14,Other,,
2287,814976,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/14,Other,,
2288,814977,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/14,Other,,
2289,814978,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/14,Other,,
2290,814979,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/14,Other,,
2291,814980,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/14,Other,,
2292,814981,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/14,Other,,
2293,814982,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/14,Other,,
2294,814983,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/14,Other,,
2295,814984,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/14,Other,,
2296,814985,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/14,Other,,
2297,814986,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/14,Other,,
2298,814987,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/14,Other,,
2299,814988,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/15,Other,,
2300,814989,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/15,Other,,
2301,814990,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/15,Other,,
2302,814991,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/15,Other,,
2303,814992,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/15,Other,,
2304,814993,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/15,Other,,
2305,814994,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/15,Other,,
2306,814995,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/15,Other,,
2307,814996,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/15,Other,,
2308,814997,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 90/15,Other,,
2309,814998,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 90/15,Other,,
2310,814999,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 90/15,Other,,
2311,815000,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 90/15,Other,,
2312,815001,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 90/15,Other,,
2313,815002,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 90/15,Other,,
2314,815003,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 90/15,Other,,
2315,815004,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 90/15,Other,,
2316,815005,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 90/16,Other,,
2317,815006,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 90/16,Other,,
2318,815007,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 90/16,Other,,
2319,815008,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 90/16,Other,,
2320,815009,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 90/16,Other,,
2321,815010,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 90/16,Other,,
2322,815011,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 90/16,Other,,
2323,815326,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 90/16,Other,,
2324,815327,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 90/16,Other,,
2325,872203,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/13,Other,,
2326,872204,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/13,Other,,
2327,872205,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/13,Other,,
2328,872206,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/13,Other,,
2329,872207,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/13,Other,,
2330,872208,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/13,Other,,
2331,872209,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/13,Other,,
2332,872210,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/13,Other,,
2333,872211,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/14,Other,,
2334,872212,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/14,Other,,
2335,872213,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/14,Other,,
2336,872214,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/14,Other,,
2337,872215,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/14,Other,,
2338,872216,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/14,Other,,
2339,872217,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/14,Other,,
2340,872218,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/14,Other,,
2341,872219,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/14,Other,,
2342,872220,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/14,Other,,
2343,872221,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/14,Other,,
2344,872222,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/14,Other,,
2345,872223,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/14,Other,,
2346,872224,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/14,Other,,
2347,872225,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/14,Other,,
2348,872226,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/14,Other,,
2349,872227,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/14,Other,,
2350,872228,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/14,Other,,
2351,872229,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/14,Other,,
2352,872230,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/14,Other,,
2353,872231,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/14,Other,,
2354,872232,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/15,Other,,
2355,872233,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/15,Other,,
2356,872234,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/15,Other,,
2357,872235,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/15,Other,,
2358,872236,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/15,Other,,
2359,872237,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/15,Other,,
2360,872238,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/15,Other,,
2361,872239,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/15,Other,,
2362,872240,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/15,Other,,
2363,872241,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/15,Other,,
2364,872242,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/15,Other,,
2365,872243,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/15,Other,,
2366,872244,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/15,Other,,
2367,872245,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/15,Other,,
2368,872246,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/15,Other,,
2369,872247,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/15,Other,,
2370,872248,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/15,Other,,
2371,872929,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/15,Other,,
2372,872930,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/15,Other,,
2373,874976,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/14,Other,,
2374,874977,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/14,Other,,
2375,874978,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/14,Other,,
2376,874979,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/15,Other,,
2377,874980,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/15,Other,,
2378,874981,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/15,Other,,
2379,875121,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/15,Other,,
2380,875122,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/15,Other,,
2381,875123,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/16,Other,,
2382,875124,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/16,Other,,
2383,875125,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/16,Other,,
2384,875126,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/16,Other,,
2385,875127,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/16,Other,,
2386,875128,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/16,Other,,
2387,875129,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/16,Other,,
2388,875130,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/16,Other,,
2389,875131,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/16,Other,,
2390,875132,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/16,Other,,
2391,875133,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/16,Other,,
2392,875134,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/16,Other,,
2393,875135,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/16,Other,,
2394,875136,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/16,Other,,
2395,875137,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/16,Other,,
2396,875138,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/16,Other,,
2397,875139,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/16,Other,,
2398,875140,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/16,Other,,
2399,875141,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/16,Other,,
2400,875142,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/16,Other,,
2401,875143,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/16,Other,,
2402,875144,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/5,Other,,
2403,875145,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/5,Other,,
2404,875146,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/5,Other,,
2405,875147,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/5,Other,,
2406,875148,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/5,Other,,
2407,875149,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/5,Other,,
2408,875150,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/5,Other,,
2409,875151,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/5,Other,,
2410,875152,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/5,Other,,
2411,875153,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/5,Other,,
2412,875154,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/5,Other,,
2413,875155,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/5,Other,,
2414,875156,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/5,Other,,
2415,875157,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/5,Other,,
2416,875158,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/5,Other,,
2417,875840,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/5,Other,,
2418,875841,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/5,Other,,
2419,875842,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/5,Other,,
2420,875843,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/5,Other,,
2421,875844,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/5,Other,,
2422,875845,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/5,Other,,
2423,875846,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/6,Other,,
2424,875847,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/6,Other,,
2425,875848,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/6,Other,,
2426,875849,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/6,Other,,
2427,877174,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/15,Other,,
2428,877175,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/15,Other,,
2429,877176,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/15,Other,,
2430,877177,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/15,Other,,
2431,877178,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/15,Other,,
2432,877179,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/15,Other,,
2433,877180,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/15,Other,,
2434,877181,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/15,Other,,
2435,877182,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/15,Other,,
2436,877183,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/15,Other,,
2437,877184,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/15,Other,,
2438,877185,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/15,Other,,
2439,877186,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/15,Other,,
2440,877187,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/15,Other,,
2441,877188,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/15,Other,,
2442,877189,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/15,Other,,
2443,877190,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/15,Other,,
2444,877191,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/15,Other,,
2445,877192,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/16,Other,,
2446,877193,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/16,Other,,
2447,877194,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/16,Other,,
2448,877195,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/16,Other,,
2449,877196,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/16,Other,,
2450,877197,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/16,Other,,
2451,877198,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/16,Other,,
2452,877199,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/16,Other,,
2453,877200,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/16,Other,,
2454,877201,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/16,Other,,
2455,877202,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/16,Other,,
2456,877203,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/16,Other,,
2457,877204,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/16,Other,,
2458,877205,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/16,Other,,
2459,877206,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/16,Other,,
2460,877282,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/9,Other,,
2461,877283,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/9,Other,,
2462,877284,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/9,Other,,
2463,877285,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/9,Other,,
2464,877286,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/9,Other,,
2465,877287,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/9,Other,,
2466,877288,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/9,Other,,
2467,877289,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/9,Other,,
2468,877290,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/9,Other,,
2469,877291,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/9,Other,,
2470,877292,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/9,Other,,
2471,877293,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/9,Other,,
2472,877294,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/9,Other,,
2473,877295,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/9,Other,,
2474,877296,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/9,Other,,
2475,877297,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/9,Other,,
2476,877885,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/16,Other,,
2477,877886,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/16,Other,,
2478,877887,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/16,Other,,
2479,877888,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/16,Other,,
2480,877889,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/16,Other,,
2481,877890,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/16,Other,,
2482,877976,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/9,Other,,
2483,877977,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/9,Other,,
2484,877978,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/9,Other,,
2485,877979,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/9,Other,,
2486,877980,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/10,Other,,
2487,877981,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/10,Other,,
2488,877982,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/10,Other,,
2489,877983,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/10,Other,,
2490,877984,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/10,Other,,
2491,877985,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/10,Other,,
2492,877986,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/10,Other,,
2493,877987,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/10,Other,,
2494,877988,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/10,Other,,
2495,877989,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/10,Other,,
2496,877990,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/10,Other,,
2497,877991,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/10,Other,,
2498,877992,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/10,Other,,
2499,877993,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/10,Other,,
2500,877994,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/10,Other,,
2501,877995,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/10,Other,,
2502,877996,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/10,Other,,
2503,877997,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/10,Other,,
2504,877998,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/10,Other,,
2505,877999,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/10,Other,,
2506,878000,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/10,Other,,
2507,878001,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/11,Other,,
2508,878002,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/11,Other,,
2509,878003,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/11,Other,,
2510,878004,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/11,Other,,
2511,878005,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/11,Other,,
2512,878006,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/11,Other,,
2513,878007,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/11,Other,,
2514,880200,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/11,Other,,
2515,880201,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/11,Other,,
2516,880202,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/11,Other,,
2517,880203,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/11,Other,,
2518,880204,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/11,Other,,
2519,880205,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/11,Other,,
2520,880206,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/11,Other,,
2521,880207,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/11,Other,,
2522,880886,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/11,Other,,
2523,880887,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/11,Other,,
2524,880888,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/11,Other,,
2525,880889,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/11,Other,,
2526,880890,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/11,Other,,
2527,880891,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/11,Other,,
2528,880892,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/12,Other,,
2529,880893,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/12,Other,,
2530,880894,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/12,Other,,
2531,880895,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/12,Other,,
2532,880896,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/12,Other,,
2533,880897,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/12,Other,,
2534,880898,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/12,Other,,
2535,880899,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/12,Other,,
2536,880900,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/12,Other,,
2537,880901,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/12,Other,,
2538,880902,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/12,Other,,
2539,880903,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/12,Other,,
2540,880904,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/12,Other,,
2541,880905,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/12,Other,,
2542,880906,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/12,Other,,
2543,880907,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/12,Other,,
2544,880908,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/12,Other,,
2545,880909,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/12,Other,,
2546,880910,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/12,Other,,
2547,880911,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/12,Other,,
2548,880912,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/12,Other,,
2549,880913,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/13,Other,,
2550,880914,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/13,Other,,
2551,880915,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/13,Other,,
2552,880916,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/13,Other,,
2553,880917,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/13,Other,,
2554,880918,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/13,Other,,
2555,880919,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/13,Other,,
2556,880920,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/13,Other,,
2557,880921,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/13,Other,,
2558,880922,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/13,Other,,
2559,880923,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/13,Other,,
2560,880924,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/13,Other,,
2561,880925,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/13,Other,,
2562,906724,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/6,Other,,
2563,906725,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/6,Other,,
2564,906726,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/6,Other,,
2565,906727,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/6,Other,,
2566,906728,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/6,Other,,
2567,906729,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/7,Other,,
2568,906730,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/7,Other,,
2569,906731,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/7,Other,,
2570,906732,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/7,Other,,
2571,906733,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/7,Other,,
2572,906734,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/7,Other,,
2573,906735,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/7,Other,,
2574,906736,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/7,Other,,
2575,906737,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/7,Other,,
2576,906738,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/7,Other,,
2577,906739,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/7,Other,,
2578,906740,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/7,Other,,
2579,906741,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/7,Other,,
2580,906742,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/7,Other,,
2581,906743,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/7,Other,,
2582,906744,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/7,Other,,
2583,906745,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/7,Other,,
2584,906746,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/7,Other,,
2585,906747,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/7,Other,,
2586,906748,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/7,Other,,
2587,906749,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/7,Other,,
2588,906750,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/8,Other,,
2589,906751,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/8,Other,,
2590,906752,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/8,Other,,
2591,906753,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/8,Other,,
2592,906754,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/8,Other,,
2593,906755,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/8,Other,,
2594,906756,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/8,Other,,
2595,906757,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/8,Other,,
2596,906758,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/8,Other,,
2597,906759,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/8,Other,,
2598,906760,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/8,Other,,
2599,906761,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/8,Other,,
2600,906762,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/8,Other,,
2601,906763,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/8,Other,,
2602,906764,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/8,Other,,
2603,906835,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/8,Other,,
2604,906836,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/8,Other,,
2605,906837,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/8,Other,,
2606,906838,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/8,Other,,
2607,906839,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/8,Other,,
2608,906840,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/8,Other,,
2609,906841,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/9,Other,,
2610,906935,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/12,Other,,
2611,906936,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/12,Other,,
2612,906937,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/13,Other,,
2613,906938,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/13,Other,,
2614,906939,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/13,Other,,
2615,906940,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/13,Other,,
2616,906941,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/13,Other,,
2617,906942,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/13,Other,,
2618,906943,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/13,Other,,
2619,906944,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/13,Other,,
2620,906945,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/13,Other,,
2621,906946,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/13,Other,,
2622,906947,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/13,Other,,
2623,906948,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/13,Other,,
2624,906949,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/13,Other,,
2625,906950,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/13,Other,,
2626,906951,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/13,Other,,
2627,906952,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/13,Other,,
2628,906953,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/13,Other,,
2629,906954,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/13,Other,,
2630,906955,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/13,Other,,
2631,906956,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/13,Other,,
2632,906957,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/13,Other,,
2633,906958,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/14,Other,,
2634,906959,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/14,Other,,
2635,906960,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/14,Other,,
2636,906961,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/14,Other,,
2637,906962,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/14,Other,,
2638,906963,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/14,Other,,
2639,906964,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/14,Other,,
2640,906965,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/14,Other,,
2641,906966,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/14,Other,,
2642,906967,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/14,Other,,
2643,906968,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/14,Other,,
2644,906969,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/14,Other,,
2645,906970,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/14,Other,,
2646,906971,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/14,Other,,
2647,906972,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/14,Other,,
2648,906973,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/14,Other,,
2649,906974,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/14,Other,,
2650,906975,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/14,Other,,
2651,907383,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/6,Other,,
2652,907384,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/6,Other,,
2653,907385,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/6,Other,,
2654,907386,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/6,Other,,
2655,907387,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/6,Other,,
2656,907388,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/6,Other,,
2657,907389,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/6,Other,,
2658,907390,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/6,Other,,
2659,907391,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/6,Other,,
2660,907392,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/6,Other,,
2661,907393,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/6,Other,,
2662,907394,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/6,Other,,
2663,907395,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/6,Other,,
2664,907396,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/6,Other,,
2665,907397,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/6,Other,,
2666,907398,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/6,Other,,
2667,907399,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/6,Other,,
2668,907400,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/7,Other,,
2669,907401,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/7,Other,,
2670,907402,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/7,Other,,
2671,907488,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/5,Other,,
2672,907489,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/5,Other,,
2673,907490,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/5,Other,,
2674,907491,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/5,Other,,
2675,907492,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/5,Other,,
2676,907493,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/5,Other,,
2677,907494,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/5,Other,,
2678,907495,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/5,Other,,
2679,907496,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/5,Other,,
2680,907497,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/5,Other,,
2681,907498,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/5,Other,,
2682,907499,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/5,Other,,
2683,907500,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/5,Other,,
2684,907501,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/5,Other,,
2685,907502,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/5,Other,,
2686,907503,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/5,Other,,
2687,907504,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 90/5,Other,,
2688,907505,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 90/5,Other,,
2689,907506,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 90/5,Other,,
2690,907507,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 90/5,Other,,
2691,907508,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 90/5,Other,,
2692,907509,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 90/6,Other,,
2693,907510,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 90/6,Other,,
2694,907511,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 90/6,Other,,
2695,907512,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 90/6,Other,,
2696,907513,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 90/6,Other,,
2697,907514,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 90/6,Other,,
2698,907515,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 90/6,Other,,
2699,907516,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 90/6,Other,,
2700,907517,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 90/6,Other,,
2701,907518,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 90/6,Other,,
2702,907519,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 90/6,Other,,
2703,907520,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 90/6,Other,,
2704,907521,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 90/6,Other,,
2705,907522,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 90/6,Other,,
2706,907523,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/7,Other,,
2707,907524,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/7,Other,,
2708,907525,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/7,Other,,
2709,907526,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/7,Other,,
2710,907527,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/7,Other,,
2711,907528,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/7,Other,,
2712,907529,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/7,Other,,
2713,907530,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/7,Other,,
2714,907531,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/7,Other,,
2715,907532,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/7,Other,,
2716,907533,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/7,Other,,
2717,907534,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/7,Other,,
2718,907535,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/7,Other,,
2719,907536,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/7,Other,,
2720,907537,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/7,Other,,
2721,907538,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/7,Other,,
2722,907539,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/7,Other,,
2723,907540,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/7,Other,,
2724,907541,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/8,Other,,
2725,907542,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/8,Other,,
2726,907543,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/8,Other,,
2727,907544,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/8,Other,,
2728,907545,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/8,Other,,
2729,907546,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/8,Other,,
2730,907547,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/8,Other,,
2731,907548,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/8,Other,,
2732,907549,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/8,Other,,
2733,907631,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 90/6,Other,,
2734,907632,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 90/6,Other,,
2735,907986,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/8,Other,,
2736,907987,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/8,Other,,
2737,907988,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/8,Other,,
2738,907989,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/8,Other,,
2739,907990,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/8,Other,,
2740,907991,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/8,Other,,
2741,907992,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/8,Other,,
2742,907993,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/8,Other,,
2743,907994,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/8,Other,,
2744,907995,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/8,Other,,
2745,907996,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/8,Other,,
2746,907997,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/8,Other,,
2747,908089,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/9,Other,,
2748,908090,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/9,Other,,
2749,908091,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/9,Other,,
2750,908092,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/9,Other,,
2751,908093,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/9,Other,,
2752,908094,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/9,Other,,
2753,908095,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/9,Other,,
2754,908096,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/9,Other,,
2755,908097,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/9,Other,,
2756,908098,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/9,Other,,
2757,908099,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/9,Other,,
2758,908100,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/9,Other,,
2759,908101,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/9,Other,,
2760,908102,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/9,Other,,
2761,908103,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/9,Other,,
2762,908104,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/9,Other,,
2763,908105,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/9,Other,,
2764,908106,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/9,Other,,
2765,908107,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/9,Other,,
2766,908108,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/9,Other,,
2767,908109,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/9,Other,,
2768,908110,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/10,Other,,
2769,908111,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/10,Other,,
2770,908112,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/10,Other,,
2771,908113,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/10,Other,,
2772,908114,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/10,Other,,
2773,908115,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/10,Other,,
2774,908116,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/10,Other,,
2775,908117,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/10,Other,,
2776,908118,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/10,Other,,
2777,908119,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/10,Other,,
2778,908120,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/10,Other,,
2779,908121,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/10,Other,,
2780,908122,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/10,Other,,
2781,908123,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/10,Other,,
2782,908540,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/10,Other,,
2783,908541,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/10,Other,,
2784,908542,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/10,Other,,
2785,908543,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/10,Other,,
2786,908634,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/10,Other,,
2787,908635,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/10,Other,,
2788,908636,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/10,Other,,
2789,908637,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/11,Other,,
2790,908638,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/11,Other,,
2791,908639,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/11,Other,,
2792,908640,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/11,Other,,
2793,908641,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/11,Other,,
2794,908642,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/11,Other,,
2795,908643,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/11,Other,,
2796,908644,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/11,Other,,
2797,908645,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/11,Other,,
2798,908646,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/11,Other,,
2799,908647,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/11,Other,,
2800,908648,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/11,Other,,
2801,908649,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/11,Other,,
2802,908650,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/11,Other,,
2803,908651,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/11,Other,,
2804,908652,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/11,Other,,
2805,908653,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/11,Other,,
2806,908654,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/11,Other,,
2807,908655,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/11,Other,,
2808,908656,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 91/11,Other,,
2809,908657,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 91/11,Other,,
2810,908658,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 91/12,Other,,
2811,908659,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 91/12,Other,,
2812,908660,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 91/12,Other,,
2813,908661,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 91/12,Other,,
2814,908662,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 91/12,Other,,
2815,908663,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 91/12,Other,,
2816,908664,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 91/12,Other,,
2817,908665,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 91/12,Other,,
2818,908666,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 91/12,Other,,
2819,908667,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 91/12,Other,,
2820,908668,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 91/12,Other,,
2821,908669,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 91/12,Other,,
2822,908670,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 91/12,Other,,
2823,908671,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 91/12,Other,,
2824,908672,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 91/12,Other,,
2825,908673,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 91/12,Other,,
2826,908674,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 91/12,Other,,
2827,908675,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 91/12,Other,,
2828,908676,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 91/12,Other,,
2829,925869,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030120,Other,,
2830,925870,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030120,Other,,
2831,925871,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030120,Other,,
2832,925872,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030120,Other,,
2833,926309,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2834,926310,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2835,928146,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030120,Other,,
2836,928147,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030120,Other,,
2837,928148,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030120,Other,,
2838,928149,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030120,Other,,
2839,928150,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030120,Other,,
2840,928151,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030120,Other,,
2841,928152,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030120,Other,,
2842,928153,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030120,Other,,
2843,928154,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030120,Other,,
2844,928155,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030120",Other,,
2845,928156,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030120,Other,,
2846,928157,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030120,Other,,
2847,928158,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030120,Other,,
2848,928159,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030120,Other,,
2849,928160,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030120,Other,,
2850,928161,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030120,Other,,
2851,928162,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030120,Other,,
2852,928163,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030120,Other,,
2853,928164,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030120,Other,,
2854,934300,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011113,Other,,
2855,934301,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011113,Other,,
2856,934302,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011113,Other,,
2857,934303,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011113,Other,,
2858,934304,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011113,Other,,
2859,934305,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011113,Other,,
2860,934306,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011113,Other,,
2861,934307,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011113,Other,,
2862,934308,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011113,Other,,
2863,934309,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011113,Other,,
2864,934310,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011113,Other,,
2865,934311,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011113,Other,,
2866,934312,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011113,Other,,
2867,934313,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011113",Other,,
2868,934314,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011113,Other,,
2869,934315,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011113,Other,,
2870,934316,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011113,Other,,
2871,934317,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011113,Other,,
2872,934318,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011113,Other,,
2873,934947,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2874,934948,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2875,934949,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2876,934950,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2877,934951,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2878,934952,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2879,934953,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2880,934954,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2881,934955,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2882,934956,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2883,934957,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2884,934958,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2885,934959,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2886,934960,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2887,934961,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2888,934962,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2889,934963,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2890,935896,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030120,Other,,
2891,935897,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030120",Other,,
2892,935898,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030120,Other,,
2893,935899,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030120,Other,,
2894,935900,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030120,Other,,
2895,935901,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030120,Other,,
2896,935902,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030120,Other,,
2897,935903,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030120,Other,,
2898,935904,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030120,Other,,
2899,935905,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030120,Other,,
2900,935906,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030120,Other,,
2901,935907,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030120,Other,,
2902,935908,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030120,Other,,
2903,935909,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030120,Other,,
2904,935910,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030120,Other,,
2905,941560,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2906,941561,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2907,941562,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2908,941563,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2909,941564,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2910,941565,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2911,941566,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2912,941567,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2913,941568,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2914,941569,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2915,941570,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2916,941571,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2917,941572,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2918,942202,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2919,942203,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2920,942204,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2921,942205,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2922,942206,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2923,942207,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2924,942208,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2925,942209,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2926,942210,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2927,942211,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2928,942212,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2929,942213,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2930,942214,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2931,942215,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2932,942216,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2933,942217,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2934,942218,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2935,942219,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2936,944240,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2937,944241,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2938,944242,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2939,944243,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2940,944244,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2941,944245,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2942,944246,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2943,944247,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2944,944248,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2945,944249,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2946,944250,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2947,944251,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2948,944252,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2949,944253,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2950,944254,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2951,944255,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2952,944256,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2953,944257,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2954,944887,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2955,944888,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2956,944889,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2957,944890,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2958,944891,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2959,944892,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2960,944893,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2961,944894,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2962,947667,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011113,Other,,
2963,947668,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011113,Other,,
2964,947669,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011113,Other,,
2965,947670,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011113,Other,,
2966,947671,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011113,Other,,
2967,947672,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011113,Other,,
2968,947673,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011113,Other,,
2969,947674,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011113",Other,,
2970,947675,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011113,Other,,
2971,947676,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011113,Other,,
2972,947677,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011113,Other,,
2973,947678,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011113,Other,,
2974,947679,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011113,Other,,
2975,947680,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011113,Other,,
2976,947681,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011113,Other,,
2977,947682,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011113,Other,,
2978,947683,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011113,Other,,
2979,947684,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011113,Other,,
2980,947685,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011113,Other,,
2981,953147,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
2982,953148,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
2983,953149,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
2984,953150,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
2985,953151,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
2986,953152,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
2987,955133,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
2988,955134,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
2989,955135,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
2990,955136,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
2991,955137,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
2992,955138,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
2993,955139,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
2994,955140,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
2995,955141,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
2996,955142,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
2997,955143,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
2998,955144,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
2999,955145,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3000,955146,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3001,955147,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3002,955148,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3003,955149,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3004,955150,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3005,955151,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3006,955152,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3007,955153,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3008,955742,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3009,955743,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3010,955744,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3011,955745,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3012,955746,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3013,955747,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3014,955748,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3015,955749,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3016,955750,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3017,955751,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3018,955752,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3019,955753,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3020,955754,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3021,955755,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3022,955756,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3023,955757,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3024,955758,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3025,955759,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3026,955760,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3027,955761,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3028,955762,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3029,955763,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3030,955764,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3031,957620,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3032,957621,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3033,957622,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3034,957623,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3035,957624,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3036,957625,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3037,957626,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3038,959979,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011113,Other,,
3039,959980,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011113,Other,,
3040,959981,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011113,Other,,
3041,959982,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011113,Other,,
3042,959983,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011113,Other,,
3043,959984,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011113,Other,,
3044,959985,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011113,Other,,
3045,959986,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011113,Other,,
3046,959987,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011113,Other,,
3047,959988,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011113,Other,,
3048,959989,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011113,Other,,
3049,959990,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011113,Other,,
3050,959991,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011113,Other,,
3051,959992,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011113,Other,,
3052,959993,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011113,Other,,
3053,959994,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011113,Other,,
3054,959995,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011113,Other,,
3055,959996,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011113,Other,,
3056,959997,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3057,959998,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3058,959999,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3059,960000,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3060,960001,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3061,960002,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3062,960003,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3063,960004,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3064,960005,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3065,960006,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3066,960440,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3067,960441,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3068,960442,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3069,960443,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3070,960444,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3071,960445,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3072,960446,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3073,960447,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3074,960448,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3075,960782,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011113,Other,,
3076,960783,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011113,Other,,
3077,960784,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011113,Other,,
3078,960785,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011113,Other,,
3079,960786,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011113,Other,,
3080,960787,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011113,Other,,
3081,960788,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011113,Other,,
3082,960789,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011113,Other,,
3083,960790,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011113,Other,,
3084,960791,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011113,Other,,
3085,960792,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011113,Other,,
3086,960793,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011113,Other,,
3087,960794,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011113,Other,,
3088,960795,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011113,Other,,
3089,960796,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011113,Other,,
3090,960797,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011113,Other,,
3091,960798,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011113,Other,,
3092,960799,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011113,Other,,
3093,960800,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011113,Other,,
3094,963548,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030120,Other,,
3095,963549,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030120,Other,,
3096,963550,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030120,Other,,
3097,963551,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030120,Other,,
3098,963552,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030120,Other,,
3099,963553,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030120,Other,,
3100,964022,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030120,Other,,
3101,964023,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030120,Other,,
3102,964024,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030120,Other,,
3103,964025,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030120,Other,,
3104,964026,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030120,Other,,
3105,964027,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030120,Other,,
3106,964028,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030120,Other,,
3107,964029,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030120,Other,,
3108,964030,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030120,Other,,
3109,964031,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030120,Other,,
3110,964032,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030120,Other,,
3111,964033,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030120,Other,,
3112,964034,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030120,Other,,
3113,965784,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011113,Other,,
3114,974932,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030120,Other,,
3115,974933,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030120,Other,,
3116,974934,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030120,Other,,
3117,974935,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030120,Other,,
3118,974936,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030120,Other,,
3119,974937,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030120,Other,,
3120,974938,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030120,Other,,
3121,974939,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030120,Other,,
3122,974940,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030120,Other,,
3123,974941,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030120,Other,,
3124,974942,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030120,Other,,
3125,974943,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030120,Other,,
3126,974944,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030120,Other,,
3127,974945,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030120,Other,,
3128,974946,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030120,Other,,
3129,974947,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030120,Other,,
3130,974948,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030120,Other,,
3131,974949,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030120,Other,,
3132,974950,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030120,Other,,
3133,986747,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3134,986748,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3135,986749,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3136,986750,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3137,986751,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3138,986752,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3139,986753,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3140,986754,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3141,986755,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3142,987338,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3143,987339,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3144,987340,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3145,987341,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3146,987342,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3147,987343,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3148,987344,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3149,987345,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3150,987346,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3151,987347,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3152,987348,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3153,987349,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3154,987350,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3155,987351,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3156,987352,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3157,987353,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3158,987354,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3159,987355,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3160,987356,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3161,987357,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3162,987358,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3163,987359,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3164,987360,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3165,987361,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3166,989189,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3167,989190,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3168,989191,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3169,989192,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3170,989193,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3171,989194,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3172,989195,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3173,989196,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3174,989197,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3175,989781,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3176,989782,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3177,989783,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3178,989784,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3179,989785,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3180,989786,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3181,989787,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3182,989788,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3183,989789,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3184,989790,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3185,989791,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3186,989792,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3187,989793,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3188,989794,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3189,989795,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3190,989796,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3191,989797,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3192,1005468,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3193,1005469,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3194,1005470,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3195,1005471,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3196,1005472,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3197,1005473,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3198,1005474,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3199,1005475,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3200,1005476,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3201,1005477,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3202,1005478,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3203,1005479,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3204,1005480,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3205,1005481,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3206,1005482,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3207,1005483,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3208,1005484,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3209,1005485,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3210,1005486,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3211,1005487,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3212,1005488,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3213,1007351,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3214,1012289,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3215,1012290,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3216,1012873,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3217,1012874,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3218,1012875,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3219,1012876,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3220,1012877,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3221,1012878,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3222,1012879,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3223,1012880,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3224,1012881,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3225,1012882,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3226,1012883,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3227,1012884,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3228,1012885,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3229,1012886,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3230,1012887,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3231,1012888,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3232,1014755,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3233,1014756,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3234,1014757,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3235,1014758,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3236,1014759,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3237,1014760,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3238,1014761,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3239,1014762,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3240,1014763,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3241,1014764,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3242,1014765,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3243,1014766,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3244,1014767,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3245,1014768,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3246,1014769,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3247,1014770,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3248,1014771,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3249,1014772,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3250,1014773,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3251,1019155,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S030120",Other,,
3252,1019156,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S030120",Other,,
3253,1019157,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S030120",Other,,
3254,1019158,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S030120",Other,,
3255,1019159,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S030120",Other,,
3256,1019160,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S030120",Other,,
3257,1019161,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S030120,Other,,
3258,1019162,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S030120",Other,,
3259,1019163,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S030120,Other,,
3260,1019164,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S030120",Other,,
3261,1019165,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S030120",Other,,
3262,1019166,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S030120",Other,,
3263,1019167,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S030120",Other,,
3264,1019168,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S030120",Other,,
3265,1019169,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S030120",Other,,
3266,1019752,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S030120",Other,,
3267,1019753,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S030120",Other,,
3268,1019754,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S030120",Other,,
3269,1019755,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S030120",Other,,
3270,1019756,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030120",Other,,
3271,1021626,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S030120",Other,,
3272,1021627,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S030120",Other,,
3273,1021628,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S030120",Other,,
3274,1021629,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S030120",Other,,
3275,1021630,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S030120",Other,,
3276,1021631,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S030120",Other,,
3277,1021632,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S030120",Other,,
3278,1021633,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S030120",Other,,
3279,1021634,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S030120",Other,,
3280,1021635,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S030120",Other,,
3281,1021636,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S030120,Other,,
3282,1021637,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S030120,Other,,
3283,1021638,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S030120",Other,,
3284,1021639,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S030120",Other,,
3285,1021640,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030120",Other,,
3286,1021641,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S030120",Other,,
3287,1021642,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S030120,Other,,
3288,1021643,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030120",Other,,
3289,1021644,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S030120",Other,,
3290,1021645,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S030120",Other,,
3291,1021646,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S030120",Other,,
3292,1021647,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S030120,Other,,
3293,1021648,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S030120",Other,,
3294,1021649,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S030120",Other,,
3295,1021650,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S030120",Other,,
3296,1021651,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S030120",Other,,
3297,1021652,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S030120",Other,,
3298,1021653,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S030120",Other,,
3299,1021654,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S030120",Other,,
3300,1021655,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S030120,Other,,
3301,1022239,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S030120",Other,,
3302,1022240,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S030120",Other,,
3303,1022241,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S030120,Other,,
3304,1022242,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S030120",Other,,
3305,1022243,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S030120",Other,,
3306,1022244,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S030120",Other,,
3307,1022245,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S030120",Other,,
3308,1022246,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S030120",Other,,
3309,1022247,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S030120",Other,,
3310,1026339,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3311,1026340,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011113",Other,,
3312,1026341,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011113",Other,,
3313,1026342,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011113",Other,,
3314,1026343,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3315,1026344,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3316,1026345,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011113",Other,,
3317,1026346,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011113",Other,,
3318,1026347,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011113",Other,,
3319,1026348,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011113",Other,,
3320,1026349,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011113,Other,,
3321,1026350,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011113",Other,,
3322,1026351,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011113,Other,,
3323,1026352,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011113",Other,,
3324,1026353,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3325,1026354,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011113",Other,,
3326,1026355,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011113",Other,,
3327,1026356,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3328,1026357,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011113",Other,,
3329,1026358,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3330,1026359,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011113",Other,,
3331,1026360,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011113",Other,,
3332,1026361,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011113",Other,,
3333,1026362,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011113",Other,,
3334,1026363,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011113,Other,,
3335,1026364,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3336,1026365,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3337,1026366,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3338,1026367,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3339,1026368,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3340,1026369,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3341,1026370,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011113",Other,,
3342,1026371,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3343,1026372,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011113",Other,,
3344,1026373,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011113",Other,,
3345,1026374,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3346,1026375,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011113",Other,,
3347,1026376,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011113",Other,,
3348,1026377,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011113",Other,,
3349,1026962,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S011113,Other,,
3350,1028833,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011113,Other,,
3351,1028834,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011113,Other,,
3352,1028835,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011113",Other,,
3353,1028836,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3354,1028837,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3355,1028838,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011113",Other,,
3356,1028839,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011113",Other,,
3357,1028840,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011113",Other,,
3358,1028841,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011113",Other,,
3359,1028842,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011113",Other,,
3360,1028843,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011113,Other,,
3361,1028844,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011113",Other,,
3362,1028845,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3363,1028846,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3364,1028847,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3365,1028848,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011113",Other,,
3366,1028849,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011113,Other,,
3367,1028850,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011113",Other,,
3368,1028851,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011113",Other,,
3369,1028852,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011113",Other,,
3370,1028853,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011113",Other,,
3371,1028854,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011113",Other,,
3372,1028855,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011113",Other,,
3373,1028856,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011113",Other,,
3374,1028857,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011113",Other,,
3375,1028858,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011113",Other,,
3376,1028859,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011113",Other,,
3377,1028860,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011113",Other,,
3378,1028861,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011113",Other,,
3379,1028862,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S011113,Other,,
3380,1028863,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011113",Other,,
3381,1028864,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011113",Other,,
3382,1028865,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011113,Other,,
3383,1028866,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011113",Other,,
3384,1028867,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011113",Other,,
3385,1028868,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011113",Other,,
3386,1029453,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011113",Other,,
3387,1029454,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011113,Other,,
3388,1029455,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3389,1029456,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011113",Other,,
3390,1029457,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011113",Other,,
3391,1031325,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3392,1031326,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011113",Other,,
3393,1031327,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011113",Other,,
3394,1031328,1,3,,103177883,3121,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011113",Other,,
3395,1033798,1,3,,103177883,3121,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011113,Other,,
3396,1049389,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/5,Other,,
3397,1049596,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/5,Other,,
3398,1049597,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/5,Other,,
3399,1049598,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/5,Other,,
3400,1049599,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/5,Other,,
3401,1049600,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/6,Other,,
3402,1049601,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/6,Other,,
3403,1049602,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/6,Other,,
3404,1049603,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/6,Other,,
3405,1049604,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/6,Other,,
3406,1049605,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/7,Other,,
3407,1049606,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/7,Other,,
3408,1049607,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/7,Other,,
3409,1049608,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/7,Other,,
3410,1049609,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/7,Other,,
3411,1049610,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/8,Other,,
3412,1049611,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/8,Other,,
3413,1049612,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/8,Other,,
3414,1049613,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/8,Other,,
3415,1050419,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/8,Other,,
3416,1050420,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/9,Other,,
3417,1050421,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/9,Other,,
3418,1050422,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/9,Other,,
3419,1050423,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/9,Other,,
3420,1050424,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/9,Other,,
3421,1050425,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/10,Other,,
3422,1050426,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/10,Other,,
3423,1050427,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/10,Other,,
3424,1050428,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/10,Other,,
3425,1050429,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/10,Other,,
3426,1050430,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/11,Other,,
3427,1050431,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/11,Other,,
3428,1050432,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/11,Other,,
3429,1050433,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/11,Other,,
3430,1050434,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/11,Other,,
3431,1050435,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/12,Other,,
3432,1050436,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/12,Other,,
3433,1050437,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/12,Other,,
3434,1050438,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/12,Other,,
3435,1050439,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/12,Other,,
3436,1050632,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/13,Other,,
3437,1050633,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/13,Other,,
3438,1050634,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/13,Other,,
3439,1050635,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/13,Other,,
3440,1050636,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/13,Other,,
3441,1050637,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/14,Other,,
3442,1050638,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/14,Other,,
3443,1050639,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/14,Other,,
3444,1050640,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/14,Other,,
3445,1050641,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/14,Other,,
3446,1050642,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/15,Other,,
3447,1050643,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/15,Other,,
3448,1050644,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/15,Other,,
3449,1050645,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/15,Other,,
3450,1050646,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/15,Other,,
3451,1050647,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 90/16,Other,,
3452,1050648,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 90/16,Other,,
3453,1050649,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 90/16,Other,,
3454,1050650,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 90/16,Other,,
3455,1050651,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 90/16,Other,,
3456,1050652,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/5,Other,,
3457,1050653,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/5,Other,,
3458,1050654,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/5,Other,,
3459,1050655,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/5,Other,,
3460,1050656,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/5,Other,,
3461,1050657,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/6,Other,,
3462,1051429,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/6,Other,,
3463,1051430,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/6,Other,,
3464,1051431,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/6,Other,,
3465,1051432,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/6,Other,,
3466,1051433,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/7,Other,,
3467,1051434,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/7,Other,,
3468,1051435,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/7,Other,,
3469,1051436,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/7,Other,,
3470,1051437,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/7,Other,,
3471,1051438,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/8,Other,,
3472,1051439,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/8,Other,,
3473,1051440,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/8,Other,,
3474,1051664,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/8,Other,,
3475,1051665,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/8,Other,,
3476,1051666,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/9,Other,,
3477,1051667,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/9,Other,,
3478,1051668,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/9,Other,,
3479,1051669,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/9,Other,,
3480,1051670,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/9,Other,,
3481,1051671,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/10,Other,,
3482,1051672,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/10,Other,,
3483,1051673,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/10,Other,,
3484,1051674,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/10,Other,,
3485,1051675,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/10,Other,,
3486,1051676,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/11,Other,,
3487,1051677,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/11,Other,,
3488,1051678,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/11,Other,,
3489,1051679,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/11,Other,,
3490,1051680,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/11,Other,,
3491,1051681,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/12,Other,,
3492,1051682,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/12,Other,,
3493,1051683,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/12,Other,,
3494,1051684,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/12,Other,,
3495,1051685,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/12,Other,,
3496,1051686,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/13,Other,,
3497,1051687,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/13,Other,,
3498,1051688,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/13,Other,,
3499,1051689,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/13,Other,,
3500,1051690,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/13,Other,,
3501,1051691,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/14,Other,,
3502,1051692,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/14,Other,,
3503,1051693,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/14,Other,,
3504,1051694,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/14,Other,,
3505,1051695,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/14,Other,,
3506,1051696,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/15,Other,,
3507,1051697,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/15,Other,,
3508,1052465,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/15,Other,,
3509,1052466,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/15,Other,,
3510,1052467,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/15,Other,,
3511,1052468,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 91/16,Other,,
3512,1052694,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 91/16,Other,,
3513,1052695,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 91/16,Other,,
3514,1052696,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 91/16,Other,,
3515,1052697,1,2,,103177883,3121,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 91/16,Other,,
3516,1053175,2,1,,178125926,3121,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3517,1053197,1,1,,49640649,3121,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3518,1058304,1,2,,103177883,3121,Active,,,,,Anticonvulsant activity in ip dosed Sprague-Dawley rat hippocampal kindling model assessed as suppression of seizure activity treated 15 for mins post suprathreshold-stimulation,Other,24205976.0,
3519,1058305,1,2,,103177883,3121,Active,,,,,"Anticonvulsant activity in Sprague-Dawley rat hippocampal kindling model assessed as complete absence of seizure activity at >300 mg/kg, ip treated 15 for mins post suprathreshold-stimulation",Other,24205976.0,
3520,1079931,1,1,,103177883,3121,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3521,1079932,1,1,,103177883,3121,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3522,1079933,1,1,,103177883,3121,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3523,1079934,1,1,,103177883,3121,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3524,1079935,1,1,,103177883,3121,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3525,1079936,1,1,,103177883,3121,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3526,1079937,1,1,,103177883,3121,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3527,1079938,1,1,,103177883,3121,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3528,1079939,1,1,,103177883,3121,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3529,1079940,1,1,,103177883,3121,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3530,1079941,1,1,,103177883,3121,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3531,1079942,1,1,,103177883,3121,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3532,1079943,1,1,,103177883,3121,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3533,1079944,1,1,,103177883,3121,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3534,1079945,1,1,,103177883,3121,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3535,1079946,1,1,,103177883,3121,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3536,1079947,1,1,,103177883,3121,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3537,1079948,1,1,,103177883,3121,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3538,1079949,1,1,,103177883,3121,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3539,1083364,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus albino (mouse) to ED50 for Mus musculus albino (mouse) by maximal electroshock-induced seizures test",Other,,
3540,1083365,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus albino (mouse) to ED50 for Mus musculus albino (mouse) by subcutaneous pentylenetetrazol-induced seizures test",Other,,
3541,1083366,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures,Other,,
3542,1083367,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures,Other,,
3543,1083369,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus albino (mouse) after 0.5 hr rotorod test,Other,,
3544,1085576,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus Swiss (mouse) to ED50 for Mus musculus Swiss (mouse) by subcutaneous pentylenetetrazole-induced seizure test",Other,,
3545,1085577,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus Swiss (mouse) to ED50 for Mus musculus Swiss (mouse) by maximal electroshock-induced seizure test",Other,,
3546,1085578,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus Swiss (mouse) assessed as minimum motor impairment by rotarod test,Other,,
3547,1085579,1,2,,103177883,3121,Unspecified,,,,,"Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Mus musculus Swiss (mouse) at 30 mg/kg, ip measured at phase 2",Other,,
3548,1085580,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against maximal electroshock-induced seizures in ip dosed Mus musculus Swiss (mouse) administered 30 min before MES induction measured at phase 2,Other,,
3549,1086600,1,2,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity to ED50 for anticonvulsant activity in Mus musculus Kunming (mouse)",Other,,
3550,1086601,1,2,,103177883,3121,Unspecified,,,,,Neurotoxicity against ip dosed Mus musculus Kunming (mouse) assessed as inability to maintain equilibrium on rod measured for 1 min by rota rod test,Other,,
3551,1086602,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus Kunming (mouse) assessed as protection against maximal electroshock-induced seizure administered 30 min prior to testing,Other,,
3552,1097305,1,2,,103177883,3121,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizures compound co-administered with losartan 50 mg/kg, ip",Other,,
3553,1097308,1,2,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizures,Other,,
3554,1117298,1,2,,170465446,3121,Inactive,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3555,1117301,1,2,,170465446,3121,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3556,1117302,1,2,,170465446,3121,Inactive,,,0.4467,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3557,1117303,1,2,,170465446,3121,Inactive,,,2.82,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3558,1117304,1,2,,170465446,3121,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3559,1117305,1,2,,170465446,3121,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3560,1117310,1,1,,170465446,3121,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3561,1117311,1,1,,170465446,3121,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3562,1117312,1,1,,170465446,3121,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3563,1117314,1,1,,170465446,3121,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3564,1117315,1,1,,170465446,3121,Inactive,,,0.446684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3565,1117318,1,1,,170465446,3121,Inactive,,,2.81838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3566,1117326,1,1,,170465446,3121,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3567,1117331,1,1,,170465446,3121,Inactive,,,33.33,IC50,insulin secretion from INS-1E cells in the presence of 5 mM glucose-IC50,Confirmatory,,
3568,1117336,1,1,,170465446,3121,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3569,1117342,1,1,,170465446,3121,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3570,1117343,1,1,,170465446,3121,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3571,1117346,1,1,,170465446,3121,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3572,1121000,1,2,,103177883,3121,Unspecified,,,57.4,IC50,Inhibition of purified calf kidney ALR1 preincubated for 10 mins by UV spectrophotometry,Confirmatory,,
3573,1124834,1,3,,103177883,3121,Unspecified,1168407.0,24192.0,56.1,IC50,Inhibition of Fischer-344 rat kidney ALR1 using D-glucuronate as substrate by spectrophotometry,Confirmatory,24630695.0,
3574,1125603,1,2,,103177883,3121,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as accumulation of cells at G1 phase at 1.5 mM after 24 hrs by flow cytometry (Rvb =64.7 %),Other,24656564.0,
3575,1125604,1,2,,103177883,3121,Unspecified,,,,,Cell cycle arrest in human DU145 cells assessed as accumulation of cells at G2 phase at 1.5 mM after 24 hrs by flow cytometry (Rvb = 22.1 %),Other,24656564.0,
3576,1125605,1,2,,103177883,3121,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed viable cells at 0.5 mM after 72 hrs by CCK-8 assay (Rvb = 99.97 +/- 0.84 %),Other,24656564.0,
3577,1125606,1,2,,103177883,3121,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed viable cells at 1.5 mM after 72 hrs by CCK-8 assay (Rvb = 100.00 +/- 2.47 %),Other,24656564.0,
3578,1156088,1,1,,103177883,3121,Active,,,,,Inhibition of HDAC in MFF assessed as increase of histone H3 and H4 acetylation at 4 mM after 6 hrs by Western blotting,Other,24944733.0,
3579,1159509,1,1,,144209161,3121,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3580,1159509,1,1,,144210920,3121,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3581,1159509,1,1,,170465446,3121,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3582,1159515,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3583,1159515,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3584,1159515,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3585,1159516,1,1,,144209161,3121,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3586,1159516,1,1,,144210920,3121,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3587,1159516,1,1,,170465446,3121,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3588,1159517,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3589,1159517,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3590,1159517,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3591,1159518,1,1,,144209161,3121,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3592,1159518,1,1,,144210920,3121,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3593,1159518,1,1,,170465446,3121,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3594,1159519,1,1,,144209161,3121,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3595,1159519,1,1,,144210920,3121,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3596,1159519,1,1,,170465446,3121,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3597,1159520,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3598,1159520,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3599,1159520,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3600,1159521,1,1,,144209161,3121,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3601,1159521,1,1,,144210920,3121,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3602,1159521,1,1,,170465446,3121,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3603,1159523,1,1,,144209161,3121,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3604,1159523,1,1,,144210920,3121,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3605,1159523,1,1,,170465446,3121,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3606,1159524,1,1,,49640649,3121,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3607,1159525,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3608,1159525,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3609,1159525,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3610,1159526,1,1,,144209161,3121,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3611,1159526,1,1,,144210920,3121,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3612,1159526,1,1,,170465446,3121,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3613,1159527,1,1,,144209161,3121,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3614,1159527,1,1,,144210920,3121,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3615,1159527,1,1,,170465446,3121,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3616,1159528,1,1,,144209161,3121,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3617,1159528,1,1,,144210920,3121,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3618,1159528,1,1,,170465446,3121,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3619,1159529,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3620,1159529,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3621,1159529,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3622,1159531,1,1,,144209161,3121,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3623,1159531,1,1,,144210920,3121,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3624,1159531,1,1,,170465446,3121,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3625,1159551,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3626,1159551,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3627,1159551,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3628,1159552,1,1,,144209161,3121,Inactive,325495463.0,5914.0,68.241,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3629,1159552,1,1,,144210920,3121,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3630,1159552,1,1,,170465446,3121,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3631,1159553,2,1,,144209161,3121,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3632,1159553,2,1,,144210920,3121,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3633,1159553,2,1,,170465446,3121,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3634,1159555,1,1,,144209161,3121,Inconclusive,325495463.0,5914.0,27.1672,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3635,1159555,1,1,,144210920,3121,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3636,1159555,1,1,,170465446,3121,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3637,1159583,2,1,,178125926,3121,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3638,1159606,1,1,,49640649,3121,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3639,1159607,2,1,,312310262,3121,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3640,1159614,1,2,,170465446,3121,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3641,1159620,1,1,,103177883,3121,Active,,,,,Summary of drug indications.,Other,,
3642,1168441,1,1,,103177883,3121,Inactive,,,,,Induction of ROS generation in human HL60 cells at 50 and 100 uM after 24 hrs by DCFH-DA staining based flow cytometry,Other,25304896.0,
3643,1168443,1,1,,103177883,3121,Inconclusive,,,,,Half life in RPMI-1640 medium containing 10% fetal calf serum assessed as compound disappearance by HPLC-DAD-ESI-MS method,Other,25304896.0,
3644,1168456,1,1,,103177883,3121,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 2 mM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 32%),Other,25304896.0,
3645,1168457,1,1,,103177883,3121,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 2 mM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 54%),Other,25304896.0,
3646,1168458,1,1,,103177883,3121,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G2M phase at 2 mM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%),Other,25304896.0,
3647,1168459,1,1,,103177883,3121,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G1 phase at 5 mM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 32%),Other,25304896.0,
3648,1168460,1,1,,103177883,3121,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at S phase at 5 mM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 54%),Other,25304896.0,
3649,1168461,1,1,,103177883,3121,Unspecified,,,,,Induction of cell cycle arrest in human HL60 cells assessed as accumulation at G2M phase at 5 mM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%),Other,25304896.0,
3650,1168477,1,1,,103177883,3121,Unspecified,,,1700.0,IC50,Cytotoxicity against human HL60 cells after 24 to 48 hrs by trypan blue dye exclusion method,Confirmatory,25304896.0,
3651,1168478,1,1,,103177883,3121,Unspecified,,,2500.0,AC50,Induction of apoptosis in human HL60 cells after 24 to 48 hrs by acridine orange and ethidium bromide staining based fluorescence microscopy,Confirmatory,25304896.0,
3652,1168483,1,1,,103177883,3121,Unspecified,,,1700.0,IC50,Growth inhibition of human HL60 cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3653,1168484,1,1,,103177883,3121,Unspecified,,,1000.0,IC50,Growth inhibition of human K562 cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3654,1168485,1,1,,103177883,3121,Unspecified,,,1800.0,IC50,Growth inhibition of human HUT78 cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3655,1168486,1,1,,103177883,3121,Unspecified,,,1000.0,IC50,Growth inhibition of human HT-29 cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3656,1168487,1,1,,103177883,3121,Unspecified,,,230.0,IC50,Growth inhibition of human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3657,1168488,1,1,,103177883,3121,Unspecified,,,1000.0,IC50,Growth inhibition of human HeLa cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3658,1168489,1,1,,103177883,3121,Unspecified,,,1000.0,IC50,Growth inhibition of human Caco2 cells after 48 hrs by MTT assay,Confirmatory,25304896.0,
3659,1168491,1,2,,103177883,3121,Active,2498443.0,3065.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3660,1168491,1,2,,103177883,3121,Active,3334210.0,8841.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3661,1168491,1,2,,103177883,3121,Active,19865267.0,9734.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3662,1168491,1,2,,103177883,3121,Active,26394832.0,79885.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3663,1168491,1,2,,103177883,3121,Active,27734403.0,83933.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3664,1168491,1,2,,103177883,3121,Active,29839394.0,55869.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3665,1168491,1,2,,103177883,3121,Active,30913097.0,51564.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3666,1168491,1,2,,103177883,3121,Active,68068066.0,3066.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3667,1168491,1,2,,103177883,3121,Active,205371758.0,10013.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3668,1168491,1,2,,103177883,3121,Active,259016348.0,9759.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3669,1168491,1,2,,103177883,3121,Active,296434519.0,10014.0,,,Inhibition of HDAC in human HL60 cells assessed as increase in histone H3 acetylation at 1 mM after 24 hrs by Western blotting method,Other,25304896.0,
3670,1173470,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity against ip dosed CF1 albino mouse seizure model after 4 hrs by 6 Hz psychomotor seizure test,Other,25454269.0,
3671,1173473,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for CF1 albino mouse neurotoxicity to ED50 for protection against 6 Hz electroshock-induced seizure in CF1 albino mouse",Other,25454269.0,
3672,1191599,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in intraperitoneally dosed Swiss albino mouse assessed as reduction in clonic seizures after 4 hrs by subcutaneous pentylenetetrazole seizure test,Other,25619635.0,
3673,1191602,1,1,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as reduction in electrical stimulus-induced seizures at 300 mg/kg, ip after 0.5 hrs by maximal electroshock seizure test",Other,25619635.0,
3674,1191603,1,1,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as reduction in electrical stimulus-induced seizures at 300 mg/kg, ip after 4 hrs by maximal electroshock seizure test",Other,25619635.0,
3675,1191604,1,1,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as reduction in clonic seizures at 300 mg/kg, ip after 0.5 hrs by subcutaneous pentylenetetrazole seizure test",Other,25619635.0,
3676,1191606,1,1,,103177883,3121,Unspecified,,,,,"Neurological toxicity in Swiss albino mouse assessed as motor impairment at at 300 mg/kg, ip after 0.5 hrs by rotarod test",Other,25619635.0,
3677,1191607,1,1,,103177883,3121,Unspecified,,,,,"Neurological toxicity in Swiss albino mouse assessed as motor impairment at at 300 mg/kg, ip after 4 hrs by rotarod test",Other,25619635.0,
3678,1195111,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse assessed as time to peak effect by maximal electroshock test,Other,25868743.0,
3679,1195112,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse assessed as time to peak effect after 2 hrs by subcutaneous pentylenetetrazole test,Other,25868743.0,
3680,1195113,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse by maximal electroshock test,Other,25868743.0,
3681,1195114,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in intraperitoneally dosed Albino Swiss CD1 mouse by subcutaneous pentylenetetrazole test,Other,25868743.0,
3682,1195115,1,1,,103177883,3121,Unspecified,,,,,Neurological toxicity in intraperitoneally dosed Albino Swiss CD1 mouse by rotarod test,Other,25868743.0,
3683,1195116,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxic TD50 in Albino Swiss CD1 mouse by rotarod test to anticonvulsant ED50 in Albino Swiss CD1 mouse by maximal electroshock test",Other,25868743.0,
3684,1195117,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxic TD50 in Albino Swiss CD1 mouse by rotarod test to anticonvulsant ED50 in Albino Swiss CD1 mouse by subcutaneous pentylenetetrazole test",Other,25868743.0,
3685,1202885,1,2,,103177883,3121,Inconclusive,1168407.0,24192.0,,IC50,"Inhibition of Wistar rat lens aldose reductase using D,L-glyceraldehyde as substrate incubated for 1 min measured for 4 mins by spectrophotometry",Confirmatory,25695864.0,
3686,1202888,1,2,,103177883,3121,Unspecified,81883332.0,116463.0,56.1,IC50,Inhibition of Wistar rat kidney aldehyde reductase using D-glucuronate as substrate by spectrophotometry,Confirmatory,25695864.0,
3687,1204829,1,2,,103177883,3121,Unspecified,113594.0,317748.0,57.4,IC50,Inhibition of ALR1 in calf kidney using sodium D-glucoronate as substrate treated with compound for 10 mins prior to substrate addition by UV spectrophotometer analysis,Confirmatory,26005026.0,
3688,1209455,1,2,,103177883,3121,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3689,1209456,1,2,,103177883,3121,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3690,1209457,1,1,,103177883,3121,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
3691,1216816,1,2,,103177883,3121,Unspecified,6686268.0,1559.0,,,Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 50 to 200 uM after 24 hrs by WST-8 assay,Other,21321060.0,
3692,1217704,1,2,,103177883,3121,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3693,1217705,1,2,,103177883,3121,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3694,1217706,1,2,,103177883,3121,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3695,1217707,1,2,,103177883,3121,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
3696,1217708,1,2,,103177883,3121,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3697,1217709,1,2,,103177883,3121,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3698,1217710,1,2,,103177883,3121,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
3699,1217711,1,2,,103177883,3121,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3700,1217712,1,2,,103177883,3121,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
3701,1217727,1,2,,103177883,3121,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
3702,1217728,1,1,,103177883,3121,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
3703,1217729,1,1,,103177883,3121,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
3704,1219365,1,1,,103177883,3121,Unspecified,,,,,Elimination half life in mouse brain,Other,23297298.0,
3705,1222892,1,2,,103177883,3121,Unspecified,119576.0,1066.0,363.0,Ki,Inhibition of human CES1,Confirmatory,23386702.0,
3706,1222893,1,2,,103177883,3121,Unspecified,46576349.0,8824.0,7900.0,Ki,Inhibition of human CES2,Confirmatory,23386702.0,
3707,1224834,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3708,1224834,3,1,,144210920,3121,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3709,1224834,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3710,1224835,1,1,,144209161,3121,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3711,1224835,1,1,,144210920,3121,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3712,1224835,1,1,,170465446,3121,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3713,1224836,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3714,1224836,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3715,1224836,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3716,1224837,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3717,1224837,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3718,1224837,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3719,1224838,1,1,,144209161,3121,Inactive,66775687.0,9970.0,54.2058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3720,1224838,1,1,,144210920,3121,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3721,1224838,1,1,,170465446,3121,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3722,1224839,1,1,,144209161,3121,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3723,1224839,1,1,,144210920,3121,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3724,1224839,1,1,,170465446,3121,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3725,1224840,3,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3726,1224840,3,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3727,1224840,3,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3728,1224841,3,1,,144209161,3121,Inactive,325495545.0,2101.0,76.5677,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3729,1224841,3,1,,144210920,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3730,1224841,3,1,,170465446,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3731,1224842,3,1,,144209161,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3732,1224842,3,1,,144210920,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3733,1224842,3,1,,170465446,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3734,1224843,1,1,,144209161,3121,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3735,1224843,1,1,,144210920,3121,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3736,1224843,1,1,,170465446,3121,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3737,1224844,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3738,1224844,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3739,1224844,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3740,1224845,1,1,,144209161,3121,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3741,1224845,1,1,,144210920,3121,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3742,1224845,1,1,,170465446,3121,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3743,1224846,1,1,,144209161,3121,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3744,1224846,1,1,,144210920,3121,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3745,1224846,1,1,,170465446,3121,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3746,1224847,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3747,1224847,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3748,1224847,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3749,1224848,3,1,,144209161,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3750,1224848,3,1,,144210920,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3751,1224848,3,1,,170465446,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3752,1224849,3,1,,144209161,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3753,1224849,3,1,,144210920,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3754,1224849,3,1,,170465446,3121,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3755,1224857,2,1,,170465446,3121,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3756,1224859,2,1,,170465446,3121,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3757,1224863,1,1,,176484206,3121,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3758,1224865,1,2,,49640649,3121,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3759,1224867,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3760,1224867,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3761,1224867,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3762,1224868,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3763,1224868,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3764,1224868,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3765,1224869,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3766,1224869,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3767,1224869,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3768,1224870,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3769,1224870,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3770,1224870,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3771,1224871,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3772,1224871,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3773,1224871,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3774,1224872,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3775,1224872,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3776,1224872,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3777,1224873,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3778,1224873,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3779,1224873,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3780,1224874,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3781,1224874,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3782,1224874,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3783,1224875,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3784,1224875,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3785,1224875,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3786,1224876,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3787,1224876,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3788,1224876,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3789,1224877,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3790,1224877,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3791,1224877,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3792,1224878,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3793,1224878,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3794,1224878,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3795,1224879,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3796,1224879,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3797,1224879,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3798,1224880,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3799,1224880,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3800,1224880,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3801,1224881,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3802,1224881,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3803,1224881,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3804,1224882,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3805,1224882,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3806,1224882,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3807,1224883,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3808,1224883,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3809,1224883,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3810,1224884,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3811,1224884,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3812,1224884,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3813,1224885,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3814,1224885,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3815,1224885,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3816,1224886,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3817,1224886,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3818,1224886,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3819,1224887,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3820,1224887,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3821,1224887,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3822,1224888,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3823,1224888,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3824,1224888,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3825,1224889,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3826,1224889,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3827,1224889,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3828,1224890,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3829,1224890,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3830,1224890,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3831,1224892,1,1,,144209161,3121,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3832,1224892,1,1,,144210920,3121,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3833,1224892,1,1,,170465446,3121,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3834,1224893,1,1,,144209161,3121,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3835,1224893,1,1,,144210920,3121,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3836,1224893,1,1,,170465446,3121,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3837,1224894,1,1,,144209161,3121,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3838,1224894,1,1,,144210920,3121,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3839,1224894,1,1,,170465446,3121,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3840,1224895,1,1,,144209161,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3841,1224895,1,1,,144210920,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3842,1224895,1,1,,170465446,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3843,1224896,1,1,,144209161,3121,Inconclusive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3844,1224896,1,1,,144210920,3121,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3845,1224896,1,1,,170465446,3121,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3846,1224905,2,1,,92308862,3121,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3847,1224905,2,1,,92308862,3121,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3848,1229802,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxic TD50 in Swiss mouse by by Chimney test to anticonvulsant ED50 in Swiss mouse measured at 0.5 hrs of time to peak effect by maximal electroshock test",Other,26052884.0,
3849,1229803,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against seizures measured at 0.5 hrs of time to peak effect by maximal electroshock test,Other,26052884.0,
3850,1229804,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against seizures measured at 0.5 hrs of time to peak effect by subcutaneous pentylenetetrazole seizure test,Other,26052884.0,
3851,1229805,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against seizures measured at 0.5 hrs of time to peak effect by 6 Hz test by 6 Hz psychomotor seizure test,Other,26052884.0,
3852,1229806,1,1,,103177883,3121,Unspecified,,,,,Toxicity in ip dosed Swiss mouse assessed as induction of motor performance impairment measured within 60 seconds measured at 0.5 hrs of time to peak effect by Chimney test,Other,26052884.0,
3853,1229807,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxic TD50 in Swiss mouse by by Chimney test to anticonvulsant ED50 in Swiss mouse measured at 0.5 hrs of time to peak effect by subcutaneous pentylenetetrazole seizure test",Other,26052884.0,
3854,1229808,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of neurotoxic TD50 in Swiss mouse by by Chimney test to anticonvulsant ED50 in Swiss mouse measured at 0.5 hrs of time to peak effect by 6 Hz test by 6 Hz psychomotor seizure test",Other,26052884.0,
3855,1232164,1,1,,103177883,3121,Unspecified,,,,,Fraction unbound in human plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
3856,1232166,1,1,,103177883,3121,Unspecified,,,,,Fraction unbound in rat plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
3857,1232843,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No. 1 mouse measured at 0.25 hrs by maximal electroshock seizure test,Other,25922183.0,
3858,1232852,1,1,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed albino Carworth Farms No. 1 mouse measured at 0.25 hrs by rotarod test,Other,25922183.0,
3859,1232854,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in ip dosed albino Carworth Farms No. 1 mouse to ED50 for anticonvulsant activity in ip dosed MES albino Carworth Farms No. 1 mouse model",Other,25922183.0,
3860,1232857,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat measured at 0.5 hrs by maximal electroshock seizure test,Other,25922183.0,
3861,1232864,1,1,,103177883,3121,Unspecified,,,,,Behavioural toxicity in po dosed albino Sprague-Dawley rat measured at 0.5 hrs,Other,25922183.0,
3862,1232867,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for behavioural toxicity in po dosed albino Sprague-Dawley rat to ED50 for anticonvulsant activity in po dosed MES albino Sprague-Dawley rat model",Other,25922183.0,
3863,1246355,1,1,,103177883,3121,Unspecified,,,,,"Anticonvulsant activity in albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure at 30 to 300 mg/kg, ip measured after 0.5 hrs",Other,26241874.0,
3864,1246356,1,1,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure at 30 to 300 mg/kg, ip measured after 2.0 hrs",Other,26241874.0,
3865,1246357,1,1,,103177883,3121,Unspecified,,,,,"Anticonvulsant activity in albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure at 30 to 300 mg/kg, ip measured after 0.5 hrs",Other,26241874.0,
3866,1246358,1,1,,103177883,3121,Inactive,,,,,"Anticonvulsant activity in albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure at 30 to 300 mg/kg, ip measured after 2.0 hrs",Other,26241874.0,
3867,1246359,1,1,,103177883,3121,Unspecified,,,,,"Neurotoxicity in albino CD-1 mouse assessed as motor impairment at 30 to 300 mg/kg mg/kg, ip measured after 0.5 hrs by rotarod test",Other,26241874.0,
3868,1246360,1,1,,103177883,3121,Unspecified,,,,,"Neurotoxicity in albino CD-1 mouse assessed as motor impairment at 30 to 300 mg/kg mg/kg, ip measured after 2 hrs by rotarod test",Other,26241874.0,
3869,1246362,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure,Other,26241874.0,
3870,1246363,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure,Other,26241874.0,
3871,1246364,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against maximal electroshock-induced seizure measured as time to peak effect,Other,26241874.0,
3872,1246365,1,1,,103177883,3121,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CD-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure measured as time to peak effect,Other,26241874.0,
3873,1246366,1,1,,103177883,3121,Unspecified,,,,,Neurotoxicity in ip dosed albino CD-1 mouse assessed as motor impairment by rotarod test,Other,26241874.0,
3874,1246367,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CD-1 mouse to ED50 for anticonvulsant activity in ip dosed maximal electoshock-induced seizure albino CD-1 mouse model",Other,26241874.0,
3875,1246368,1,1,,103177883,3121,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CD-1 mouse to ED50 for anticonvulsant activity in ip dosed subcutaneous pentylenetetrazole-induced seizure albino CD-1 mouse model",Other,26241874.0,
3876,1259241,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3877,1259241,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3878,1259241,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3879,1259242,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3880,1259242,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3881,1259242,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3882,1259243,1,1,,144209161,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3883,1259243,1,1,,144210920,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3884,1259243,1,1,,170465446,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3885,1259244,1,1,,144209161,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3886,1259244,1,1,,144210920,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3887,1259244,1,1,,170465446,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3888,1259247,1,1,,144209161,3121,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3889,1259247,1,1,,144210920,3121,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3890,1259247,1,1,,170465446,3121,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3891,1259248,1,1,,144209161,3121,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3892,1259248,1,1,,144210920,3121,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3893,1259248,1,1,,170465446,3121,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3894,1259309,1,1,,178125926,3121,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3895,1259310,1,1,,104170082,3121,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3896,1259310,1,1,,332949828,3121,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3897,1259311,1,1,,178125926,3121,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3898,1259313,1,1,,49640649,3121,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3899,1259318,1,1,,49640649,3121,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3900,1259325,1,2,,336954410,3121,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3901,1259344,1,1,,144204642,3121,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3902,1259355,1,1,,144204642,3121,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3903,1259356,1,1,,144204642,3121,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3904,1259364,1,1,,144209161,3121,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3905,1259364,1,1,,144210920,3121,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3906,1259364,1,1,,170465446,3121,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3907,1259365,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3908,1259365,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3909,1259365,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3910,1259366,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3911,1259366,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3912,1259366,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3913,1259367,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3914,1259367,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3915,1259367,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3916,1259368,1,1,,144209161,3121,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3917,1259368,1,1,,144210920,3121,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3918,1259368,1,1,,170465446,3121,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3919,1259369,1,1,,144209161,3121,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3920,1259369,1,1,,144210920,3121,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3921,1259369,1,1,,170465446,3121,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3922,1259377,1,1,,144209161,3121,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3923,1259377,1,1,,144210920,3121,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3924,1259377,1,1,,170465446,3121,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3925,1259378,1,1,,144209161,3121,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3926,1259378,1,1,,144210920,3121,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3927,1259378,1,1,,170465446,3121,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3928,1259379,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3929,1259379,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3930,1259379,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3931,1259380,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3932,1259380,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3933,1259380,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3934,1259381,1,1,,144209161,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3935,1259381,1,1,,144210920,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3936,1259381,1,1,,170465446,3121,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3937,1259382,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3938,1259382,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3939,1259382,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3940,1259383,1,1,,144209161,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3941,1259383,1,1,,144210920,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3942,1259383,1,1,,170465446,3121,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3943,1259384,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3944,1259384,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3945,1259384,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3946,1259385,1,1,,144209161,3121,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3947,1259385,1,1,,144210920,3121,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3948,1259385,1,1,,170465446,3121,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3949,1259386,1,1,,144209161,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3950,1259386,1,1,,144210920,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3951,1259386,1,1,,170465446,3121,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3952,1259387,1,1,,144209161,3121,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3953,1259387,1,1,,144210920,3121,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3954,1259387,1,1,,170465446,3121,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3955,1259388,1,1,,144209161,3121,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3956,1259388,1,1,,144210920,3121,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3957,1259388,1,1,,170465446,3121,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3958,1259390,1,1,,144209161,3121,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3959,1259390,1,1,,144210920,3121,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3960,1259390,1,1,,170465446,3121,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3961,1259391,1,1,,144209161,3121,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3962,1259391,1,1,,144210920,3121,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3963,1259391,1,1,,170465446,3121,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3964,1259392,1,1,,144209161,3121,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3965,1259392,1,1,,144210920,3121,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3966,1259392,1,1,,170465446,3121,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3967,1259393,1,1,,144209161,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3968,1259393,1,1,,144210920,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3969,1259393,1,1,,170465446,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3970,1259394,1,1,,144209161,3121,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3971,1259394,1,1,,144210920,3121,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3972,1259394,1,1,,170465446,3121,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3973,1259395,1,1,,144209161,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3974,1259395,1,1,,144210920,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3975,1259395,1,1,,170465446,3121,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3976,1259396,1,1,,144209161,3121,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3977,1259396,1,1,,144210920,3121,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3978,1259396,1,1,,170465446,3121,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3979,1259400,1,1,,170465446,3121,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3980,1259401,1,1,,144209161,3121,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3981,1259401,1,1,,144210920,3121,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3982,1259401,1,1,,170465446,3121,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3983,1259402,1,1,,144209161,3121,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3984,1259402,1,1,,144210920,3121,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3985,1259402,1,1,,170465446,3121,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3986,1259403,1,1,,144209161,3121,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3987,1259403,1,1,,144210920,3121,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3988,1259403,1,1,,170465446,3121,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3989,1259404,1,1,,144209161,3121,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3990,1259404,1,1,,144210920,3121,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3991,1259404,1,1,,170465446,3121,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3992,1259406,1,1,,363920243,3121,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3993,1259406,1,1,1.0,363920243,3121,Inactive,26638650.0,3778.0,-0.016888999999999998,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3994,1259406,1,1,2.0,363920243,3121,Inactive,4758626.0,3779.0,-0.0194962,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3995,1259406,1,1,3.0,363920243,3121,Inactive,5031823.0,10242.0,0.0329168,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3996,1259406,1,1,4.0,363920243,3121,Inactive,26051275.0,27345.0,0.013444,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3997,1259406,1,1,5.0,363920243,3121,Inactive,160410009.0,389816.0,-0.0230222,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3998,1259406,1,1,6.0,363920243,3121,Inactive,26638650.0,3778.0,0.037609699999999996,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3999,1259406,1,1,7.0,363920243,3121,Inactive,4758626.0,3779.0,-0.03939840000000001,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4000,1259406,1,1,8.0,363920243,3121,Inactive,5031823.0,10242.0,0.0233924,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
4001,1259406,1,1,9.0,363920243,3121,Inactive,26051275.0,27345.0,0.0353777,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
4002,1259406,1,1,10.0,363920243,3121,Inactive,5031823.0,10242.0,-0.042226099999999996,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
4003,1259413,1,2,,104170082,3121,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
4004,1259415,1,1,,49640649,3121,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
4005,1259416,1,2,,340079838,3121,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4006,1259421,1,1,,340079838,3121,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4007,1259423,1,2,,354776809,3121,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4008,1259423,1,2,,354861055,3121,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4009,1259423,1,2,,354888600,3121,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4010,1259423,1,2,,354947261,3121,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4011,1259423,1,2,,354984139,3121,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
